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ABSTRACT

Obi, Engels Nnamdi. Ph.D., Purdue University, December 2013. Patients’ Perceptions of
Provider Communication, Provider Knowledge, and Provider Competence and
Associations with Potentially Inappropriate Medication Use among Medicare Part D
Beneficiaries. Major Professor: Joseph Thomas III

The objectives for this study were to determine prevalence and incidence of potentially
inappropriate medication (PIM) use among community-dwelling Medicare Part D
beneficiaries, and to assess associations between patients’ perceptions of provider
communication, provider knowledge, and provider competence with PIM use. A
retrospective observational analysis was conducted using data from the Medicare Current
Beneficiary Survey. Individuals were included in the prevalence sample if they were
aged 65 years or older in 2008, continuously enrolled in Medicare Part D from October
2007 through December 2008, and living in the community from October 2007 through
December 2008. Individuals were included in the incidence sample if they were aged 65
years or older in 2008, continuously enrolled in Medicare Part D from October 2007
through December 2008, living in the community from October 2007 through December
2008, and did not receive any PIMs during the last quarter of 2007. Potentially
inappropriate medications were identified based on the 2012 Beers criteria in each of four
broad categories including inappropriate drug choice, excess dose, excess duration, and
drug-disease interaction. Patients’ perceptions of provider communication, provider
knowledge, and provider competence were assessed using previously validated indices.

xx

Multiple logistic regression models were developed to examine associations between
patients’ perceptions of provider communication, provider knowledge, and provider
competence and PIM use. One-year prevalence of PIM use among community-dwelling
Medicare Part D beneficiaries was 27.6 percent for inappropriate drug choice PIMs, 3.3
percent for excess dose PIMs, 3.5 percent for excess duration PIMs, and 3.2 percent for
drug-disease interaction PIMs. Overall one-year prevalence of use of any PIM was 33.0
percent. One-year incidence of PIM use among community-dwelling Medicare Part D
beneficiaries was 17.2 percent for inappropriate drug choice PIMs, 1.2 percent for excess
dose PIMs, 2.6 percent for excess duration PIMs, and 1.8 percent for drug-disease
interaction PIMs. Overall one-year incidence of use of any PIM was 20.7 percent.
Individuals with more positive perceived provider knowledge scores of six (OR=0.62,
95% CI=0.39 to 0.97, p=0.036), seven (OR=0.44, 95% CI=0.22 to 0.87, p=0.018), or
eight (OR=0.55, 95% CI=0.34 to 0.88, p=0.012) were less likely than those with scores
ranging from two to five to receive PIMs identified in the inappropriate drug choice
category after adjusting for demographic and clinical characteristics. There were no
associations found between perceived provider communication or perceived provider
competence and PIM use.

1

INTRODUCTION

Background
Medications with adverse risks outweighing potential benefits in older adults or
persons aged 65 years or older are considered potentially inappropriate (Beers, Ouslander
et al., 1991; Stuck, Beers et al., 1994). Older adults are at risk for potentially
inappropriate medication (PIM) use because of high prevalence of chronic disease and
multiple medication use, and age-related changes in pharmacokinetic and
pharmacodynamic parameters of many medications (Dimitrow, Airaksinen et al., 2011;
Mangoni and Jackson 2004; Spinewine, Schmader et al., 2007). There is evidence of
associations between PIM use and adverse health outcomes including higher risk for
adverse drug events, hospitalization, mortality, and more healthcare expenditure
(Dedhiya, Hancock et al., 2010; Guaraldo, Cano et al., 2011; Spinewine, Schmader et al.
2007). Nevertheless, with a rapidly aging US population and greater medication
availability, use of PIMs by older adults may increase and become a larger public health
concern (Gallagher, Barry et al., 2007).
Literature Review
Medication Therapy Challenges in Older Adults
Medication therapy in persons aged 65 years or older or older adults can be
challenging and complex because of age-related factors including polypharmacy, altered

2

pharmacokinetics, altered pharmacodynamics, and use of medications that are potentially
inappropriate.
Polypharmacy
Medication consumption increases with advancing age (Barat, Andreasen et al.,
2000; Kaufman, Kelly et al., 2002). Older adults frequently have complex medical
conditions and multiple comorbidities that require polypharmacy or concurrent use of
multiple medications (Barat, Andreasen et al. 2000). Studies examining drug utilization
patterns in older adults have found estimates of concurrent use of five or more
medications to range from 23 percent to 34 percent (Barat, Andreasen et al. 2000;
Kaufman, Kelly et al. 2002; Qato, Alexander et al., 2008). Kaufman et al. surveyed
2,590 non-institutionalized adults in the US using data from February 1998 through
December 1999 and found 23 percent of women aged 65 years or older took 5 or more
prescription medications and 12 percent took 10 or more prescription medications
(Kaufman, Kelly et al. 2002). Qato et al. surveyed 3,000 US community dwelling
individuals aged 57 to 85 years between June 2005 and May 2006 and found 29 percent
of individuals used at least 5 prescription medications concurrently (Qato, Alexander et
al. 2008). A 46 percent prevalence of concurrent use of over-the-counter (OTC)
medications, and a 52 percent prevalence of concurrent use of dietary supplements was
reported in the same study (Qato, Alexander et al. 2008). Barat et al. surveyed 492
community dwelling adults in Denmark aged 75 years and found that 34 percent of
individuals used five or more prescription medications concurrently, 60 percent used
three or more prescription medications concurrently, and 30 percent used 3 or more OTC
medications concurrently (Barat, Andreasen et al. 2000).
A higher risk for adverse drug-related outcomes including adverse events, drugdrug, and drug-disease interactions has been reported in individuals using multiple
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medications concurrently (Goldberg, Mabee et al., 1996). Goldberg et al. found the risk
for adverse drug interactions in a high-risk population of emergency department patients
increased from 13 percent in patients taking two drugs, to 38 percent in patients taking
four drugs, and 82 percent in patients taking seven or more drugs (Goldberg, Mabee et al.
1996). Older adults frequently use multiple medications and are vulnerable to the
adverse drug-related outcomes associated with such medication use because of agerelated changes in pharmacokinetic and pharmacodynamic parameters of many drugs
(Everitt and Avorn 1986; Gallagher, Barry et al. 2007), prevalent but frequently
unrecognized duplicate prescribing of drugs in the same class (Goldberg, Mabee et al.
1996; Hajjar, Cafiero et al., 2007), and use of even more drugs to treat drug-related
adverse events (Hajjar, Cafiero et al. 2007).
Altered Pharmacokinetics
Older adults present age-related alterations in many pharmacokinetic processes
including drug distribution, metabolism and excretion that may increase or decrease their
sensitivity to medications.
Drug Distribution
As people age, there is decrease in lean body mass and total body water, and a
corresponding increase in adipose tissue (Everitt and Avorn 1986; Gallagher, Barry et al.
2007). The change in body composition increases the volume of distribution for lipid
soluble drugs such as diazepam, thiopentone, and lignocaine in older adults leading to
prolongation of half-life and delayed therapeutic effect (Christensen, Andreasen et al.,
1981; Greenblatt, Allen et al., 1980; Nation, Triggs et al., 1977; Turnheim 2003).
Conversely, the volume of distribution for water-soluble drugs such as digoxin, and
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ethanol decreases leading to higher serum levels of such drugs in older adults and greater
risk for adverse effects (Cusack, Kelly et al., 1979; Vestal, McGuire et al., 1977).
Several drugs are distributed in the body in both an inactive protein-bound and
active unbound state (Everitt and Avorn 1986). Although, no significant age-related
decreases in the amount of proteins available for drug binding have been observed,
malnutrition and chronic illness often seen in older adults may decrease serum albumin
levels (Fu and Nair 1998). Low serum albumin levels increase the active unbound drug
fraction for highly protein-bound drugs such as phenytion, wafarin, digoxin, theophylline,
furosemide, and phenylbutazone (Everitt and Avorn 1986; Gallagher, Barry et al. 2007).
Because the unbound drug fraction is responsible for pharmacological action, having
above normal serum concentrations of unbound drug can increase the risk for adverse
effects. The concurrent use of multiple medications frequently observed in older adults
may result in displacement of protein-bound drugs and further increase the risk for
adverse effects (Everitt and Avorn 1986).
Drug Metabolism
Advancing age is associated with a reduction in liver mass and blood flow which
may reduce the metabolism of drugs that undergo first-pass metabolism in the liver such
as beta-blockers, tricyclic antidepressants, and nitrates (Anantharaju, Feller et al., 2002;
Page, Linnebur et al., 2010; Woodhouse and Wynne 1988). A consequence of reduced
first-pass metabolism of such drugs is significantly increased bioavailability (Castleden
and George 1979; Greenblatt, Harmatz et al., 1991), which can in turn lead to potentially
dangerous accumulation of the drug in the body and adverse effects. For pro-drugs such
as enalapril and perindopril that are activated in the liver, a reduction in first-pass
metabolism due to advancing age reduces their bio-availability (Davies, Gomez et al.,
1984; Todd and Fitton 1991).
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Age-related changes in liver mass and blood flow have also been associated with
significant reductions in the clearance of several drugs metabolized via hepatic phase I
reactions (Schmucker 2001; Swift, Homeida et al., 1978). Therefore, drugs metabolized
primarily through hepatic phase I oxidation reactions such as flurazepam, diazepam,
qunidine, and theophylline tend to be more bioavailable in older adults (Everitt and
Avorn 1986).
Drug Excretion
Advancing age has been associated with a reduction in many aspects of renal
function including renal blood flow, glomerular filtration, and active tubular secretion
(Everitt and Avorn 1986). A reduction in renal function decreases the clearance of
several drugs including digoxin (Portnoi 1979), indomethacin (Oberbauer, Krivanek et
al., 1993), diuretics (Somogyi, Hewson et al., 1990), lithium (Hewick, Newbury et al.,
1977), and water soluble antibiotics (Lumholtz, Kampmann et al., 1974; Triggs, Johnson
et al., 1980). Decreased renal clearance prolong the half-lives of potentially toxic drugs
such as aminoglycoside antibiotics, digoxin, and lithium drugs resulting in drug
accumulation and possibly serious adverse effects (Mangoni and Jackson 2004).
Altered Pharmacodynamics
Advancing age is associated with increased individual patient variability in drug
response. An increase in receptor sensitivity in older adults has been found for
analgesics, cardiovascular drugs such as digoxin (Everitt and Avorn 1986), and
psychotropic drugs such as diazepam and lorazepam (Gallagher, Barry et al. 2007;
Mangoni and Jackson 2004). Thus drug levels within the ‘normal’ therapeutic range may
have a larger than normal pharmacologic effect. Adjusting drug doses in older adults to
account for possible potentiation of pharmacological action as a result of increased
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receptor sensitivity, is especially important for drugs with a narrow therapeutic index
such as digoxin to reduce the risk for severe adverse reactions.
Conversely, a decrease in receptor sensitivity has been found in older adults for
beta-agonists such as salbutamol, beta-blockers such as propanolol (Gallagher, Barry et
al. 2007; Vestal, Wood et al., 1979), as well as for verapamil (Mangoni and Jackson
2004), and insulin (Everitt and Avorn 1986). The inhibition of synthesis of vitamin Kdependent clotting factors was found to be greater in persons aged between 62 years and
89 years when compared to persons between the ages of 27 years and 37 years (Shepherd,
Hewick et al., 1977). Doses of drugs having decreased receptor sensitivity in older adults
may need to be increased in to order to achieve an adequate therapeutic response.
Potentially Inappropriate Medications (PIMs)
Gallagher et al. define potentially inappropriate medications (PIMs) as
“medications that introduce a significant risk of an adverse event where there is evidence
for an equally or more effective but lower risk alternative therapy available for treating
the same condition” (Gallagher, Barry et al. 2007). Inappropriate medication use may
also include the “underuse of beneficial medicines which are clinically indicated but not
prescribed for ageist or irrational reasons” (Gallagher, Barry et al. 2007). Older adults
are at higher risk of receiving medications considered to be inappropriate, and having
adverse drug-related events as a result of such medication use (Dimitrow, Airaksinen et
al. 2011; Mangoni and Jackson 2004; Spinewine, Schmader et al. 2007). The higher risk
of adverse drug-related events from inappropriate medication use in older adults has been
linked to age-related factors including polypharmacy, altered pharmacokinetics, and
altered pharmacodynamics, all of which make pharmacotherapy in this population
challenging.
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Approaches used to examine Appropriateness of Medications
in Older Adults
The approaches commonly used to identify inappropriate medication use in older
adults are categorized as explicit (criteria-based), or implicit (judgment-based).
Explicit Approaches
Explicit approaches for identifying potentially inappropriate medication use in
older adults are drug or disease-specific criteria that can be applied with little or no
clinical judgment. They are established from published reviews and expert consensus for
the purpose of identifying potential mis-prescribing or under-prescribing of medications
to older adults (Spinewine, Schmader et al. 2007). Mis-prescribing involves the use of
medications that ought to be avoided in older adults either in the presence or absence of
comorbid conditions (Chang and Chan 2010). Under-prescribing involves the under-use
of medications that although beneficial and clinically indicated, are not prescribed
because of ageist or otherwise invalid reasons (Gallagher, Barry et al. 2007; Spinewine,
Schmader et al. 2007).
A major advantage of explicit approaches is their ease of implementation in a
large number of people (Dimitrow, Airaksinen et al. 2011; Spinewine, Schmader et al.
2007) because of the limited range of medications and clinical conditions specified
(Chang and Chan 2010). Disadvantages include concerns about their validity, reliability
(Anderson, Beers et al., 1997; Tinetti, Bogardus et al., 2004), specificity, and scope
(Spinewine, Schmader et al. 2007). Explicit criteria used to assess appropriateness of
medication use in older adults include the Beers criteria, Zhan criteria, McLeod criteria,
Improved Prescribing in the Elderly Tool (IPET), Screening Tool of Older Person’s
Prescriptions (STOPP), and Screening Tool to Alert doctors to Right Treatment
(START). The criteria are described below.
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Beers criteria
The Beers criteria was developed in 1991 as a guide for determining inappropriate
medication use in nursing home residents aged 65 years or older (Beers, Ouslander et al.
1991). It is the most commonly used criteria for identifying potentially inappropriate
medication use in older adults. The criteria were developed using a consensus expert
panel of US geriatric specialists and pharmacotherapists, and consisted of a list of
medications to be avoided in persons aged 65 years or older because of their
ineffectiveness or because of the unnecessary risk use of such medications posed to
persons aged 65 years or older. The list also included doses and durations of therapy that
should not be exceeded for certain drugs. The Beers criteria were updated and expanded
in 1997 and 2002 to include inappropriate prescribing for persons aged 65 years or older
living in the community or other settings (Beers 1997; Fick, Cooper et al., 2003).
In 2012, a fourth edition of the Beers criteria was published (American Geriatrics
Society 2012 Beers Criteria Update Expert Panel 2012). The latest version of the Beers
criteria was developed using enhanced evidence-based methodology recommended by
the Institute of Medicine in its 2011 report on developing practice guidelines. The 2012
Beers criteria differed from 2002 criteria in that drugs available after publication of the
2002 criteria were added, drugs no longer available were removed, and a new group of
drugs to be used with caution in older adults was added. The 2012 Beers criteria consist
of 53 medications or medication classes divided into 4 categories. The first category
consists of drugs considered generally inappropriate in older adults. The second category
consists of drugs considered potentially inappropriate because of dose limitations. The
third category consists of drugs considered potentially inappropriate because of duration
of use limitations. The fourth category consists of drugs considered potentially
inappropriate in persons with specific concomitant disease.
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Zhan Criteria
Although the Beers criteria is accepted as an indicator of inappropriate medication
use (Viswanathan, Bharmal et al., 2005), the use of some drugs on the criteria may be
justified for use in certain patients if the benefits outweigh the risk (Anderson, Beers et
al. 1997; Beers, Ouslander et al. 1991; Zhan, Sangl et al., 2001). To account for this,
Zhan et al. (Zhan, Sangl et al. 2001) convened a panel of experts in geriatrics,
pharmacoepidemiology, and pharmacy and categorized drugs listed in the 1997 Beers
criteria according to their level of risk. The updated criteria consisted of 33 drugs
categorized as drugs to always avoid, drugs that are rarely appropriate, and drugs that are
sometime appropriate.
McLeod Criteria / Improved Prescribing in the Elderly Tool (IPET)
The McLeod Criteria (McLeod, Huang et al., 1997) was developed in Canada in
1997 to assess inappropriate prescribing practices in older adults. The criteria was
developed using a 32-member expert panel of Canadian clinical pharmacologists,
geriatricians, family practitioners, and pharmacists, and consisted of a list of medications
that are considered inappropriate in older adults due to the risk of serious adverse effect
when there was equally or more effective and less risky alternative therapy available.
The clinical significance of each medication was rated on a scale of 1 being none
significant, to 4 being highly significant. The final criteria consisted of 38 distinct
therapies or therapeutic combinations with a mean clinical significance rating of at 3.0 or
greater, divided into 3 categories including medications contraindicated in older adults
due to unacceptable benefit-risk ratios, medications involved in drug-drug interactions,
and medications involved in drug-disease interactions.
The Improved Prescribing in the Elderly Tool or IPET (Naugler, Brymer et al.,
2000) was developed in Canada in 2000 and is a shortened practical version of the
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McLeod Criteria. This screening tool was developed by applying the McLeod Criteria to
abstracted hospital charts to identify what PIMs were most prevalent in older adults, and
consisted of 14 instances of potentially inappropriate prescribing. Although brief and
easy to use (Naugler, Brymer et al. 2000), IPET was found to be less sensitive than the
2002 Beers criteria at detecting PIMs because it does not include many of the drugs
found in the Beers list (Barry, O'Keefe et al., 2006). IPET has been seldom used in nonCanadian studies (Laroche, Charmes et al., 2009; O'Mahony and Gallagher 2008).
Screening Tool of Older Person’s Prescriptions (STOPP)
The Screening Tool of Older Person’s Prescriptions (STOPP) was developed by
Gallagher et al. (Gallagher, Ryan et al., 2008) and consists of criteria for identifying
PIMs in older adults. The screening tool was developed using an 18-member consensus
expert panel of specialists in geriatric pharmacotherapy in Ireland and the United
Kingdom and consists of 65 criteria grouped according to 7 physiological systems, drugs
adversely affecting persons who fall, analgesic drugs, and duplicate drug classes.
Screening Tool to Alert doctors to Right Treatment (START)
The Screening Tool to Alert doctors to Right Treatment (START) consists of
criteria for appraising under-prescribing of appropriate drugs in older adults (Gallagher,
Ryan et al. 2008). START was developed using an 18-member consensus expert panel of
specialists in geriatric pharmacotherapy in Ireland and the United Kingdom and
comprises of 22 criteria grouped according to 6 physiological systems. It was designed
to be ideally used with STOPP to obtain a holistic appraisal of appropriateness of
medication therapy in older adults.

11

Implicit Approach
Implicit approaches used to examine potentially inappropriate medication use in
older adults are person-oriented, and rely on a clinician’s judgment rather than predefined criteria to determine medication appropriateness (Dimitrow, Airaksinen et al.
2011; Spinewine, Schmader et al. 2007). They are based on an individual’s clinical
information and published literature (Spinewine, Schmader et al. 2007). Advantages of
implicit approaches include their higher sensitivity, and ability to account for patient
preferences (Spinewine, Schmader et al. 2007). Disadvantages of implicit approaches
include they require more time to apply relative to explicit approaches, and can have low
reliability because different clinicians may judge appropriateness differently (Dimitrow,
Airaksinen et al. 2011; Spinewine, Schmader et al. 2007). Because of the issues with
their practicality of use, implicit approaches are less commonly used in health outcomes
studies examining potentially inappropriate medication use (Dimitrow, Airaksinen et al.
2011). The Medication Appropriateness Index was the only implicit approach found that
was used to assess potentially inappropriate medication use in older adults and is
described below.
Medication Appropriateness Index (MAI)
The MAI (Hanlon, Schmader et al., 1992) was developed in 1992 to evaluate the
appropriateness of drug therapy and consists of 10 criteria that assess various elements of
drug prescribing including indication, effectiveness, dosage, directions, practicality, drugdrug interaction, drug-disease interaction, duplication, duration, and expense. The index
provides operational definitions and explicit instructions for each criterion to aid
standardization of use. Each evaluator uses these guidelines as well their implicit
judgment to rate the appropriateness of drug use on a 3 point Likert scale. Individual
ratings obtained for all 10 criteria are then combined to obtain a summary score reflecting
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the overall appropriateness of a specific drug. To enhance the utility of the MAI, a
weighing scheme was developed in 1994 that generates a single summated score for each
medication evaluated (Samsa, Hanlon et al., 1994).
Prevalence of PIM use in Older Adults
Sixty-eight studies were found that reported PIM prevalence rates among older
adults. The PIMs were identified in individuals receiving care from various care settings
including ambulatory care (38 of 68 studies), hospitals (13 of 68 studies), nursing homes
(11 of 68 studies), residential care/assisted living facilities (5 of 68 studies), and
emergency departments (4 of 68 studies). Four studies did not specify the setting at
which care was received (Akazawa, Imai et al., 2010; Fahlman, Lynn et al., 2007; Mort
and Sailor 2011; Simon, Chan et al., 2005). The studies identified PIMs using various
criteria including the Beers criteria (49 of 68 studies), Zhan criteria (13 of 68 studies),
STOPP criteria (9 of 68 studies), McLeod criteria/IPET (4 of 68 studies), and the MAI (4
of 68 studies). PIM prevalence was reported either as patient based rates i.e. percentage
of individuals in the study population receiving PIMs (63 studies) or as visit-based
prevalence rates i.e. percentage of visits involving the prescription of PIMs (5 studies).
Ambulatory Settings
Thirty-eight studies were found that determined prevalence of PIM use in older
adults in ambulatory settings. Potentially inappropriate medications were identified using
Beers criteria (1991, 1997, and/or 2002 versions), Zhan criteria, McLeod criteria/IPET,
STOPP criteria, and the MAI.

13

Beers criteria
Four studies were found that estimated PIM prevalence in ambulatory settings
using the 1991 Beers criteria (Aparasu and Fliginger 1997; Aparasu and Sitzman 1999;
Stuck, Beers et al. 1994; Willcox, Himmelstein et al., 1994). Aparasu et al. estimated
prevalence of PIMs prescribing by office-based physicians to persons aged 65 years or
older using data from the 1992 National Ambulatory Care Survey (Aparasu and Fliginger
1997). They defined PIMs based on a subset of the 1991 Beers criteria consisting of
drugs considered generally inappropriate in older adults. They found 7.6 percent of
individuals receiving prescriptions were prescribed PIMs. The most frequently
prescribed PIMs were propoxyphene, amitriptyline, dipyridamole, diazepam, and
chlorporpamide.
Stuck et al. determined prevalence of PIM use among 414 community-dwellers
aged 75 years or older in Santa Monica, California (Stuck, Beers et al. 1994).
Inappropriate medications were identified with a subset of the 1991 Beers criteria
consisting of drugs considered generally inappropriate in older adults. They found 14.0
percent of individuals received at least one PIMs with such drug use comprising 16.9
percent of all reported prescription medications received. The most common
inappropriate drugs or drug classes were long-acting benzodiazepines, persantine,
amitriptyline, and chlorpropamide.
Willcox et al. determined prevalence of PIM use among 6,171 community
residents aged 65 years or older using data from the 1987 National Medical Expenditure
Survey (Willcox, Himmelstein et al. 1994). Potentially inappropriate medications were
identified based on a subset of 1991 Beers criteria consisting of drugs considered
generally inappropriate in older adults. They found 23.5 percent of individuals received
at least one PIM, with 79.6 percent receiving only one PIM, 16.5 percent receiving 2
PIMs, 3.0 percent receiving 3 PIMs, and 0.9 percent receiving 4 PIMs. The most
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frequently received PIMs were dipyridamole (6.4%), propranolol (6.3%), propoxyphene
(4.8%), methyldopa (4.5%), and amitriptyline (3.1%).
Aparasu et al. estimated prevalence of PIM use in outpatients aged 65 years or
older based on a subset of the 1991 Beers criteria consisting of drugs considered
generally inappropriate in older adults (Aparasu and Sitzman 1999). They examined
outpatient records from the 1994 National Hospital Ambulatory Medical Care Survey,
and reported visit-based PIM prevalence rates. They found approximately 4.5 percent of
visits involving prescriptions, or 2.9 percent of total outpatient visits, were associated
with receiving PIMs. The most commonly prescribed PIMs were diazepam (0.8%),
propoxyphene (0.7%), dipyridamole (0.4%), amitriptyline (0.3%), and chlordiazepoxide
(0.3%).
Nine studies were found that determined prevalence of PIM use in ambulatory
settings based on the 1997 Beers criteria (Cannon, Choi et al., 2006; de Oliveira Martins,
Soares et al., 2006; Fialova, Topinkova et al., 2005; Fick, Waller et al., 2001; Goulding
2004; Howard, Dolovich et al., 2004; Rigler, Jachna et al., 2005; Stuart, Kamal-Bahl et
al., 2003; Viswanathan, Bharmal et al. 2005). Stuart et al. assessed prevalence of PIM
use among community dwellers aged 65 years or older (Stuart, Kamal-Bahl et al. 2003).
They analyzed data from the Medicare Current Beneficiary Survey data for 7,628
individuals in the 1995 survey and 8,902 individuals in the 1999 survey. Potentially
inappropriate drugs were identified with a subset of the 1997 Beers criteria consisting of
drugs considered generally inappropriate in older adults, with the exception of oral
meperidine. They found PIM use decreased from 24.8 percent in 1995 to 21.3 percent in
1999. A decrease in prevalence of PIMs associated with high severity adverse outcomes
(from 11.8% in 1995 to 8.7% in 1999) accounted for most of the decrease in overall PIM
prevalence. The most commonly used inappropriate drugs or drug classes were the same
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in 1991 and 1999 and included propoxyphene, antihistamines, gastrointestinal
antispasmodics, and amitriptyline.
Goulding et al. examined trends in PIM prescribing at 22,031 ambulatory care
visits by older adults using 1995 to 2000 data from the National Ambulatory Medical
Care Survey, and National Hospital Ambulatory Medical Care Survey (Goulding 2004).
Potentially inappropriate medications were defined based on a subset of the 1997 Beers
criteria consisting of drugs considered generally inappropriate in older adults. They
found PIMs were prescribed at 7.8 percent of all ambulatory care visits. The most
frequently prescribed PIMs comprised 58.0 percent of all PIMs prescribed and included
propoxyphene (1.5%), hydroxyzine (1.1%), diazepam (0.7%), amitriptyline (0.7%), and
oxybutynin (0.7%).
Viswanathan et al. determined prevalence of PIM use in an ambulatory population
with subsets of 1997 and 2002 Beers criteria that consisted of drugs considered generally
inappropriate in older adults (Viswanathan, Bharmal et al. 2005). They examined
ambulatory visits for 7,243 patients aged 65 years or older using data from the 2001
National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical
Care Survey. Visit-based PIM prevalence rates were reported. They found PIMs
identified with the 1997 Beers criteria were received in 8.8 percent of visits and PIMs
identified with the 2002 Beers criteria were received in 13.4 percent of visits. The most
commonly prescribed PIMs based on 2002 Beers criteria were propoxyphene, doxazosin,
amiodarone, nitrofurantion, and amitriptyline.
Rigler et al. characterized patterns of PIM use among 858 Kansas Medicaid
beneficiaries aged 60 years or older receiving home and community-based services, and
among 1,163 beneficiaries not receiving such services, using pharmacy claims data from
2000 to 2001 (Rigler, Jachna et al. 2005). Potentially inappropriate medication were
identified based on a subset of the 1997 Beers criteria consisting of drugs considered
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generally inappropriate in older adults. Forty-eight percent of individuals receiving home
and community-based services were found to use PIMs, whereas, 21.0 percent of
individuals not receiving such services used PIMs. The most common potentially
inappropriate drug or drug classes among Medicaid beneficiaries receiving home and
community-based services versus those not receiving such services were analgesics
(23,4% vs. 8.7%), antihistamines (12.9% vs. 5.3%), antidepressants (11.1% vs. 5.4%) ,
muscle relaxants (6.3% vs. 4.4%), and oxybutynin (5.8% vs. 1.6%).
Fialova et al. applied 1997 Beers criteria to determine prevalence of PIM use in
2,707 patients aged 65 years of older receiving home care in metropolitan areas of eight
European countries including the Czech Republic, Denmark, Finland, Iceland, Italy, the
Netherlands, Norway, and the United Kingdom between September 2001 to January 2002
(Fialova, Topinkova et al. 2005). Potentially inappropriate medications were identified
with a subset of the 1997 Beers criteria consisting of drugs considered generally
inappropriate in older adults (excluding stimulant laxatives), and drugs considered
inappropriate at doses or durations beyond specific limits. They found PIM prevalence
rates of 3.2 percent in Denmark, 5.9 percent in Iceland and the United Kingdom, 9.1
percent in the Netherlands, 9.8 percent in Norway, 13.6 percent in Italy, 15.7 percent in
the Czech Republic, and 17.1 percent in Finland.
De Oliviera Martin et al. determined prevalence of PIM use among 213
outpatients aged 65 years or older visiting 12 community pharmacies in Lisbon, Portugal
between October 2002 and January 2003 (de Oliveira Martins, Soares et al. 2006). They
defined inappropriate medications with a subset of 1997 Beers criteria consisting of drugs
considered generally inappropriate in older adults, and drugs considered inappropriate at
doses or durations beyond specific limits. They found a PIM prevalence of 27.7 percent,
with approximately 78.0 percent of individuals receiving one PIM, 17.0 percent receiving
two PIMs, and 5.0 percent receiving three PIMs. Diazepam and ticlopidine were the
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most frequently received inappropriate medications accounting for 56.0 percent of
inappropriate medications based on the 1997 Beers criteria
Howard et al. determined prevalence of PIM use among 889 older adults visiting
family physicians in Southern Ontario, Canada (Howard, Dolovich et al. 2004). They
identified PIMs using a modified subset of the 1997 Beers criteria consisting of drugs
considered generally inappropriate in older adults, and drugs considered inappropriate at
doses or durations beyond specific limits. The Beers criteria was modified to include
short-acting benzodiazepines of more than 30 days’ supply, and simultaneous
prescription of more than one benzodiazepine or non-steroidal anti-inflammatory drug.
The authors reported a PIM prevalence of 16.3 percent. The most frequently prescribed
inappropriate drugs or drug classes were short-acting benzodiazepines (6.4%), and
oxybutynin (3.7%).
Cannon et al. identified prevalence of PIM use among 786 Medicare beneficiaries
aged 65 years or older receiving home health care after discharge from a Texas hospital
(Cannon, Choi et al. 2006). Potentially inappropriate medications were identified based a
subset of the 1997 Beers criteria that consisted of drugs considered generally
inappropriate in older adults. Thirty-one percent of Medicare beneficiaries were
identified as PIM users.
Fick et al. determined the prevalence of PIM use in ambulatory Medicare
managed care beneficiaries (Fick, Waller et al. 2001). They reviewed 1997 to 1998
claims data for 2,336 Medicare beneficiaries aged 65 years or older enrolled in a
Southeastern health maintenance organization. Potentially inappropriate medications
were identified based on a subset of 1997 Beers criteria consisting of drugs considered
generally inappropriate in older adults. They found PIM prevalence of 24.2 percent for
individuals receiving at least one PIM and prevalence of 6.3 percent for those receiving
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two or more PIMs. The most frequently prescribed PIMs were propoxyphene (9.6%),
amitriptyline (3.1%), cyclopenzaprine (2.1%), hyroxyzine (1.6%), and diazepam (1.5%).
Twelve studies were found that determined PIM prevalence in ambulatory
settings based on 2012 Beers criteria (Bao, Shao et al., 2012; Buck, Atreja et al., 2009;
Chang, Chen et al., 2011; de Oliveira Martins, Soares et al. 2006; Fialova, Topinkova et
al. 2005; Fick, Mion et al., 2008; Golden, Qiu et al., 2011; Lund, Carnahan et al., 2010;
Ryan, O'Mahony et al., 2009; Skaar and O'Connor 2012; Thorpe, Thorpe et al., 2012;
Woelfel, Patel et al., 2011). Thorpe et al. determined the prevalence of PIM use in
dementia patients and their informal caregivers using study data from a 6-site,
randomized intervention study conducted from 1996 to 2001 (Thorpe, Thorpe et al.
2012). The authors identified PIM use with a subset of the 2002 Beers criteria consisting
of drugs considered generally inappropriate in older adults. The study sample comprised
of 566 dyads of older patients with dementia and their caregivers. Approximately 30.0
percent of dementia patients and 39 percent of their caregivers were found to receive at
least one PIM. The most common inappropriate drugs or drug classes were
antihistamines with anticholinergic effects (11.8%), oral estrogens (11.6%), muscle
relaxant or antispasmodics (9.4%), fluoxetine (8.0%), and short-acting nifedipine (6.6%).
The most common inappropriate drugs or drug classed received by caregivers of
dementia patients were oral estrogens (34.9%), NSAIDs (8.6%), long-acting
benzodiazepine (6.2%), and fluoxetine (5.5%).
Bao et al. estimated prevalence of PIM use among 3,124 home health patients
aged 65 years or older using data from the 2007 National Home and Hospice Care Survey
(Bao, Shao et al. 2012). They identified PIMs with a subset of the 2002 Beers criteria
comprising of drugs considered generally inappropriate in older adults. Potentially
inappropriate medications were further categorized based on 2002 Beers criteria into
medications associated with high-severity adverse outcomes or medications associated
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with low-severity adverse outcomes. Thirty percent of home care patients were found to
receive PIMs with 26.0 percent of patients receiving PIMs associated with high-severity
adverse outcomes and 18.0 percent receiving PIMs associated with low-severity adverse
outcomes. The most frequently used inappropriate drugs or drug classes were
propoxyphene (9.0%), antiadrenergics (7.0%), and antihistamines (6.0%).
Golden et al. assessed prevalence of PIM use in nursing home-eligible older
adults enrolled in a Florida home and community-based Medicaid waiver program in
2009 (Golden, Qiu et al. 2011). They identified PIMs with a subset of the 2002 Beers
criteria comprised of drugs considered generally inappropriate in older adults and
associated with high severity adverse outcomes. The study sample included 3,911 dually
eligible Medicare and Medicaid beneficiaries, aged 65 years and older. A total of 25.2
percent of beneficiaries in the study sample were using PIMs. The most commonly used
potentially inappropriate drugs or drug classes among beneficiaries were
diphenhydramine (10.3%), oxybutynin (3.5%), fluoxetine (3.2%), promethazine (2.5%),
high doses of short-acting benzodiazepines (2.4%), and hydroxyzine (2.4%).
Chang et al. determined prevalence of PIM use among 193 outpatients aged 65
years or older visiting two hospitals in Taipei, Taiwan (Chang, Chen et al. 2011). They
identified PIMs based a subset of the 2002 Beers criteria consisting of medications
considered generally inappropriate in older adults and associated with high severity
adverse outcomes. Fifty-five percent of outpatients were found to have received PIMs.
The most commonly received PIMs were doxazocin (12.4%), alprazolam (7.8%), and
dipyridamole (7.3%).
Fialova et al. in their study of 2,707 patients aged 65 years or older receiving
home care in eight European countries from September 2001 to January 2002 applied
2002 Beers criteria to assess PIM prevalence (Fialova, Topinkova et al. 2005).
Potentially inappropriate medications were defined with a subset of 2002 Beers criteria
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consisting of drugs considered generally inappropriate in older adults with the exclusion
of stimulant laxatives, and drugs considered inappropriate at doses or durations beyond
specific limits. The authors reported PIM prevalence rates of 5.8 percent in Denmark,
13.1 percent in the Netherlands, 13.5 percent in the United Kingdom, 14.7 percent in
Norway, 15.1 percent in Iceland, 20.3 percent in Finland, 25.2 percent in the Czech
Republic, and 25.7 percent in Italy.
Woelfel et al. determined prevalence of PIM use in ambulatory Medicare
beneficiaries (Woelfel, Patel et al. 2011). Prevalence rates were based on a subset of the
2002 Beers criteria consisting of drugs considered generally inappropriate in older adults
and drugs considered inappropriate at doses or durations beyond specific limits. The
authors analyzed 295 Medicare beneficiaries aged 65 years to 98 years attending nine
community outreach events throughout central and northern California in 2008 and found
a PIM prevalence rate of 18.3 percent. The most common drug classes among PIMs
received were benzodiazepines (27%), and antiarrhythmics (25.5%). The most common
PIMs among individuals receiving PIMs were alprazolam (17%), clonidine (15%),
estrogen (15%), amiodarone (11%), digoxin (11%).
Buck et al. examined prevalence of PIMs received at outpatient primary care
clinics in Utah and Ohio using electronic health records (Buck, Atreja et al. 2009).
Prescription claims for 37,247 patients from Utah primary care clinics and 24,004
patients from Ohio primary care clinics were analyzed. They identified PIMs with a
subset of 2002 Beers criteria consisting of drugs considered generally inappropriate in
older adults (excluding estrogens), and drugs considered inappropriate at doses or
durations beyond specific limits. The prevalence of PIMs was higher in patients
receiving care from Utah primary care clinics (23.3%) than patients receiving care from
Ohio primary care clinics (23.0%). Receipt of PIMs associated with high-severity
adverse outcomes was more prevalent in Utah primary care clinics (19.1%) than Ohio
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primary care clinics (15.8%, p<.001). The most common high-severity PIMs in both
Utah and Ohio patients were fluoxetine (4.1% vs. 1.5%), amitriptyline (2.4% vs. 1.7%),
and promethazine (2.2% vs. 0.6%).
Skarr et al. estimated prevalence of PIM use among older community dwellers
visiting the dentist (Skaar and O'Connor 2012). Potentially inappropriate medications
were defined based on a subset of the 2002 Beers criteria that included drugs considered
generally inappropriate in older adults and drugs considered inappropriate at doses or
durations beyond specific limits. They examined 2006 Medicare Current Beneficiary
Survey data for continuously enrolled beneficiaries aged 65 years or older and found 34.4
percent of beneficiaries received at least one PIM and 13.3 percent received two PIMs.
The most commonly prescribed PIMs were estrogens (5.3%), digoxin (4.3%), naproxen
(3.5%), alprazolam (3.3%), and lorazepam (3.3%).
De Oliviera Martin et al. determined prevalence of inappropriate prescriptions
among 213 outpatients aged 65 years or older visiting 12 community pharmacies in
Lisbon, Portugal between October 2002 and January 2003 (de Oliveira Martins, Soares et
al. 2006). They defined inappropriate medications with a subset of 2002 Beers criteria
consisting of drugs considered generally inappropriate in older adults and drugs
considered inappropriate at doses or durations beyond specific limits. The prevalence of
PIM use based on the 2002 Beers criteria was 38.5 percent. Approximately 70.0 percent
of individuals received one inappropriate prescription, 23.2 percent received two
inappropriate medications, and 6.8 percent received three inappropriate medications.
Diazepam and ticlopidine were the most frequently received PIMs (36.8%).
Fick et al. examined prevalence of PIM use among older community dwellers
(Fick, Mion et al. 2008). Potentially inappropriate medications were identified with a
subset of the 2002 Beers criteria consisting of drugs considered generally inappropriate in
older adults and drugs considered inappropriate at doses or durations beyond specific
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limits. A total of 17,971 individuals 65 years or older continuously enrolled in a large
managed care organization in the Southeast United States from January 2000 to June
2000 were included in the study sample. The authors found 40.0 percent of individuals
received at least one PIM, and 13.0 percent received 2 or more. The most commonly
received potentially inappropriate drugs or drug classes among individuals in the study
population were estrogens (9.6%), propoxyphene (7.4%), short-acting benzodiazepines
(7.4%), digoxin (4.7%), and NSAIDs (4.6%).
Ryan et al. determined the rate of potentially inappropriate prescriptions in
primary care practices in Ireland using 2002 Beers criteria (Ryan, O'Mahony et al. 2009).
Potentially inappropriate prescriptions were defined based on all drugs in the 2002 Beers
criteria. They examined 1,329 patients 65 years or older prescribed at least one daily
medication in three large general practices in County Cork, Ireland, between January
2007 and July 2008 and found PIM prescriptions in 18.3 percent of patients. The most
commonly prescribed potentially inappropriate drugs or drug classes among all PIMs
prescribed were long-acting benzodiazepines (31.8%), and doxazosin (30.1%).
Lund et al. determined prevalence of inappropriate prescribing among 236
veterans aged 65 years or older visiting primary care clinics at the Iowa City Veterans
Affairs Medical Center (Lund, Carnahan et al. 2010). The authors defined PIMs using all
drugs in the 2002 Beers criteria and found 48.7 percent of veterans received a
prescription for one or more PIMs.
Zhan Criteria
Nine studies were found that determined prevalence of PIM use in ambulatory
settings based on Zhan criteria (Barnett, Perry et al., 2006; Buck, Atreja et al. 2009;
Goulding 2004; Lane, Bronskill et al., 2004; Pugh, Fincke et al., 2005; Pugh, Rosen et al.,
2008; Viswanathan, Bharmal et al. 2005; Zhan, Sangl et al. 2001; Zhang, Liu et al.,
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2011). Pugh et al. reported prevalence of PIM use in a sample of 850,154 veterans aged
65 years or older, using national inpatient and outpatient administrative data from a
national Veterans Affairs healthcare database (Pugh, Rosen et al. 2008). The study
sample comprised of individuals having with a minimum of one outpatient clinic visit in
1999 or 2000, and receiving a prescription medication in 2000. Potentially inappropriate
medications were defined based on all medications and medication categories listed in
Zhan criteria. Approximately 26.2 percent of veterans were found to have received PIMs
based on the Zhan criteria.
Barnett et al. compared rates of PIM use between ambulatory veterans receiving
care from the Veterans Affairs healthcare system and enrollees from private sector
Medicare health maintenance organizations (Barnett, Perry et al. 2006). They analyzed
Veteran Affairs healthcare administrative claims from ten different regions in the US for
123,633 veterans 65 years of age or older. Potentially inappropriate medications were
identified based on all 33 medications in the Zhan criteria. The PIM prevalence rate for
private sector patients was obtained from a prior study (Simon, Chan et al. 2005). The
authors found lower prevalence of PIM use in ambulatory veterans (21.3%) than private
sector patients (29.0%). Compared to private sector patients, ambulatory veterans had
lower prevalence of PIM use for all categories of medications in the Zhan criteria
including medications to always avoid (2.0% vs. 5%), medications that are rarely
appropriate (8.0% vs. 13.0%), and medication with some indications (15% vs. 17%).
Buck et al. compared prevalence of PIM use at ambulatory clinics in Utah and
Ohio using 2006 data from hospital electronic health records (Buck, Atreja et al. 2009).
They identified PIMs using all medications or medication categories listed in Zhan
criteria. The study population comprised of 61,251 patients aged 65 years or older with
multiple clinic visits within the prior two years. A total of 37,247 patients were from
Utah primary care clinics and 24,004 were from Ohio primary care clinics. Patients
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receiving care at ambulatory clinics in Utah had a lower prevalence of PIM prescriptions
(16.2%) than those receiving care in Ohio (17.3%). The receipt of PIMs classified in
Zhan criteria as “always avoid” was more prevalent in Utah clinics (1.7%) than Ohio
clinics. Compared to persons receiving care from Ohio clinics, those receiving care from
Utah clinics had a lower prevalence of PIMs classified as “always avoid” (1.7% vs.
1.9%), and “rarely appropriate” (7.0% vs. 9.5%). However, PIMs classified as having
some indications were more prevalent in Utah clinics than Ohio clinics (9.2% vs. 7.7%).
Fluoxetine and propoxyphene were the most commonly prescribed PIMs among patients
receiving care from Utah and Ohio clinics.
Pugh et al. determined extent of inappropriate prescribing among veterans aged
65 years or older using national Veteran Affairs Claims data from October 1999 to
September 2000 (Pugh, Fincke et al. 2005). They identified inappropriate medications
using all medications listed in Zhan criteria and dose-limitation criteria defined in the
1997 Beers criteria. They found 23 percent of individuals were prescribed at least one
PIM based on Zhan criteria and dose-limited drugs. Among individuals receiving PIMs,
17.5 percent received two PIMs, while 4.4 percent received 3 or more PIMs. The four
most commonly received PIM drug classes comprised 61.0 percent of all PIM use and
included pain relievers, musculoskeletal agents, antidepressants, and
benzodiazepines/hypnotics.
Zhang et al. compared prevalence of PIM use in older adults in 1996 and 2007
using Medical Expenditure Panel Survey data (Zhang, Liu et al. 2011). The study
population comprised of community-dwelling adults aged 65 years or older. They
identified PIMs using all medications and medication categories listed in Zhan criteria.
They found PIM rates decreased from 21.3 percent in 1996 to 13.8 percent in 2007.
Zhan et al. applied Zhan criteria to determine prevalence of PIM use in
community-dwelling adults aged 65 years or older using data from the 1996 Medical
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Expenditure Panel Survey (Zhan, Sangl et al. 2001). Potentially inappropriate
medications were identified using all medications and medication categories in the Zhan
criteria. They found 21.3 percent of individuals received at least one PIM. The most
frequently received PIMs were propoxyphene and amitriptyline.
Lane et al. applied a subset of Zhan criteria, consisting of medications classified
as always avoid or rarely appropriate, to 2001 data from a Canadian provincial drug plan
to examine patterns of PIM prescribing (Lane, Bronskill et al. 2004). A total of
1,216,900 community-dwelling adults aged 66 years and older were included in the study
sample. About 3.3 percent of individuals were found to have received PIMs and the most
commonly dispensed PIMs were diazepam, flurazepam, chlordiazepoxide, and
chlorpropamide.
Viswanathan et al. determined PIM prevalence using 2001 data from the National
Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care
Survey (Viswanathan, Bharmal et al. 2005). The study sample consisted of 7,243
ambulatory visits by individuals aged 65 years or more. They applied the “always avoid”
and “rarely appropriate” subset of medications listed in Zhan criteria and reported visitbased PIM prevalence rates. The authors found PIMs were prescribed in 4.2 percent of
ambulatory visits.
Goulding et al. examined trends in prevalence of PIM prescribing from 1995 to
2000 in patients aged 65 years or older visiting office-based physicians using data from
the National Ambulatory Care Survey (Goulding 2004). Potentially inappropriate
medications were identified using a subset of Zhan criteria that included medications
classified as to always avoid or rarely appropriate. The authors found of 3.7 percent of
all visits in 1995 and 3.8 percent of visits in 2000 were associated with the prescription of
PIMs. The prevalence of PIM use in 1995 was not significantly different from the rate of
use in 2000.
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McLeod Criteria/Improved Prescribing in the Elderly Tool
Only one study was found that determined prevalence of PIM use in ambulatory
settings based on McLeod Criteria (Fialova, Topinkova et al. 2005). Fialova et al.
estimated prevalence of PIM use among older adults receiving home care services in
metropolitan areas of eleven European countries including the Czech Republic, Denmark,
Finland, Iceland, Italy, the Netherlands, Norway, and the United Kingdom. A subset of
McLeod criteria was applied that consisted of medications considered inappropriate
regardless of drug-drug and drug-disease limitations. The study sample included 2,707
patients aged 65 years or older. The prevalence of PIM use based on McLeod criteria
varied significantly across the countries examined. Potentially inappropriate medication
rates were found to be 3.0 percent in Denmark, 4.4 percent in Iceland, 5.2 percent in the
United Kingdom, 6.8 percent in Italy, 7.6 percent in the Netherlands, 11.3 percent in
Norway, 14.4 percent in Finland, and 31.8 percent in the Czech Republic.
Screening Tool of Older Person’s potentially
Inappropriate Prescriptions (STOPP)
Two studies were found that determined PIM prevalence in ambulatory settings
based on the Screening Tool of Older Person’s potentially Inappropriate Prescriptions or
STOPP criteria (Bradley, Fahey et al., 2012; Ryan, O'Mahony et al. 2009). Ryan et al.
applied STOPP criteria to determine the prevalence of PIM prescriptions among 1329
ambulatory patients aged 65 years of age or older in the United Kingdom (Ryan,
O'Mahony et al. 2009). Study data was obtained from case records for patients visiting
two urban and one rural general practices in the Munster region of Ireland from 2007 to
2008. The authors reported that 21.4 percent of patients received PIMs. The five most
commonly prescribed PIM categories based on STOPP criteria among all PIMs
prescribed were proton-pump inhibitors for peptic ulcer disease at full therapeutic dosage
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for more than eight weeks (24.5%), long-term long-acting benzodiazepines (19.9%),
NSAIDs in patients with hypertension (11.3%), duplicate drug classes (8.4%), and
cardio-selective beta blockers in individuals with chronic obstructive pulmonary disease
(6.3%).
Bradley et al. estimated prevalence of PIM use in persons aged 70 years or older
in Northern Ireland (Bradley, Fahey et al. 2012). They applied STOPP criteria to July
2009 to June 2010 United Kingdom National Health Service Enhanced Prescribing data
and found 34 percent of the 166,108 individuals in the study population received PIMs.
Approximately 24.0 percent of individuals received one PIM, 7.2 percent received two
PIMs, and 2.8 percent received three or more PIMs. The most frequently received PIMs
among individuals in the study population were proton-pump inhibitors at maximum
therapeutic dose for more than 8 weeks (10.8%), non-steroidal anti-inflammatory drugs
for more than three months (8.8%), long-term long-acting benzodiazepines (6.1%), and
first-generation antihistamines (3.6%).
Medication Appropriateness Index
Three studies were found that determined prevalence of PIM use in ambulatory
settings based on the Medication Appropriateness Index or MAI (Castelino, Bajorek et
al., 2010; Lund, Carnahan et al. 2010; Rossi, Young et al., 2007). Lund et al. determined
the prevalence of inappropriate prescribing in ambulatory patients aged 65 years or older
based on all 10 criteria comprising the MAI (Lund, Carnahan et al. 2010). The study
population consisted of 231 veterans seen at primary care clinics at the Iowa City
Veterans Affairs Medical Center. They found that 98.7 percent of patients and 54.3
percent of medications had inappropriate rating on at least one MAI criterion. The
criteria with most frequent inappropriate ratings in patients were correct directions
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(93.2%), cost (74.6%), dosage (72.0%), practical directions (51.7%), and duration of
therapy (50.0%).
Castelino et al. assessed appropriateness of prescribing in 270 cases from a
collaborative service provided to community-dwelling older adults in Australia between
February 2006 and October 2009 (Castelino, Bajorek et al. 2010). Inappropriate
prescriptions were identified with all 10 criteria in the MAI. Prior to initiation of the
collaborative service almost all (99.0%) individuals had at least one inappropriate rating
on the MAI with 50.0 percent of individuals having a cumulative MAI score of 16 or
more.
Rossi et al. determined prevalence of unnecessary drug use among 128
community-dwelling veterans aged 60 years or older visiting a Veterans Affairs primary
care clinic in Pittsburgh (Rossi, Young et al. 2007). Unnecessary drug use was defined
with a subset of the MAI consisting of 3 specific questions on whether there was drug
indication, whether medication was effective for specific condition, and whether
unnecessary drug duplications were made. The authors reported 58.6 percent of patients
received one or more unnecessary prescriptions. The most common reasons for
unnecessary drug prescriptions were lack of effectiveness (41.4%), no indication
(39.8%), and therapeutic duplication (8.6%). The five most frequently prescribed
unnecessary drug classes were drugs affecting the central nervous system (19.5%),
gastrointestinal drugs (18.5%), vitamins (16.4%), nutrients/minerals/electrolytes (10.2%),
and cardiac drugs (10.2%).
Hospital Settings
Thirteen studies were found that determined prevalence of PIM use among older
adults in hospital settings (Barry, O'Keefe et al. 2006; Edwards, Harrison et al., 2003;
Finlayson, Maselli et al., 2011; Gallagher and O'Mahony 2008; Hajjar, Hanlon et al.,
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2005; Hanlon, Artz et al., 2004; Lang, Hasso et al., 2010; Liu, Peng et al., 2012; Onder,
Landi et al., 2005; Page and Ruscin 2006; Rothberg, Pekow et al., 2008; Vishwas,
Harugeri et al., 2012; Wawruch, Zikavska et al., 2006). Potentially inappropriate
medications were identified based several criteria including Beers criteria (1997 and 2002
versions), Zhan criteria, McLeod criteria/IPET, STOPP criteria, and MAI.
Beers criteria
Only one study was found that determined prevalence of PIM use in hospital
settings based on the 1997 Beers criteria (Edwards, Harrison et al. 2003). Edwards et al.
applied all drugs in 1997 Beers criteria to examine PIM prescribing at two units of a
tertiary care teaching hospital in North Carolina. Study participants were 65 years of age
or older and comprised of 176 patients from the hospital’s acute care of the elderly unit
and 173 patients from the hospital’s general medicine service unit. Potentially
inappropriate medications were grouped according to potential associations with high or
low severity adverse outcomes. Prevalence rates for PIMs with high or low-severity
outcomes in the acute care elderly unit were not significantly different from rates in the
general medicine service unit. Eleven percent of patients in the acute care of the elderly
unit were prescribed PIMs with high-severity outcomes as compared to 12.7 percent of
elderly patients in the general medicines unit. Also, 33.5 percent of patients in the acute
care elderly unit were prescribed PIMs with low-severity outcomes as compared to 30.1
percent of patients in the general medicine service unit. The most commonly prescribed
PIMs associated with high-severity outcomes were long-acting benzodiazepines (28.0%),
gastrointestinal antispasmodics (18.0%), ticlodipine (18.0%), and digoxin (18.0%) were
the most common. The most commonly prescribed PIMs associated with low-severity
outcomes were iron at doses greater than 325 mg per day (31%), and anticholinergic
antihistamines (23%).
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There were seven studies found that determined PIM prevalence in hospital
settings based on 2002 Beers criteria (Barry, O'Keefe et al. 2006; Gallagher and
O'Mahony 2008; Onder, Landi et al. 2005; Page and Ruscin 2006; Rothberg, Pekow et al.
2008; Vishwas, Harugeri et al. 2012; Wawruch, Zikavska et al. 2006). Wawruch et al.
compared the prevalence of PIM use at admission and discharge from a Slovak general
hospital between December 2003 and March 2005 (Wawruch, Zikavska et al. 2006).
They identified PIMs using all drugs in the 2002 Beers criteria. A total of 600 patients
aged 65 years and older were included in the study population. They found no significant
difference between PIM prevalence rates at hospital admission and discharge. Overall,
20.2 percent of patients received PIMs at admission compared to 20.0 percent of patients
receiving PIMs at discharge. The prevalence of PIM use for patients receiving one or
two PIMs was similar at hospital admission and discharge. Among patients receiving
PIMs at hospital admission, 18.2 percent received one PIM and 2.0% received two PIMs.
Among patients receiving PIMs at hospital discharge, 18.0% received one PIM and 2.0%
received two PIMs. The three most commonly prescribed PIM among patients at
admission and discharge were the same and included digoxin (7.3% vs. 7.2%), ticlopidine
(4.7% vs. 4.7%), and amiodarone (3.2% vs. 3.0%)
Vishwas et al. determined the prevalence of PIM prescribing in 540 patients aged
60 years or older, hospitalized between June 2009 and February 2010 in a tertiary care
hospital in India (Vishwas, Harugeri et al. 2012). Potentially inappropriate medications
were identified using all drugs in the 2002 Beers criteria. The reported PIM prevalence
rate based on the 2002 Beers criteria was 24.6%. The most frequently prescribed PIMs
were mineral oil, diazepam, digoxin, dicycloverine and chlorpheniramine
Gallagher et al. prospectively evaluated PIM use in a sample of 715 patients aged
65 years or older admitted to a university teaching hospital in the United Kingdom over a
four-month interval in 2007 (Gallagher and O'Mahony 2008). They defined PIMs using
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all drugs in the 2002 Beers criteria and found a PIM prevalence rate of 25.0 percent. The
most frequently used potentially inappropriate drugs or drug classes were
diphenhydramine, oxybutynin, fluoxetine, promethazine, and short-acting
benzodiazepines.
Barry et al. assessed the incidence of PIM prescribing among patients admitted to
an geriatric medicine unit in Ireland (Barry, O'Keefe et al. 2006). They identified PIMs
using all drugs in 2002 Beers criteria. The study population included 350 communitydwelling patients 65 years of age or older consecutively admitted to the hospital for acute
care between January and April 2003. Thirty-four percent of patients were found to have
received PIMs.
Page et al. reviewed data for 389 patients aged 75 years or older admitted to two
adult internal medicine units of a US university teaching hospital between 2000 and 2001
(Page and Ruscin 2006). They applied a subset of 2002 Beers criteria that consisted of
drugs considered generally inappropriate in older adults (excluding estrogens and
doxazosin), and drugs considered inappropriate beyond specific dose limits. A total of
27.5 percent of patients were found to have been prescribed PIMs. The most common
potentially inappropriate drugs or drug classes were amiodarone, oxybutin,
anticholinergics/antihistamines, long-acting benzodiazepines, and propoxyphene.
Onder et al. used a 2002 Beers criteria subset consisting of drugs considered
generally inappropriate in older adults and drugs considered inappropriate at doses
beyond specific limits, to identify PIM use in a sample of hospital patients in Italy
(Onder, Landi et al. 2005). They examined 5,152 patients aged 65 years or older
admitted to hospitals between 1997 and 1998 and found 28.6 percent of patients received
PIMs during their hospital stay. The PIMs most commonly received by patients were
ticlopidine, amiodarone, ketorolac, digoxin, and short-acting nifedipine.
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Rothberg et al. applied a subset of the 2002 Beers criteria consisting of drugs
considered generally inappropriate in older adults (excluding laxatives), and drugs
considered inappropriate at doses or durations beyond specific limits, to determine rate of
PIM prescribing in a large US inpatient sample (Rothberg, Pekow et al. 2008). They
examined medical records of 493,971 patients aged 65 years or more admitted to US
hospitals between September 2002 and June 2005, and found 49 percent of patients
received at least one PIM. The most prevalent PIMs were promethazine,
diphenhydramine, propoxyphene, clonidine, and amiodarone.
Zhan Criteria
One study was found that reported PIM prevalence in a hospital setting based on
Zhan criteria (Finlayson, Maselli et al. 2011). The authors determined PIM prevalence in
older adults undergoing surgery using data from the 2006 to 2008 Perspective database.
The study sample included 272,351 patients aged 65 years or older who underwent
elective inpatient surgery. Approximately 55.0 percent of patients were found to have
received PIMs during their hospital admission. One-quarter of patients received
medications categorized in Zhan criteria as always avoid or rarely appropriate.
Meperidine was the most commonly used PIM among medications categorized in Zhan
criteria as always avoid. Diazepam and cyclobenzaprine were the most commonly used
PIMs among medications categorized in Zhan criteria as rarely appropriate.
Diphenhydramine and promethazine were the most commonly used PIMs among
medications categorized in Zhan criteria as having some indications.
McLeod Criteria/Improved Prescribing in the Elderly Tool
One study was found that used the Improved Prescribing in the Elderly Tool or
IPET, an abbreviated version of the McLeod criteria to identify PIM prevalence in older
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hospitalized patients (Barry, O'Keefe et al. 2006). Barry et al. applied IPET to 350
patients aged 65 years or older admitted to an Irish geriatric medicine unit over a fourmonth period from January 2003 to April 2003. They reported a PIM prevalence rate of
22 percent, with approximately 14.6 percent of patients receiving one PIM, 5.1 percent
receiving two or more PIMs, and 2.3 percent receiving three or more PIMs. The most
frequently received inappropriate drugs or drug classes were benzodiazepines, chronic
NSAID use in persons with osteoarthritis, and NSAID use in persons with a history of
hypertension.
Screening Tool of Older Person’s potentially
Inappropriate Prescriptions (STOPP)
Four studies were found that used the STOPP criteria to examine PIM prevalence
in hospitalized older adults (Gallagher, Ryan et al. 2008; Lang, Hasso et al. 2010; Liu,
Peng et al. 2012; Vishwas, Harugeri et al. 2012). Vishwas et al. applied STOPP criteria
to determine prevalence of PIM use in 540 patients aged 60 years or older hospitalized
between June 2009 and February 2010 in a tertiary care hospital in India (Vishwas,
Harugeri et al. 2012). They reported a PIM prevalence of 13.3 percent. The most
frequently prescribed PIMs were glibenclamide in persons with type 2 diabetes mellitus,
chlorpheniramine, and diazepam in persons prone to falls.
Gallagher et al. determined prevalence of PIM use in 715 patients aged 65 years
or older admitted to a university teaching hospital in the United Kingdom over a fourmonth interval in 2007 (Gallagher and O'Mahony 2008). The authors reported PIM
prevalence of 35 percent based on STOPP criteria. The most common PIMs were longterm long-acting benzodiazepines, duplicate drugs, proton pump inhibitors for peptic
ulcer disease at full dose more than 8 weeks, and NSAIDs in persons with moderate to
severe hypertension.
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Liu et al. applied STOPP criteria to evaluate the prevalence of PIM use among
520 patients 65 years of age or older discharged from a Veterans general hospital in
Taiwan (Liu, Peng et al. 2012). They found 36.2 percent of patients received at least one
PIM, twenty-six percent received only one PIM, 6.3 percent received two PIMs, 2.7
percent received 3 PIMs, and 1.2 percent received 4 PIMs.
Lang et al. used STOPP criteria to examine prevalence of PIM use in 150 older
patients with cognitive and/or psychiatric comorbidities admitted to two geriatric units in
Switzerland between January 2008 and December 2008 (Lang, Hasso et al. 2010).
Seventy-seven percent of patients were found to have received PIMs. The most
frequently used PIMs were benzodiazepines and neuroleptics in persons prone to falls,
anti-depressants in persons with depression, calcium and vitamin D supplements in
persons with osteoporosis, and proton-pump inhibitors for peptic ulcer disease at full
therapeutic dosage for more than eight weeks.
Medication Appropriateness Index
Two studies were found that determined PIM prevalence in hospital settings
based on the Medication Appropriateness Index or MAI (Hajjar, Hanlon et al. 2005;
Hanlon, Artz et al. 2004). Hajjar et al. determined prevalence of unnecessary drug use at
hospital discharge among 384 frail patients aged 65 years or older at medical or surgical
wards of eleven US Veterans Affairs Medical Centers (Hajjar, Hanlon et al. 2005). The
authors applied a MAI subset consisting of three of ten MAI criteria including questions
on indication, efficacy, and therapeutic duplication. They found 44 percent of individuals
received at least one unnecessary drug at discharge. The most common reasons for
unnecessary drug use were lack of indication, lack of efficiency, and therapeutic
duplication.
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Hanlon et al. determined prevalence of inappropriate prescribing in hospitalized
older veterans using all criteria included in the MAI (Hanlon, Artz et al. 2004). They
examined 397 veterans aged 65 years or older at medical or surgical wards of eleven US
Veterans Affairs Medical Centers. Approximately 92.0 percent of patients had one or
more medications rated as inappropriate by one or more MAI criteria. The most common
reasons for inappropriate drug use were lack of cost-effectiveness, lack of practical
directions, and inappropriate dosage.
Nursing Home Settings
Eleven studies were found that determined PIM prevalence among older adult
residents of nursing homes (Beers, Ouslander et al., 1992; Chen, Tangiisuran et al., 2012;
Dedhiya, Hancock et al., 2010; Dhall, Larrat et al., 2002; Dhalla, Anderson et al., 2002;
Garcia-Gollarte, Baleriola-Julvez et al., 2012; Lane, Bronskill et al. 2004; Lau, Kasper et
al., 2004; Papaioannou, Bedard et al., 2002; Rigler, Jachna et al. 2005; Zuckerman,
Hernandez et al., 2005). Potentially inappropriate medications were identified based on
several criteria including Beers criteria (1991, 1997, and 2002 versions), Zhan criteria,
McLeod criteria, and STOPP criteria.
Beers criteria
Only one study was found that determined prevalence of PIM use in nursing
home settings based on 1991 Beers criteria (Beers, Ouslander et al. 1992). Beers et al.
evaluated appropriateness of prescriptions among 1,106 nursing home residents in Los
Angeles using the 1991 Beers criteria (Beers, Ouslander et al. 1992). Receipt of all
drugs comprising the 1991 Beers criteria was assessed. They found 40.0 percent of
individuals received at least one PIM and 10.0 percent received two or more PIMs.
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Five studies were found that applied 1997 Beers criteria to determine prevalence
of PIM use in nursing home settings (Dhall, Larrat et al. 2002; Dhalla, Anderson et al.
2002; Lau, Kasper et al. 2004; Rigler, Jachna et al. 2005; Zuckerman, Hernandez et al.
2005). Lau et al. examined data from the Nursing Home Component of the 1996 Medical
Expenditure Panel Survey to estimate prevalence of PIM prescriptions among 3,372
nursing home residents aged 65 years or older (Lau, Kasper et al. 2004). Potentially
inappropriate medications were identified using all drugs in the 1997 Beers criteria.
Among residents with a nursing home stay of 3 months or longer, 50.0 percent received
at least one PIM. The five most-commonly received PIMs were propoxyphene,
diphendydramine, hydroxine, oxybutynin, and cyproheptadine.
Dhall et al. used data from the Systematic Assessment of Geriatric Drug Use via
Epidemiology database on 44,562 older adults admitted to nursing homes, to examine
patterns of PIM use (Dhall, Larrat et al. 2002). They applied a subset of 1997 Beers
criteria consisting of drugs considered generally inappropriate in older adults and drugs
considered inappropriate at doses or durations beyond specific limits. Thirty-three
percent of individuals were found to use PIMs at admission to nursing home. The most
frequently used PIMs were propoxyphene (10.1%), digoxin (>0.125 mg/day, 5.2%), iron
supplements (ferrous sulphate >325 mg/day, 5.1%), amitriptyline (2.5%), and
diphendydramine (2.5%). Approximately 18.0 percent of individuals not using PIMs at
admission received them after admission. The most frequently initiated PIMs were
propoxyphene (5.1%), diphenhydramine (2.3%), hydroxyzine (1.6%), amitriptyline
(1.4%), and digoxin (1.5%).
Dhalla et al. used a subset of the 1997 Beers criteria to compare prevalence of
PIM prescribing before and after admission to nursing homes in Ontario, Canada (Dhalla,
Anderson et al. 2002). The subset of 1997 Beers criteria consisted of medications
considered generally inappropriate in older adults. The study population included 19,911
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individuals aged 65 years or older recently admitted to nursing homes in Ontario between
April 1997 and March 1999. The authors found prevalence of PIM use decreased from
25.4 percent before nursing home admission to 20.8 percent after nursing home
admission. The most frequently received potentially inappropriate drugs or drug classes
were benzodiazepines (7.7%), antidepressants (7.4%), oxybutynin (5.4%), platelet
inhibitors (2.9%), and narcotics (2.3%) in the one year before nursing home admission,
and antidepressants (6.4%), benzodiazepines (5.9%), oxybutynin (5.3%), platelet
inhibitors (2.8%), and NSAIDs (1.5%) in the one year after admission.
Zukerman et al. applied a subset of 1997 Beers criteria to compare prevalence of
PIM prescribing before and after nursing home admission in residents with and without
dementia (Zuckerman, Hernandez et al. 2005). The subset of 1997 Beers criteria
consisted of medications considered generally inappropriate in older adults. The study
population consisted of 546 dually eligible Medicaid and Medicare residents aged 65
years or older and admitted one of 59 nursing homes in Maryland between 1992 and
1995. Among nursing home residents without dementia, the mean monthly prevalence of
PIM use increased from 20 percent before nursing home admission to 28 percent after
admission. Among residents with dementia, mean monthly prevalence of PIM use
decreased from 23 percent before nursing home admission to 19 percent after admission.
The likelihood of receiving PIMs in residents with and without dementia was not
significantly different before and after nursing home admission.
Rigler et al. identified PIM use in a sample of 1,164 Kansas Medicaid
beneficiaries aged 60 years or older and resident in nursing homes, using a subset of 1997
Beers criteria consisting of drugs considered generally inappropriate in older adults
(Rigler, Jachna et al. 2005). Thirty-eight percent of individuals in the study sample were
found to have received PIMs. The most commonly used inappropriate drug classes were
analgesics (18.1%), and antihistamines (17.4%).
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Only one study was found that determined estimates of PIM use in nursing home
settings based on 2002 Beers criteria (Dedhiya, Hancock et al. 2010). Dedhiya et al.
applied 2002 Beers criteria to determine one-year incidence of PIM use among 7,594
nursing home residents 65 years of age or older enrolled in Indiana Medicaid in 2003.
Potentially inappropriate medications were identified using all drugs in the 2002 Beers
criteria. The one-year incidence of PIM use was found to be 42.1 percent.
Zhan Criteria
Only one study was found that determined prevalence of PIM use in nursing
home settings based on Zhan criteria (Lane, Bronskill et al. 2004). Lane et al. applied a
subset of Zhan criteria consisting of medications classified as always avoid and rarely
appropriate, to determine PIM prevalence in 58,719 nursing home residents aged 66 years
or older receiving drugs from a Canadian provincial drug plan in 2001. The authors
found 2.3 percent of nursing home residents were received PIMs. More specifically, 0.8
percent of nursing home residents received at least one PIM in the always avoid category,
and 1.5 percent received at least one PIM in the rarely appropriate category. The most
commonly received PIMs were diazepam (1.23%), Flurazepam (0.58%), and
chlordiazepoxide (0.25%).
McLeod Criteria/Improved Prescribing in the Elderly Tool
Only one study was found that determined prevalence of PIM use in nursing
home settings based on McLeod criteria (Papaioannou, Bedard et al. 2002). Papaioannou
et al. applied McLeod criteria to identify PIM prevalence using prescription data from a
single pharmacy serving long-term facilities in Ontario, Canada. Because disease
diagnosis could not be identified from the prescription data, drug prescriptions specific to
certain disease conditions were used to define PIMs listed under the “drug-disease
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interactions” category of McLeod criteria. The disease conditions were chronic
obstructive pulmonary disease, gout, glaucoma, benign prostrate hyperplasia, heart
failure, hypertension, peptic ulcer disease, and osteoarthritis. The authors examined 356
older long-term care residents receiving prescriptions in November 2000 and found a
PIM prevalence rate of 14.9 percent. Among PIM recipients, 37.7 percent received two
PIMs and 15.1 percent received three or more PIMs. The most commonly received PIM
prescriptions were long-term NSAID for osteoarthritis (21.7%), tricyclic antidepressants
with active metabolites for depression (20.5), and long-term NSAIDs in patients with a
history of heart failure or hypertension (15.7%).
Screening Tool of Older Person’s potentially
Inappropriate Prescriptions (STOPP)
Two studies were found that examined PIM prevalence in nursing home settings
based on STOPP criteria (Chen, Tangiisuran et al. 2012; Garcia-Gollarte, BaleriolaJulvez et al. 2012). Chen et al. applied STOPP criteria to determine PIM prevalence in
211 older residents of four nursing homes in Malaysia over a 2 month period in 2011
(Chen, Tangiisuran et al. 2012). They found 23.7 percent of individuals were prescribed
at least one PIM, and 5.2 percent prescribed 2 or more PIMs. The most common PIMs
prescriptions were for first generation antihistamines in individuals with a history of falls
(23.4%), duplicate drugs (15.6%), glibenclamide or chlorpropamide in individuals with
type II diabetes (10.9%), anticholinergics to treat extrapyramidal side-effects of
neuroleptic medications (9.4%).
Garcia-Gollarte et al. used STOPP criteria to determine prevalence of PIM use in
100 patients more than 65 years of age admitted to six assisted living nursing facilities in
Valencia, Spain in 2008 (Garcia-Gollarte, Baleriola-Julvez et al. 2012). Seventy-nine
percent of nursing home residents were found to have received at least one PIM, and 33
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percent received 2 or more PIMs. The most frequently prescribed PIMs were protonpump inhibitors for peptic ulcer disease at full therapeutic dosage for more than 8 weeks
(52%), benzodiazepines in persons prone to falls (36%), neuroleptic drugs in persons
prone to falls (26%), long-term neuroleptics as long term hypnotics (23%), and long-term
long-acting benzodiazepines and benzodiazepines with long-term metabolites (13%).
Residential Care/Assisted Living Settings
Five studies were found that determined prevalence of PIM use among older
adults living in residential care/assisted living facilities (Gray, Hedrick et al., 2003;
Parsons, Johnston et al., 2012; Rhoads and Thai 2003; Sloane, Zimmerman et al., 2002;
Stafford, Alswayan et al., 2011). The studies identified PIMs using several criteria
including Beers criteria (1997 and 2002 versions), McLeod criteria, and STOPP criteria.
Beers criteria
Three studies were found that examined PIM prevalence in residential care or
assisted living settings using 1997 Beers criteria (Gray, Hedrick et al. 2003; Rhoads and
Thai 2003; Sloane, Zimmerman et al. 2002). Sloane et al. applied a subset of 1997 Beers
criteria to examine PIM use in 2,014 residential care/assisted living residents aged 65
years and older from 193 facilities in four US states (Sloane, Zimmerman et al. 2002).
The Beers criteria subset consisted of medications considered generally inappropriate in
older adults, with the exception of flecainide, phenylbutazone, cyclandelate, haloperidol,
thioridazine, non-sedating antihistamines, oral iron preparations, digoxin, short-acting
benzodiazepines, and trazodone. About 16 percent of individuals received PIMs with the
most frequently received PIMs including oxybutin (16,8%), propoxyphene (15.2%),
amitriptyline (12.2%), diphendydramine (7.0%), and ticlopidine (7.0%).
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Rhoads et al. examined medication profiles of 456 residents aged 65 years or
older living in 124 US assisted living facilities (Rhoads and Thai 2003). The authors
defined PIMs using a subset of the 1997 Beers criteria consisting of medications
considered generally inappropriate in older adults and drugs considered inappropriate at
doses or durations beyond specified limits. They found 31.6 percent of residents received
PIMs. The most frequently received PIMs were oxybutin (19.6%), diphenhydramine
(15.2%), propoxyphene (10.8%), and promethazine (7.4%).
Gray et al. applied a modified subset of 1997 Beers criteria to determine PIM
prevalence and incidence in community residential care facilities (Gray, Hedrick et al.
2003). The study population comprised of 282 Medicaid recipients aged 65 years or
older admitted to a community residential facility in Washington State between April
1998 and December 1998. The criteria which consisted of medications considered
generally inappropriate in older adults (excluding digoxin), and drugs considered
inappropriate at doses or durations beyond specified limits, was modified to include
clonazepam, clorazepate, and prazepam. The prevalence of PIM use was found to be
22.0 percent at baseline and 43.7 percent during the follow-up period. The most
commonly received inappropriate drug classes at baseline were tricyclic antidepressants
(6.0%), antihistamines (5.3%), urinary antispasmodics (3.5%), and long-acting
benzodiazepines (3.5%). The most commonly received inappropriate drug classes during
the one-year follow up period were antihistamines (15.9%), tricyclic antidepressants
(9.0%), analgesics (9.0%), and urinary antispasmodics (6.9%). The incidence of new-use
of PIMs within the follow up period was 23.4 percent.
Only one study was found that determined PIM prevalence in residential care or
assisted living settings using 2002 Beers criteria (Stafford, Alswayan et al. 2011).
Stafford et al. applied 2002 Beers criteria to determine prevalence of inappropriate
prescribing in a sample of 2,345 individuals aged 65 years or older living in residential
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care homes in Tasmania, Australia between 2006 and 2007. They found 35.3 percent of
care home residents received at least one PIM. The most commonly received PIMs were
temazepam (30.6%), amitriptyline (16.3%), oxybutynin (11.7%), and estradiol (8.7%).
McLeod Criteria/Improved Prescribing in the Elderly Tool
Only one study determined prevalence of PIM use in residential care or assisted
living settings based on McLeod criteria (Stafford, Alswayan et al. 2011). In their study
on older adults living in residential care homes in Tasmania, Australia between 2006 and
2007, Stafford et al. applied McLeod criteria to determine prevalence of inappropriate
prescribing and found a PIM prevalence of 18.7 percent. The most commonly received
PIMs were dipyridamole in individuals with stroke or cerebrovascular accident (11.9%),
celecoxib in individuals with hypertension (7.3%), diazepam in individuals with dementia
(7.1%), celecoxib in individuals with osteoarthrosis (6.8%), and oxybutynin in
individuals with dementia (6.6%).
Screening Tool of Older Person’s potentially
Inappropriate Prescriptions (STOPP)
One study examined prevalence of PIM use in residential care settings using
STOPP criteria (Parsons, Johnston et al. 2012). Parsons et al. applied STOPP criteria to
estimate prevalence of inappropriate prescribing in 133 older adults with dementia living
in six residential care homes in England in 2011. A subset of STOPP criteria was used
consisting of 31 inappropriate medications identifiable in absence of concomitant disease
diagnosis. The prevalence of inappropriate prescribing was determined at two timepoints sixteen weeks apart. At the first time-point, 46.2 percent of individuals were
prescribed PIMs, and 9.2 percent prescribed two or more PIMs. At the second timepoint, 40.9 percent of individuals were prescribed PIMs, and 9.1 percent prescribed two
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or more PIMs. The most frequently used PIMs were the same at both time points and
included long term neuroleptics (21.0% versus 19.1%), proton-pump inhibitors at
maximum therapeutic dosage for more than 8 weeks (8.4% versus 9.1%), and long-term
use of NSAID for pain relief (9.2% versus 7.3%).
Emergency Department Settings
Five studies were found that assessed PIM prevalence in emergency department
patients (Chen, Hwang et al., 2009; Hustey, Wallis et al., 2007; Meurer, Potti et al., 2010;
Nixdorff, Hustey et al., 2008). Potentially inappropriate medications were defined based
on 1997 or 2002 Beers criteria.
Beers criteria
One study determined prevalence of PIM use in emergency department settings
based on 1997 Beers criteria (Chin, Wang et al., 1999). Chin et al. determined the
frequency of PIM prescriptions in 898 patients 65 years of age or older visiting an urban
academic emergency department in Chicago from October 1995 to June 1996. They
identified PIMs with a subset of the 1997 Beers criteria that consisted of medications
generally considered inappropriate in older adults, medications considered inappropriate
beyond specific duration limits, and medications considered inappropriate in individuals
with specific concomitant conditions. The prevalence of PIM use was assessed at three
time points including at presentation to emergency department, during emergency
department care, and at discharge from emergency department. The authors found PIM
prevalence was 10.6 percent at presentation to emergency department, 3.6 percent during
emergency department care, and 5.6 percent at discharge from emergency department.
The most commonly received PIMs during emergency department care were
diphenhydramine (25.7%), meperidine (20.0%), indomethacin (14.2%), and
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cyclobenzaprine (14.2%). The most commonly received PIMs at discharge from
emergency department were indomethacin (30.4%), diphenhydramine (26.0%), and
cyclobenzaprine (13.0%).
Four studies determined prevalence of PIM use in emergency department settings
using the 2002 Beers criteria (Chen, Hwang et al. 2009; Hustey 2008; Meurer, Potti et al.
2010; Nixdorff, Hustey et al. 2008). Chen et al. assessed PIM use with a subset of 2002
Beers criteria consisting of drugs considered generally inappropriate in older adults and
associated with high severity adverse outcomes (Chen, Hwang et al. 2009). They
examined 2001 to 2004 emergency department claims for older adults covered under
Taiwan’s National Health Insurance. They found 19.3 percent of patients visiting
emergency departments received at least one PIM annually, and 14.7 percent of all
emergency department visits were associated with PIM prescriptions. The most
commonly prescribed inappropriate drugs or drug categories were short acting nifedipine
(5.3%), muscle relaxants and antispasmodics (2.8%), antihistamines with anticholinergic
effect (1.9%), ketorolac (1.8%), and gastrointestinal antispasmodic drugs (1.4%).
Meurer et al. applied a 2002 Beers criteria subset consisting of drugs considered
generally inappropriate in older adults to examine emergency department visits of
discharged older adults using data from the 2000 to 2006 National Hospital Ambulatory
Medical Care Survey (Meurer, Potti et al. 2010). The authors found 16.8 percent of visits
were associated PIM prescriptions. Patients received one PIM in 13.3% of emergency
department visits, two PIMs in 3.0% of such visits, three PIMs in 0.5% of such visits, and
four PIMs in 0.04% of such visits. The most frequently received PIMs were
promethazine (5.1%), ketorolac (3.2%), propoxyphene (2.6%), meperidine (2.4%), and
diphenhydramine (1.2%).
Nixdorff et al. applied 2002 Beers criteria to examine PIM prevalence in 174
older adults presenting to the emergency department of an urban, tertiary care hospital
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(Nixdorff, Hustey et al. 2008). They found 29 percent of patients used PIMs at
presentation to the emergency department, 6.5 percent of patients received PIMs during
emergency department care, and 13 percent of patients prescribed medications at
discharge received PIMs. The most frequently prescribed PIMs were propoxyphene,
diphenhydramine, clonidine, naproxen, and doxazosin.
Hustey et al. determined prevalence of PIM use in 352 consecutive emergency
department visits by older adults at an urban teaching hospital during a two-week period
in June 2004 (Hustey, Wallis et al. 2007). Inappropriate medications were identified with
the 2002 Beers criteria. Thirty-two percent of patients were using PIMs upon
presentation at the emergency department with the most common inappropriate drugs or
drug classes including propoxyphene (7%), muscle relaxants (4%), antihistamines (3%),
and amiodarone (3%). Thirteen percent of patients receiving a prescription at discharge
from the emergency department were prescribed PIMs.
Unspecified Care Settings
Four studies were found that determined prevalence of PIM use among older
adults without indicating setting of care (Akazawa, Imai et al. 2010; Fahlman, Lynn et al.
2007; Mort and Sailor 2011; Simon, Chan et al. 2005). The patient populations included
managed care beneficiaries (Fahlman, Lynn et al. 2007; Simon, Chan et al. 2005),
Medicare Part D beneficiaries (Mort and Sailor 2011), and beneficiaries from an
employer’s health insurance plan (Akazawa, Imai et al. 2010). Potentially inappropriate
medications were identified using 2002 Beers criteria (Akazawa, Imai et al. 2010; Mort
and Sailor 2011), and Zhan criteria (Fahlman, Lynn et al. 2007; Simon, Chan et al. 2005).
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Beers criteria
Akazawa et al. applied a modified subset of 2002 Beers criteria to determine PIM
use among Japanese patients aged 65 years or older (Akazawa, Imai et al. 2010). The
modified Beers criteria subset consisted of drugs that should generally be avoided in
older Japanese patients. Health insurance claims data from 2006 to 2007 were examined
for 6,628 patients receiving at least two pharmacy claims in separate months. The
prevalence of PIM use in the study population was 43.6 percent with the most commonly
prescribed inappropriate drug classes including histamine blockers (20.5%),
benzodiazepines (11.4%), and anticholinergics and antihistamines (7.9%).
Mort and Ryan compared the prevalence of PIM use between American Indians
and all other Medicare Part D beneficiaries in South Dakota using Medicare Part D
claims data from April 2009 to September 2009 (Mort and Sailor 2011). They used a
subset of the 2002 Beers criteria comprising of 18 PIMs selected by the Center for
Medicaid and Medicare Services. The prevalence of PIM use was over two times higher
in American Indian Medicare Part D beneficiaries (28.7%) than in other Medicare Part D
beneficiaries (14.4%). The PIMs most frequently received by American Indian Medicare
beneficiaries were skeletal muscle relaxants (37.9%), propoxyphene (33.7%),
antihistamines (19.3%), nitrofurantoin (16.1%), and ketorolac (6.6%). The PIMs most
frequently received by other Medicare beneficiaries were propoxyphene (43.7%),
nitrofurantoin (19.4%), skeletal muscle relaxants (18.6%), oral estrogens (13.4%),
antihistamines (7.9%).
Zhan Criteria
Simon et al. applied Zhan criteria to determine prevalence of PIM use in 157, 517
managed care enrollees aged 65 years or older, using 2001 to 2002 data from managed
care plans in the US (Simon, Chan et al. 2005). They found 28.8 percent of enrollees
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received PIMs. The most commonly prescribed PIMs included propoxyphene (7.0%),
amitriptyline (3.7%), oxybutynin (3.4%), cyclobenzaprine (2.9%), diazepam (2.8%), and
promethazine (2.8%).
Fahlman et al. applied Zhan criteria to examine PIM use in 4,602 Medicare plus
Choice beneficiaries in their last year of life, using January 1998 to December 2000 data
from a large national managed care organization (Fahlman, Lynn et al. 2007). Forty-four
percent of beneficiaries received at least one PIM and 15 percent received two or more
PIMs. The most frequently received PIMs were propoxyphene (15%), zolpiderm (3.8%),
and amitriptyline (2.8%).
Summary
Sixty-eight studies were found that reported PIM prevalence rates among older
adults, with reported rates varying from 2.3 percent to 99.0 percent according to the
specific criteria used to identify PIMs, whether all elements of these criteria or subsets
were applied, the setting care was received in, and how PIM prevalence rates were
calculated. Higher rates were reported in studies identifying PIMs with the MAI
followed by studies identifying PIMs with STOPP or Beers criteria. Higher PIM rates
were reported in studies identifying PIMs using all drugs or drug classes in the Beers
criteria, Zhan criteria, McLeod criteria, STOPP criteria, or the MAI relative to studies
identifying PIMs with subsets of these criteria. Higher PIM rates were reported in studies
on ambulatory populations relative to studies on hospital, nursing home, residential
care/assisted living, or emergency department populations. Studies reporting patientbased PIM prevalence had higher rates than those reporting visit-based PIM prevalence.
The studies using Beers criteria to identify PIMs applied 1991, 1997, or 2002
versions of the criteria. No studies were found that determined prevalence of PIM use
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among older adults using the 2012 Beers criteria which is the most current version of the
Beers criteria.
Risk Factors for PIM Use
Forty-four studies were found that examined patient, health-system, and provider
risk-factors for PIM use in older adults. The studies and findings are described below.
Patient
Patient factors examined for associations with PIM use in older adults include
age, gender, race, education, polypharmacy, number of comorbid conditions, mental
comorbidity, self-reported health status, functional status, and number of physician visits.
Age
Studies examining associations between age and PIM use report mixed findings.
Of nineteen studies found examining such associations, advancing age was associated
with higher risk for PIM use in six studies (Cahir, Fahey et al., 2010; Lin, Liao et al.,
2008; Liu, Peng et al. 2012; Maio, Del Canale et al., 2010; Mort and Aparasu 2000;
Wawruch, Fialova et al., 2008), advancing age was associated with lower risk of PIM use
in seven studies (Chen, Hwang et al. 2009; Dhalla, Anderson et al. 2002; Finlayson,
Maselli et al. 2011; Goulding 2004; Lau, Kasper et al. 2004; Meurer, Potti et al. 2010;
Rothberg, Pekow et al. 2008), and no associations were found between advancing age
and PIM use in six studies (Akazawa, Imai et al. 2010; Hajjar, Hanlon et al. 2005;
Howard, Dolovich et al. 2004; Parsons, Johnston et al. 2012; Skaar and O'Connor 2012;
Stuck, Beers et al. 1994).
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Gender
The findings on associations between gender and PIM use in older adults are
mixed. Of twenty-two studies examining such associations, females were found to be at
higher risk for PIM use than men in sixteen studies (Buck, Atreja et al. 2009; Cahir,
Fahey et al. 2010; Chen, Hwang et al. 2009; Dhall, Larrat et al. 2002; Fahlman, Lynn et
al. 2007; Finlayson, Maselli et al. 2011; Goulding 2004; Howard, Dolovich et al. 2004;
Lin, Liao et al. 2008; Maio, Del Canale et al. 2010; Meurer, Potti et al. 2010; Pugh,
Fincke et al. 2005; Rothberg, Pekow et al. 2008; Skaar and O'Connor 2012; Zhan, Sangl
et al. 2001; Zhang, Liu et al. 2011), and gender was not associated with PIM use in six
studies (Akazawa, Imai et al. 2010; Chen, Tangiisuran et al. 2012; Hajjar, Hanlon et al.
2005; Parsons, Johnston et al. 2012; Stuck, Beers et al. 1994; Wawruch, Fialova et al.
2008).
Ethnicity
The findings on associations between ethnicity and PIM use in older adults are
mixed. Of nine studies examining such associations, whites were found to be at higher
risk for PIM use than non-whites in three studies (Fahlman, Lynn et al. 2007; Finlayson,
Maselli et al. 2011; Rothberg, Pekow et al. 2008), Hispanics were found to be at higher
risk for PIM use than non-Hispanics in one study (Pugh, Fincke et al. 2005) and race was
not associated with PIM use in five studies (Goulding 2004; Hajjar, Hanlon et al. 2005;
Meurer, Potti et al. 2010; Skaar and O'Connor 2012; Zhan, Sangl et al. 2001).
Education
Studies examining associations between education and PIM use in older adults
report mixed findings. Of five studies that examined such associations, less education
was found to be associated with higher risk for PIM use in two studies (Lau, Kasper et al.
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2004; Skaar and O'Connor 2012), while education was not associated PIM use in three
studies (Hajjar, Hanlon et al. 2005; Howard, Dolovich et al. 2004; Zhan, Sangl et al.
2001).
Income
Three studies were found that examined associations between income and PIM
use in older adults and they report mixed findings (Skaar and O'Connor 2012; Stuck,
Beers et al. 1994; Zhang, Liu et al. 2011). Skaar et al. found associations between
belonging to a lower income bracket and higher risk for PIM use. Zhang et al. found
associations between belonging to a middle income bracket and higher risk for PIM use.
Stuck et al. found no associations between income and PIM use.
Polypharmacy
Polypharmacy in older adults was associated with higher risk for PIM use in all
twenty-nine studies found that examined such associations (Akazawa, Imai et al. 2010;
Aparasu and Mort 2000; Aparasu and Sitzman 1999; Bao, Shao et al. 2012; Bradley,
Fahey et al. 2012; Buck, Atreja et al. 2009; Cahir, Fahey et al. 2010; Chen, Tangiisuran et
al. 2012; Chen, Hwang et al. 2009; Dhall, Larrat et al. 2002; Gallagher, Lang et al., 2011;
Goulding 2004; Gray, Hedrick et al. 2003; Hajjar, Hanlon et al. 2005; Hanlon, Artz et al.
2004; Lang, Hasso et al. 2010; Lau, Kasper et al. 2004; Lau, Mercaldo et al., 2010; Lin,
Liao et al. 2008; Liu, Peng et al. 2012; Maio, Del Canale et al. 2010; Meurer, Potti et al.
2010; Parsons, Johnston et al. 2012; Pugh, Fincke et al. 2005; Sloane, Zimmerman et al.
2002; Stafford, Alswayan et al. 2011; Wawruch, Fialova et al. 2008; Zhan, Sangl et al.
2001; Zhang, Liu et al. 2011).
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Number of Comorbid Conditions
There were mixed findings from studies examining associations between number
of comorbid conditions and PIM use in older adults. Of nine studies examining such
associations, having more comorbid conditions was associated with higher risk for PIM
use in six studies (Hanlon, Artz et al. 2004; Lin, Liao et al. 2008; Maio, Del Canale et al.
2010; Rigler, Perera et al., 2004; Skaar and O'Connor 2012; Stafford, Alswayan et al.
2011). The number of comorbid conditions was not associated with PIM use in three
studies (Chen, Tangiisuran et al. 2012; Hajjar, Hanlon et al. 2005; Stuck, Beers et al.
1994).
Mental Status
Eleven studies were found that examined associations between mental status and
PIM use in older adults. Five studies specifically examined associations between
depression diagnosis and PIM use and found individuals with depression had higher risk
for PIM use (Akazawa, Imai et al. 2010; Aparasu and Sitzman 1999; Finlayson, Maselli
et al. 2011; Stuck, Beers et al. 1994; Wawruch, Fialova et al. 2008). Two studies
examined associations between psychiatric comorbidity and PIM use and found
individuals with psychiatric comorbidities had higher risk for PIM use (Pugh, Fincke et
al. 2005; Stafford, Alswayan et al. 2011). Four studies specifically examined
associations between cognitive impairment and PIM use in older adults and they reported
mixed findings (Dhall, Larrat et al. 2002; Gray, Hedrick et al. 2003; Lang, Hasso et al.
2010; Sloane, Zimmerman et al. 2002). Cognitive impairment was associated with
higher risk for PIM use in the study by Lang et al., but associated with lower risk for PIM
use in the studies by Dhall et al. and Sloane et al. The study by Gray et al. found no
associations between cognitive impairment and PIM use.
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Self-Reported Health Status
The findings on associations between older adults’ self-reported health status and
PIM use in older adults are mixed. Of seven studies assessing such associations, a lower
health status rating was associated with higher risk for PIM use in five studies (Gray,
Hedrick et al. 2003; Hanlon, Artz et al. 2004; Skaar and O'Connor 2012; Zhan, Sangl et
al. 2001; Zhang, Liu et al. 2011), and health status was not associated with PIM use in
two studies (Hajjar, Hanlon et al. 2005; Howard, Dolovich et al. 2004).
Functional Status
Four studies were found that assessed associations between functional status and
PIM use in older adults and they report mixed findings (Dhall, Larrat et al. 2002; Hajjar,
Hanlon et al. 2005; Stuck, Beers et al. 1994; Wawruch, Fialova et al. 2008). The studies
by Dhall et al. and Wawruch et al. found associations between lower functional status and
PIM use, but studies by Hajjar et al. and Stuck et al. found no such associations.
Number of Care Visits
Two studies were found that examined associations between number of care visits
by older adults and PIM use (Buck, Atreja et al. 2009; Pugh, Fincke et al. 2005). Both
studies found associations between higher number of care visits and higher risk for PIM
use.
Health-System
Health-system factors that have been assessed for associations with PIM use in
older adults include geographic location, rural/urban location, and facility size.
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Geographic Location
Studies examining associations between geographic location and PIM use in older
adults report mixed findings. Five studies found a lower risk for PIM use in individuals
receiving care in the US northeast region as compared to those receiving care in other US
regions (Finlayson, Maselli et al. 2011; Meurer, Potti et al. 2010; Mort and Aparasu
2000; Rothberg, Pekow et al. 2008; Zhang, Liu et al. 2011). One study found a higher
risk for PIM use in individuals receiving care in the southern or western US regions as
compared to those receiving care in other US regions (Skaar and O'Connor 2012). Two
studies found no associations between the geographic location care was received in and
PIM use (Goulding 2004; Zhan, Sangl et al. 2001).
Metropolitan Status
Two studies were found that examined associations between metropolitan status
of residence and PIM use in older adults (Meurer, Potti et al. 2010; Mort and Aparasu
2000). Both studies found individuals receiving care in non-metropolitan areas were
more likely than those in metropolitan areas to use PIMs.
Size
Three studies were found that examined associations between facility size and
PIM use in older adults (Beers, Ouslander et al. 1992; Lau, Kasper et al. 2004; Sloane,
Zimmerman et al. 2002). The studies by Beers et al. and Lau et al. found associations
between larger facility size and higher risk for PIM use, whereas, the study by Sloane et
al. found no such associations.
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Provider
Provider factors assessed for associations with PIM use in older adults include
age, sex, specialty, location, knowledge, communication, and competence.
Age
In the two studies found that examined associations between provider age and
PIM use by older adults, advancing provider age was associated with higher risk for PIM
use (Chen, Hwang et al. 2009; Dhalla, Anderson et al. 2002).
Gender
Three studies were found that examined associations between provider gender and
PIM use in older adults and report mixed findings (Chen, Wynia et al., 2009; Dhalla,
Anderson et al. 2002; Howard, Dolovich et al. 2004). The study by Dhalla et al. found
higher risk for PIM use in individuals seeing male providers as compared to those seeing
female providers. In contrast, the study by Chen et al. found higher risk for PIM use in
individuals seeing female providers as compared to those seeing male providers. The
study by Howard et al. found no associations between provider gender and PIM use.
Specialty
Seven studies were found that examined associations between provider specialty
and PIM use in older adults. Two studies found higher risk for PIM use found in
individuals receiving care from general medicine practitioners (Akazawa, Imai et al.
2010; Dhalla, Anderson et al. 2002) or psychiatrists/neurologists (Akazawa, Imai et al.
2010) than those receiving care from other specialist providers. One study found higher
risk for PIM use in individuals receiving care from orthopedic surgeons as compared to
those receiving care from general surgeons (Finlayson, Maselli et al. 2011). Four studies
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found higher risk for PIM use in individuals receiving care from non-geriatricians as
compared to those receiving care from geriatricians (Monroe, Carter et al., 2011; Pugh,
Rosen et al. 2008; Rothberg, Pekow et al. 2008). One study found no associations
between provider specialty and PIM use (Hanlon, Artz et al. 2004).
Location
Four studies were found that examined associations between provider location
and PIM use in older adults (Aparasu and Sitzman 1999; Dhalla, Anderson et al. 2002;
Goulding 2004; Mort and Aparasu 2000). The studies by Aparasu et al., Dhalla et al.,
and Mort et al. found that providers practicing in non-metropolitan areas were more
likely than those practicing in metropolitan areas to prescribe PIMs, but the study by
Goulding et al. found no associations between provider location and the likelihood of
older adults receiving PIMs.
Communication
Only one study was found that examined associations between objective
assessments of provider communication and medication use (Kawasumi, Ernst et al.,
2011). Kawasumi et al. found no associations between provider communication based on
test scores from a physician licensing examination and use of recommended
corticosteroids in individuals with out-of-control asthma. However, they focused on use
of only one medication class and excluded persons aged 65 years or older who are at
higher risk for problems with drug therapy.
Patients’ perceptions of care quality are considered to be an essential component
of care quality assessment (Haddad, Potvin et al., 2000; Sofaer and Firminger 2005).
Patients who perceive their providers as effective communicators have been reported to
have outcomes that suggest higher care quality including higher satisfaction with care
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(Curtis, Patrick et al., 1999; Little, Everitt et al., 2001; Ruiz-Moral, Perez Rodriguez et
al., 2006; Zachariae, Pedersen et al., 2003), increased adherence to therapy (Schneider,
Kaplan et al., 2004; Schoenthaler, Chaplin et al., 2009), less anxiety during treatment
(Rouse and Hamilton 1990), better disease self-management (Heisler, Bouknight et al.,
2002), and lower diagnostic testing expenditures (Epstein, Franks et al., 2005). No
studies were found that examined associations between perceptions of provider
communication and PIM use in older adults. Such information may provide important
information on PIM use in this population.
Knowledge
Only one study was found that examined associations between objective
assessments of provider knowledge and medication use (Grad, Tamblyn et al., 1997).
Grad et al. found no associations between provider knowledge of appropriate nonsteroidal anti-inflammatory drug prescribing in older adults and quality of therapeutic
management. However, the authors focused on use of only one medication class and
analyzed a sample size of 37 physicians raising questions as to whether the study was
adequately powered to detect significant associations.
Patients who perceive their providers to have adequate knowledge have been
reported to have outcomes that suggest improved care quality including higher
satisfaction with care (Sullivan, Stein et al., 2000; Topacoglu, Karcioglu et al., 2004) and
increased adherence to provider advice (Safran, Taira et al., 1998). No studies were
found that examined associations between perceptions of provider knowledge and PIM
use in older adults. Such information may provide important information on PIM use in
this population.
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Competence
Only one study was found that examined associations between objective
assessments of provider competence and medication use (Kawasumi, Ernst et al. 2011).
Providers with higher competence, based on test scores from Part I (OR=1.06, 95%
CI=1.02 to 1.11) and Part II (OR=1.07, 95% CI=1.02 to 1.11) of a physician licensing
examination, were more likely to engage in appropriate prescribing of recommended
corticosteroids in individuals with out-of-control asthma.. The authors focused on use of
one medication class and excluded persons aged 65 years or older who are at higher risk
for problems with drug therapy.
Patients who perceive their providers to be competent have been reported to have
outcomes that suggest higher healthcare quality including higher satisfaction with care
(Mehta, Zenilman et al., 2005; Rhee and Bird 1996) and increased adherence to
medications (Cecere, Slatore et al., 2012). No studies have examined associations
between perceptions of provider competence and PIM use in older adults. Such
information may provide important information on PIM use in this population.
Summary
Factors consistently found to be risk factors for PIM use in older adults include
polypharmacy (29 of 29 studies), depression or other psychiatric mental comorbidity (7
of 7 studies), non-geriatric or general medicine provider specialty (5 of 5 studies), and
advancing provider age (2 of 2 studies). Patient factors including female gender (16 of
22 studies), higher number of comorbid conditions (6 of 9 studies), and poor or fair selfreported health status (5 of 7 studies), were found to be significant risk factors for PIM
use in over 65 percent of studies assessing such relationships. Similarly, health system
factors including non-northeast US geographic region (5 of 7 studies), rural location (2 of
3 studies), and larger facility size (2 of 3 studies) were found to be significant risk factors
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for PIM use in over 65 percent of studies examining these relationships. A nonmetropolitan provider location was found to be a significant risk-factor for receiving
PIMs in 3 of 4 studies assessing such associations. Patient race (4 of 9 studies),
education level (2 of 5 studies), and income (1 of 3 studies) were found to be significant
risk-factors for PIM use in less than half of studies assessing such relationships. An
equal number of studies found positive associations, negative associations, or no
associations between patient age, functional status, or provider gender and PIM use.
Studies examining the impact of provider communication, provider knowledge, or
provider competence on medication use based on objective assessments of such provider
behavior are rare. The two studies found that assessed associations between these
provider behaviors and medication use only examined use of one specific medication
class, and neither study examined medication use in a broad category such as PIMs. No
studies were found that examined associations between patient perceptions of provider
communication, provider knowledge, or provider competence and PIM use.
Need for Research
The challenges of medication therapy in older adults place them at risk for PIM
use and associated adverse outcomes including higher morbidity, mortality and increased
healthcare expenditures (Guaraldo, Cano et al. 2011; Spinewine, Schmader et al. 2007).
The Beers criteria are the most accepted and commonly used measure of PIM use in older
adults, and were recently revised in 2012. However, prevalence of PIM use in older
adults based on the 2012 Beers criteria has not been reported.
Providers who are effective communicators, knowledgeable, and competent
should be able to elicit adequate information from patients about their conditions and
medication history, and translate such information into accurate diagnoses and
appropriate therapy. Because patient perceptions of provider communication, provider
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knowledge, and provider competence have been associated with measures of healthcare
quality including satisfaction with care and adherence to therapy, it is expected that
patient perceptions of such provider behavior would be associated with PIM use, another
measure of health quality. However, evidence is lacking on whether patient perceptions
of provider communication, provider knowledge, or provider competence are associated
with PIM use. This study will inform on possible associations between perceived
communication, perceived provider knowledge, and perceived provider competence and
PIM use and findings may provide important insights on PIM use in older adults.
Objectives
Study objectives were to:
1. Determine prevalence of PIM use among community-dwelling Medicare Part D
beneficiaries
2. Determine incidence of PIM use among community-dwelling Medicare Part D
beneficiaries,
3. Examine associations between perceived provider communication and PIM use
among community-dwelling Medicare Part D beneficiaries,
4. Examine associations between perceived provider knowledge and PIM use among
community-dwelling Medicare Part D beneficiaries, and
5. Examine associations between perceived provider competence and PIM use
among community-dwelling Medicare Part D beneficiaries.
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METHODS

Objectives
The objectives of this study were to determine prevalence and incidence of PIM
use among community-dwelling Medicare Part D beneficiaries and to assess associations
between patient perceptions of provider communication, provider knowledge, and
provider competence with PIM use among community-dwelling Medicare Part D
beneficiaries.
Data Source
Data for analysis was obtained from the Medicare Current Beneficiary Survey
files maintained by the Centers for Medicare and Medicaid Services. The Medicare
Current Beneficiary Survey includes a nationally representative sample of the Medicare
population, covering ambulatory and institutionalized Medicare beneficiaries who are
aged and/or disabled. Medicare Current Beneficiary Survey files contain enrollmentrelated information, responses to survey questions, data on use of medical services, and
pharmacy claims linked to the survey.
Ethical Considerations
Permission for use of the Medicare Current Beneficiary Survey data was obtained
via a data use agreement. Institutional Review Board approval for the study was obtained
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from the Committee on the Use of Human Subjects in Research at Purdue University,
West Lafayette, Indiana.
Study Sample for Prevalence of PIM Use
Inclusion criteria for individuals in the prevalence sample were age 65 years or
older in 2008, enrolled in Medicare Part D for consecutive months from October 2007 to
December 2008, and living in the community from October 2007 to December 2008.
There were no exclusion criteria for the prevalence sample.
Study Sample for Incidence of PIM Use
Inclusion criteria for individuals in the incidence sample were age 65 years or
older in 2008, enrolled in Medicare Part D for consecutive months from October 2007 to
December 2008, and living in the community from October 2007 to December 2008.
The exclusion criterion for individuals in the incidence sample was receiving PIMs at any
time between October 2007 and December 2007.
Study Variables
Demographic Variables
Demographic variables included age, gender, ethnicity, education, income, and
region. Age was identified in each of two categories, 65 to 84 years, or 85 years or older.
Ethnicity was identified in each of two categories, white, or non-white. Education was
identified in each of four categories, 8th grade or less, 9th to 12th grade/high school
graduate, post high school education excluding college graduation, or college
graduate/post graduate. Income was identified in each of four categories, zero to 15,000
dollars; 15,001 to 30,000 dollars; 30,001 to 45,000 dollars; or more than 45,000 dollars.
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United States census regions were identified in each of four categories, West, Midwest,
Northeast, or South/Puerto Rico.
Clinical Variables
Depression Diagnosis
Individuals with depression were identified using ICD-9 CM codes for depression
from January 2007 through December 2008. Three sources of information were used to
identify ICD-9 CM codes for depression. The first source was a systematic search of the
Medline database from 2008 to 2013, using ‘ICD-9 CM code’ and ‘depression’ as
keywords to identify published articles describing use of ICD-9 CM codes to identify
diagnosis for depression. The second source was an online searchable database of ICD-9
CM codes compiled from files available from the National Center for Health Statistics
(National Center for Health Statistics 2009). To identify ICD-9 CM codes for depression
using this database, the term ‘depression’ was entered into the database search engine.
The third source was the Clinical Classifications Software for ICD 9-CM maintained by
the Agency for Healthcare Resource and Quality and available online (Agency for
Healthcare Research and Quality 2010). Depression specific ICD-9 CM codes were
identified from the Clinical Classification Software by manually searching appendices
documenting ICD-9 CM codes for specific diagnoses. The ICD-9 CM codes for
depression identified in at least two of the three sources were used to identify individuals
with depression. A variable was created to indicate whether individuals had diagnosis for
depression in 2007 or 2008 and assigned a value of ‘1’ if the individual had an ICD-9
CM code for depression in 2007 or 2008. Otherwise a value of ‘0’ was assigned to the
variable.
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Self-reported Health Status
Self-reported health status in 2008 was assessed using individuals’ response to the
survey question asking them to compare their general health to others the same age.
Individuals’ responses were categorized as poor, fair, good, or very good/excellent.
Number of Unique Medications
A variable indicating the number of unique medications received by each
individual in 2008 was created. A unique medication was defined as one count of a
unique and distinct active ingredient. A count of unique medications prescribed to each
individual was calculated by summing all unique medications prescribed to each
individual in 2008. The number of unique medications received by each individual was
identified in each of four categories, 0 to 5 medications, 6 to 10 medications, 11 to 15
medications, or more than 15 medications.
Potentially Inappropriate Medications (PIMs)
Potentially inappropriate medications (PIMs) listed in the 2012 Beers criteria
(American Geriatrics Society 2012 Beers Criteria Update Expert Panel 2012) (Appendix
Table A1) were identified in each of four broad categories including inappropriate drug
choice, excess dose, excess duration, and drug-disease interaction.
Inappropriate Drug Choice Category
These represent medications considered always potentially inappropriate in
persons aged 65 years or older. For each individual, the receipt of medications in 2008 in
the inappropriate drug choice category was identified. A separate variable was created
for each medication and the variable assigned a value of ‘1’ if the individual received
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medication associated with that specific variable in 2008. Otherwise, a value of ‘0’ was
assigned to the variable.
Some medications in the inappropriate drug choice category are considered
potentially inappropriate except when used to treat certain conditions. For each
individual, the receipt of medications considered potentially inappropriate except for
certain conditions in 2008 were identified. A separate variable was created for each
medication and the variable assigned a value of ‘1’ if the individual received the
medication in 2008 but not as treatment for the specific condition for which use of the
medication is not considered inappropriate. Otherwise, a value of ‘0’ was assigned to the
variable. Individual medications and medication classes considered inappropriate except
for certain conditions include growth hormone, metoclopramide, methyltestosterone,
testosterone, topical vaginal estrogen creams, and antispasmodics.
Growth hormone is considered potentially inappropriate, except when used as
hormone replacement after pituitary gland removal. An individual was considered to
have received growth hormone as hormone replacement after pituitary gland removal in
2008 if they received growth hormone in 2008 and had a prior record of pituitary gland
removal in 2007 or 2008. Metoclopramide is considered potentially inappropriate except
when used to treat gastroparesis. An individual was considered to have received
metoclopramide for treatment of gastroparesis if they received metoclopramide in 2008,
had prior diagnosis for gastroparesis in 2007 or 2008, and did not have prior diagnosis in
2007 or 2008 for another condition for which metoclopramide is indicated. A list of
conditions for which metoclopramide is indicated was compiled using the Micromedex,
and Drugs Facts and Comparison databases.
Methyltestosterone and testosterone are considered potentially inappropriate
except when used for treatment of moderate to severe hypogonadism. However, because
records to identify hypogonadism severity were not available, use of these drugs were
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neither identified nor included in PIM analysis. Topical vaginal estrogen creams are
considered potentially inappropriate except when low-dose estrogen creams are used for
treatment of dyspareunia, lower urinary tract infections, or other vaginal symptoms.
However, because conditions comprising ‘other vaginal symptoms’ were neither
mentioned in the 2012 Beers criteria nor could be independently identified, these drugs
were neither identified nor included in PIM analysis. Antispasmodics including
belladonna alkaloids, clidinium-chlordiazepoxide, dicyclomine, hyoscyamine,
propantheline, and scopolamine are considered potentially inappropriate except when
used in short-term palliative care to decrease oral secretions. However, because records
to identify individuals receiving short-term palliative care were not available, these drugs
were neither identified nor included in PIM analysis.
Individuals with a diagnosis of each condition were identified using ICD-9 CM
codes from January 2007 through December 2008. Three sources of information were
used to identify ICD-9 CM codes for each condition. The first source was a systematic
search of the Medline database from 2008 to 2013, using ‘ICD-9 CM code’ and the name
of the condition as keywords to identify published articles describing use of ICD-9 CM
codes to identify diagnosis for the specific condition. The second source was an online
searchable database of ICD-9 CM codes compiled from files available from the National
Center for Health Statistics (National Center for Health Statistics 2009). To identify
ICD-9 CM codes for a specific condition using this database, the name of the condition
was entered into the database search engine. The third source was the Clinical
Classifications Software for ICD 9-CM maintained by the Agency for Healthcare
Resource and Quality and available online (Agency for Healthcare Research and Quality
2010). The ICD-9 CM codes for specific conditions were identified from the Clinical
Classification Software by manually searching appendices documenting ICD-9 CM codes
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for specific diagnoses. Condition-specific ICD-9 CM codes identified in at least two of
the three sources were used to identify individuals with that condition (Appendix Table
B1).
Excess Dose Category
These represent medications considered inappropriate at certain daily doses
including reserpine, digoxin, doxepin, and spironolactone. For each individual, the
receipt of each medication in 2008 was identified and the daily dose calculated as the
product of the medication’s dosage strength and quantity divided by the number of days
supplied. According to the 2012 Beers criteria, daily doses of reserpine greater than 0.1
milligram; digoxin greater than 0.125 milligrams; and doxepin greater than 6 milligrams
are considered inappropriate. The variable associated with potentially inappropriate
dosage of each medication was assigned a value of ‘1’ if the individual received the
medication in 2008 and had a daily dose that exceeds the dose limit set for that
medication in the 2012 Beers criteria. Otherwise, a value of ‘0’ was assigned to the
variable.
Spironolactone dosage of more than 25 micrograms per day is considered
inappropriate in persons with heart failure. The receipt of a spironolactone daily dose of
more than 25 micrograms by individuals with heart failure was identified. The variable
associated with potentially inappropriate dosage of spironolactone was assigned a value
of ‘1’ if the individual had a spironolactone daily dose greater than 25 micrograms in
2008 and had prior diagnosis for heart failure in 2007 or 2008. Otherwise, the variable
was assigned a value of ‘0’. Individuals with a diagnosis of heart failure were identified
using ICD-9 CM codes from January 2007 through December 2008. Three sources of
information were used to identify ICD-9 CM codes for heart failure. The first source was
a systematic search of the Medline database from 2008 to 2013, using ‘ICD-9 CM code’
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and ‘heart failure’ as keywords to identify published articles describing use of ICD-9 CM
codes to identify diagnosis for heart failure. The second source was an online searchable
database of ICD-9 CM codes compiled from files available from the National Center for
Health Statistics (National Center for Health Statistics 2009). To identify ICD-9 CM
codes for heart failure using this database, the term ‘heart failure’ was entered into the
database search engine. The third source was the Clinical Classifications Software for
ICD 9-CM maintained by the Agency for Healthcare Resource and Quality and available
online (Agency for Healthcare Research and Quality 2010). Heart failure specific ICD-9
CM codes were identified from the Clinical Classification Software by manually
searching appendices that documented ICD-9 CM codes for specific diagnoses. The
ICD-9 CM codes for heart failure identified in at least two of the three sources were used
to identify individuals with heart failure.
The use of spironolactone daily dose of more than 25 micrograms is considered
potentially inappropriate in individuals with creatinine clearance less than 30 ml/min
according to the 2012 Beers criteria. However, because creatinine clearance records were
not available, the receipt of spironolactone daily dose of more than 25 micrograms by
individuals with creatinine clearance less than 30ml/min was neither identified nor
included in PIM analysis.
Excess Duration Category
These represent medications or medication classes considered inappropriate
when used beyond a certain length of time including eszopiclone, zolpiderm, zaleplon,
nitrofurantoin, and oral non-COX-selective non-steroidal anti-inflammatory drugs
(NSAIDs). For each individual, the receipt of each medication in 2008 was identified
and the duration of use calculated as the sum of the number of days supplied for
consecutive prescriptions of that medication. According to the 2012 Beers criteria,
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excess duration of eszopiclone, zolpiderm, or zaleplon is defined as duration of use
greater than 90 days. The variable associated with excess duration of each medication
was assigned a value of ‘1’ if the individual received the medication in 2008 and had
duration of use greater than 90 days. Otherwise, a value of ‘0’ was assigned to the
variable.
Nitrofurantoin is considered potentially inappropriate when used for long-term
suppression of infection. Nitrofurantoin use for long-term suppression of infection has
been reported as duration of use greater than 6 months (Drug Facts and Comparisons
2013). The variable associated with potentially inappropriate duration of use of
nitrofurantoin was assigned a value of ‘1’ if the individual received nitrofurantoin in
2008 and had duration of use greater than six months. Otherwise, a value of ‘0’ was
assigned to the variable. Duration of use of oral non-COX-2 NSAIDs greater than 90
days is considered potentially inappropriate unless other treatment alternatives are not
effective and the individual receives proton pump inhibitors or misoprostol. However,
because records on effectiveness of other treatment alternatives were not available, use of
these drugs were neither identified nor included in PIM analysis.
Drug-Disease Interaction Category
These represent medications in the 2012 Beers criteria considered inappropriate in
persons having specific concomitant conditions. The PIMs listed in the drug-disease
interaction category include both individual medications and medication classes. When
not listed in the 2012 Beers criteria, medications associated with specific medication
classes were identified using the Drug Facts and Comparison database. An individual
was considered to have received a PIM in the drug-disease interaction category if they
had a diagnosis in 2007 or 2008 for a condition listed in the drug-disease interaction
category prior to first receipt in 2008 of medication considered inappropriate in
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individuals with that specific condition. A separate variable was created for each
medication-disease combination listed in the drug-disease interaction category. The
variable was assigned a value of ‘1’ if the individual had a diagnosis in 2007 or 2008 for
the condition associated with that variable prior to first receipt in 2008 of medication
considered potentially inappropriate in individuals with that specific condition.
Otherwise, a value of ‘0’ was assigned to the variable.
Dronedarone is considered potentially inappropriate when used in individuals
with permanent atrial fibrillation. However, because records to identify individuals with
permanent atrial fibrillation were not available, the use of dronedarone in patients with
permanent atrial fibrillation was neither identified nor included in PIM analysis.
Nitrofurantoin is considered potentially inappropriate in individuals with creatinine
clearance less than 60 ml/min. However, because creatinine clearance records were not
available, the use of nitrofurantoin by individuals with creatinine clearance less than
60ml/min was neither identified nor included in PIM analysis.
Some medications in the drug-disease interaction category are considered
potentially inappropriate when used for treatment of certain conditions. For each
individual, the receipt of medications in 2008 considered potentially inappropriate when
used for treatment of certain conditions was identified. A separate variable was created
for each medication and the variable assigned a value of ‘1’ if the individual received the
drug in 2008, had prior to drug receipt diagnosis in 2007 or 2008 for a condition for
which use of the drug is considered inappropriate, and did not have prior to drug receipt
diagnosis in 2007 or 2008 for another condition for which the drug is indicated.
Otherwise, a value of ‘0’ was assigned to the variable. A list of conditions for which
each medication is indicated was compiled using the Micromedex, and Drugs Facts and
Comparison databases.
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Alpha-one blockers including doxazosin, prazosin, and terazosin are considered
potentially inappropriate when used to treat hypertension. An individual was considered
to have received a specific alpha-one blocker to treat hypertension if they received the
alpha-one blocker in 2008, had prior to drug receipt diagnosis for hypertension in 2007 or
2008, and did not have prior to drug receipt diagnosis for benign prostatic hyperplasia in
2007 or 2008. Benzodiazepines are considered potentially inappropriate when used to
treat insomnia, agitation, or delirium. An individual was considered to have received a
benzodiazepine to treat insomnia, agitation, or delirium if they received the specific
benzodiazepine in 2008, had prior to drug receipt diagnosis for insomnia, agitation, or
delirium in 2007 or 2008, and did not have prior to drug receipt diagnosis another
condition for which the specific benzodiazepine is indicated. Some medications are
considered potentially inappropriate when used as first-line therapy for certain conditions
including clonidine as first-line treatment for hypertension and antiarrhythmic drugs as
first-line treatment for atrial fibrillation. However, because of unavailability of
information to identify such drug use as first-line therapy they were neither identified nor
included in PIM analysis.
Some medications in the drug-disease interaction category are considered
potentially inappropriate when used by individuals with certain conditions except when
safer alternatives are not available or effective. They include aspirin daily dose greater
than 325 milligrams, or non-COX-2 selective NSAIDs in individuals with history of
gastric or duodenal ulcers; antipsychotics, benzodiazepines, non-benzodiazepine
hypnotics, tricyclic antidepressants, or selective serotonin reuptake inhibitors in
individuals with history of falls or fractures, and; oral antimuscarinics,
nondihydropyridine calcium channel blockers, first-generation antihistamines,
anticholinergics, or antispasmodics in individuals with chronic constipation. However,
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because there are no records on the availability, safety, or effectiveness of treatment
alternatives, the use of these drugs was neither identified nor included in PIM analysis.
Individuals having disease conditions listed in the drug-disease category were
identified using ICD-9 CM codes from January 2007 through December 2008. Three
sources of information were used to identify ICD-9 CM codes for each condition. The
first source was a systematic search of the Medline database from 2008 to 2013, using
‘ICD-9 CM code’ and the name of the condition as keywords to identify published
articles describing use of ICD-9 CM codes to identify diagnosis for the specific
condition. The second source was an online searchable database of ICD-9 CM codes
compiled from files available from the National Center for Health Statistics (National
Center for Health Statistics 2009). To identify ICD-9 CM codes for a specific condition
using this database, the name of the condition was entered into the database search
engine. The third source was the Clinical Classifications Software for ICD 9-CM
maintained by the Agency for Healthcare Resource and Quality and available online
(Agency for Healthcare Research and Quality 2010). The ICD-9 CM codes for specific
conditions were identified from the Clinical Classification Software by manually
searching appendices documenting ICD-9 CM codes for specific diagnoses. Conditionspecific ICD-9 CM codes identified in at least two of the three sources were used to
identify individuals with that condition.
Overall PIM Use
Individuals were identified as PIM users if they received a medication identified
in any of the four PIM categories including inappropriate drug choice, excess dose,
excess duration, or drug-disease interaction. A variable reflecting overall PIM use was
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created. The variable was assigned a value of ‘1’ if individuals received one or more
PIMs. Otherwise, the variable was assigned a value of ‘0’ if the individual received no
PIMs.
Perceived Provider Communication
Patient perceptions of provider communication were assessed using a previously
validated index created using Medicare Current Beneficiary Survey data (Ward and
Thomas 2013). The perceived communication index was created from patient responses
to five questions including ‘your doctor answers all of your questions,’ ‘your doctor often
does not explain your medical problems to you,’ ‘you often have health problems that
should be discussed but are not,’ ‘your doctor often acts as though they are doing you a
favor by talking to you,’ and ‘your doctor tells you all you want to know about your
condition and treatment.’
All questions included in each domain must have been answered for the index to
be created. The response to each question was given a value from one to four. One
indicated a response of strongly disagree, two indicated disagree, three indicated agree,
and four indicated strongly agree. Negatively worded questions were reverse coded and
values within each domain summed to create each index. The communication index had
a theoretical range of 4 to 20 and a higher score indicated more positive perceptions of
providers.
Perceived Provider Knowledge
Patient perceptions of provider knowledge were created using a previously
validated index (Ward and Thomas 2013). The perceived knowledge index was created
from patient responses to two questions including ‘your doctor has good understanding of
your medical history,’ and ‘your doctor has complete understanding of the things that are

87

wrong with you.’ All questions included in each domain must have been answered for
the index to be created. The response to each question was given a value from one to
four. One indicated a response of strongly disagree, two indicated disagree, three
indicated agree, and four indicated strongly agree. Negatively worded questions were
reverse coded and values within each domain summed to create each index. The
knowledge index had a range of 2 to 8 and a higher score indicated more positive
perceptions of providers.
Perceived Provider Competence
Patient perceptions of provider competence were assessed using a previously
validated index (Ward and Thomas 2013). The perceived competence index was created
from patient responses to two questions including ‘your doctor is very careful to check
everything when examining you,’ and ‘your doctor is competent and well trained.’ All
questions included in each domain must have been answered for the index to be created.
The response to each question was given a value from one to four. One indicated a
response of strongly disagree, two indicated disagree, three indicated agree, and four
indicated strongly agree. Negatively worded questions were reverse coded and values
within each domain summed to create each index. The competence index had a range of
2 to 8 and a higher score indicated more positive perceptions of providers.
Statistical Analysis
Statistical analyses were conducted using SAS for Linux version 9.2 (SAS
Institute Inc., Cary, NC). An a priori alpha level of 0.05 was used to test for statistical
significance.
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Prevalence of PIM Use
Prevalence estimates were determined for individuals receiving PIMs from
January 2008 through December 2008. The total number of individuals and the
proportion of individuals in the prevalence sample receiving PIMs were calculated.
Potentially inappropriate medication users were identified as individuals receiving PIMs
identified in the inappropriate drug choice, excess dose, excess duration, or drug-disease
interaction categories. The total number of PIM users was calculated by summing all
individuals receiving at least one PIM. The proportion of individuals receiving PIMs was
calculated by dividing the total number of individuals receiving at least one PIM by the
total number of individuals in the prevalence sample.
The total number of individuals and proportions of individuals in the prevalence
sample receiving PIMs identified in each of inappropriate drug choice, excess dose,
excess duration, and drug-disease interaction categories, were also calculated. The total
number of individuals receiving PIMs identified in each category was calculated by
summing all individuals receiving at least one PIM identified in the specific category.
The proportion of individuals receiving PIMs identified in each category was calculated
by dividing the total number of individuals receiving at least one PIM identified in the
specific category by the total number of individuals in the prevalence sample. Ninetyfive percent confidence intervals were calculated for all PIM prevalence estimates.
Incidence of PIM Use
Incidence estimates for PIM use were determined for individuals who received
PIMs from January 2008 through December 2008 and did not receive any PIM from
October 2007 through December 2007. The total number of individuals and the
proportion of individuals in the incidence sample receiving PIMs were calculated.
Potentially inappropriate medication users were identified as individuals receiving PIMs
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identified in the inappropriate drug choice, excess dose, excess duration, or drug-disease
interaction categories. The total number of individuals receiving PIMs was calculated by
summing all individuals receiving at least one PIM. The proportion of individuals
receiving PIMs was calculated by dividing the total number of individuals receiving at
least one PIM by the total number of individuals in the incidence sample.
The total number of individuals and the proportions of individuals in the
incidence sample receiving PIMs identified in each of inappropriate drug choice, excess
dose, excess duration, and drug-disease interaction categories, were also calculated. The
total number of individuals receiving PIMs identified in each category was calculated by
summing all individuals receiving at least one PIM identified in the specific category.
The proportion of individuals receiving PIMs identified in each category was calculated
by dividing the total number of individuals receiving at least one PIM identified in the
specific category by the total number of individuals in the incidence sample. Ninety-five
percent confidence intervals were calculated for all PIM prevalence estimates.
Unadjusted Comparisons of PIM Users and PIM Non-Users on Study Variables
Frequencies and percents were calculated for the demographic characteristics,
age, gender, ethnicity, education, income, and region by PIM use or non-use.
Frequencies and percents were calculated for the clinical characteristics, depression
diagnosis, self-reported health status, and number of unique medications by PIM use or
non-use. Frequencies and percents were calculated for perceived provider
communication, perceived provider knowledge, and perceived provider competence by
PIM use or non-use. Comparisons of the distribution of PIM users and PIM non-users on
demographic and clinical characteristics, perceived provider communication, perceived
provider knowledge, and perceived provider competence were made using chi-square
tests and analysis of variance.
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Associations between Perceived Provider Communication and
PIM Use
Simple logistic regression models were developed to assess associations between
perceived provider communication and incident use of PIMs identified in each of
inappropriate drug choice, excess dose, excess duration, and drug-disease interaction
categories. The response variable in each bivariate model was incident use of PIMs
identified in one of the four specific PIM categories at any time in 2008. The predictor
variable was perceived provider communication. Simple logistic regression models were
also developed to assess associations between perceived provider communication and
incident overall PIM use. The response variable in the bivariate model was incident
overall PIM use at any time in 2008. The predictor variable was perceived provider
communication.
Multiple logistic regression models were developed to assess associations
between perceived provider communication and incident use of PIMs identified in each
of inappropriate drug choice, excess dose, excess duration, and drug-disease interaction
categories, adjusting for variables identified as risk factors for PIM use including age,
gender, ethnicity, region, education, income, depression diagnosis, number of
medications, and self-reported health status. The response variable in each multiple
logistic regression model was incident use of PIMs identified in one of the four specific
PIM categories at any time in 2008. The predictor variable was perceived provider
communication. Covariates included in the model were age, gender, ethnicity, region,
education, income, depression diagnosis, number of medications, and self-reported health
status. Age was dichotomized such that the reference group was “65 to 84 years.” The
reference group for gender was “female.” White was the reference group for ethnicity.
The reference group for education was “8th grade or less.” The reference category for
income was “zero to 15,000 dollars.” The reference group for depression diagnosis was
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“having no depression diagnosis.” The reference group for self-reported health status
was “poor.” The reference group for number of unique medications was “zero to five.”
Multiple logistic regression models were also developed to assess associations
between perceived provider communication and incident overall PIM use, adjusting for
age, gender, ethnicity, region, education, income, depression diagnosis, number of
medications, and self-reported health status. The response variable in the model was
incident overall PIM use at any time in 2008. The predictor variable was perceived
provider communication. Covariates included in the model were age, gender, ethnicity,
region, education, income, depression diagnosis, number of medications, and selfreported health status.
The PROC LOGISTIC procedure in SAS with DESCENDING option was used
for all models. All two-way interactions were examined using the FORWARD
SELECTION procedure in SAS PROC LOGISTIC. A reduced model was developed
that included only significant covariates and two-way interactions from the initial models
and the reduced model used for final analyses. To correct for multiple comparisons of
levels of perceived provider communication which increase probability of false positive
findings, a false discovery rate method was used. The false discovery rate (FDR) was
selected as the preferred multiplicity adjustment measure because it is considered more
powerful in finding truly significant results than other multiplicity adjustment measures
(Benjamini and Yekutieli 2001; Genovese, Lazar et al., 2002; Nichols and Hayasaka
2003). The SAS PROC MULTEST (INPVALUES, FDR) option was used to derive
FDR adjusted p-values, and the FDR p-values <0.05 taken as statistically significant.
Overall model fit for the multiple logistic regression models were assessed using
the Hosmer and Lemeshow goodness of fit test (Hosmer and Lemeshow 2000).
Bivariate probit models developed using STATA were used to test for selection bias
(Pregibon 1980). The link test was used to assess whether the model was properly

92

specified, using STATA (UCLA: Statistical Consulting Group 2013). Influential subjects
were identified graphically using plots of influence statistics against case number and
predicted probability. Revised analyses of models after removing subjects identified as
having influential covariate patterns were conducted. If significance of model parameter
estimates were not altered in revised analyses then initial models were retained. If
significance of model parameter estimates were altered in revised analyses, then revised
models were used.
Associations between Perceived Provider Knowledge and
PIM Use
Simple logistic regression models were developed to assess associations between
perceived provider knowledge and incident use of PIMs identified in each of
inappropriate drug choice, excess dose, excess duration, and drug-disease interaction
categories. The response variable in each bivariate model was incident use of PIMs
identified in one of the four specific PIM categories at any time in 2008. The predictor
variable was perceived provider knowledge. Simple logistic regression models were also
developed to assess associations between perceived provider knowledge and incident
overall PIM use. The response variable in the bivariate model was incident overall PIM
use at any time in 2008. The predictor variable was perceived provider communication.
Multiple logistic regression models were developed to assess associations
between perceived provider knowledge and incident use of PIMs identified in each of
inappropriate drug choice, excess dose, excess duration, and drug-disease interaction
categories, adjusting for variables identified as risk factors for PIM use including age,
gender, ethnicity, region, education, income, depression diagnosis, number of
medications, and self-reported health status. The response variable in each multiple
logistic regression model was incident use of PIMs identified in one of the four specific

93

PIM categories at any time in 2008. The predictor variable was perceived provider
knowledge. Covariates included in the model were age, gender, ethnicity, region,
education, income, depression diagnosis, number of medications, and self-reported health
status. Age was dichotomized such that the reference group was 65 to 84 years. The
reference group for gender was female. White was the reference group for ethnicity. The
reference group for education was 8th grade or less. The reference category for income
was zero to 15,000 dollars. The reference group for depression diagnosis was not having
depression diagnosis. The reference group for self-reported health status was poor. The
reference group for number of unique medications was zero to five.
Multiple logistic regression models were also developed to assess associations
between perceived provider knowledge and incident overall PIM use, adjusting for age,
gender, ethnicity, region, education, income, depression diagnosis, number of
medications, and self-reported health status. The response variable in the model was
incident overall PIM use at any time in 2008. The predictor variable was perceived
provider knowledge. Covariates included in the model were age, gender, ethnicity,
region, education, income, depression diagnosis, number of medications, and selfreported health status.
The PROC LOGISTIC procedure in SAS with DESCENDING option was used
for all models. All two-way interactions were examined using the FORWARD
SELECTION procedure in SAS PROC LOGISTIC. A reduced model was developed
that included only significant covariates and two-way interactions from the initial models
and the reduced model used for final analyses. To correct for multiple comparisons of
levels of perceived provider knowledge which increase probability of false positive
findings, a false discovery rate (FDR) method was used. The SAS PROC MULTEST
(INPVALUES, FDR) option was used to derive FDR adjusted p-values, and the FDR pvalues <0.05 taken as statistically significant.
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Overall model fit for the multiple logistic regression models were assessed using
the Hosmer and Lemeshow goodness of fit test (Hosmer and Lemeshow 2000).
Bivariate probit models developed using STATA were used to test for selection bias
(Pregibon 1980). The link test was used to assess whether the model was properly
specified, using STATA (UCLA: Statistical Consulting Group 2013). Influential subjects
were identified graphically using plots of influence statistics against case number and
predicted probability. Revised analyses of models after removing subjects identified as
having influential covariate patterns were conducted. If significance of model parameter
estimates were not altered in revised analyses then initial models were retained. If
significance of model parameter estimates were altered in revised analyses, then revised
models were used.
Associations between Perceived Provider Competence and
PIM use
Simple logistic regression models were developed to assess associations between
perceived provider competence and incident use of PIMs identified in each of
inappropriate drug choice, excess dose, excess duration, and drug-disease interaction
categories. The response variable in each bivariate model was incident use of PIMs
identified in one of the four specific PIM categories at any time in 2008. The predictor
variable was perceived provider competence. Bivariate logistic regression models were
also developed to assess associations between perceived provider competence and
incident overall PIM use. The response variable in the bivariate model was incident
overall PIM use at any time in 2008. The predictor variable was perceived provider
communication.
Multiple logistic regression models were developed to assess associations
between perceived provider competence and incident use of PIMs identified in each of
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inappropriate drug choice, excess dose, excess duration, and drug-disease interaction
categories, adjusting for variables identified as risk factors for PIM use including age,
gender, ethnicity, region, education, income, depression diagnosis, number of
medications, and self-reported health status. The response variable in each multiple
logistic regression model was incident use of PIMs identified in one of the four specific
PIM categories at any time in 2008. The predictor variable was perceived provider
competence. Covariates included in the model were age, gender, ethnicity, region,
education, income, depression diagnosis, number of medications, and self-reported health
status. Age was dichotomized such that the reference group was 65 to 84 years. The
reference group for gender was female. White was the reference group for ethnicity. The
reference group for education was 8th grade or less. The reference category for income
was zero to 15,000 dollars. The reference group for depression diagnosis was not having
depression diagnosis. The reference group for self-reported health status was poor. The
reference group for number of unique medications was zero to five.
Multiple logistic regression models were also developed to assess associations
between perceived provider competence and incident overall PIM use, adjusting for age,
gender, ethnicity, region, education, income, depression diagnosis, number of
medications, and self-reported health status. The response variable in the model was
incident overall PIM use at any time in 2008. The predictor variable was perceived
provider competence. Covariates included in the model were age, gender, ethnicity,
region, education, income, depression diagnosis, number of medications, and selfreported health status.
The PROC LOGISTIC procedure in SAS with DESCENDING option was used
for all models. All two-way interactions were examined using the FORWARD
SELECTION procedure in SAS PROC LOGISTIC. A reduced model was developed
that included only significant covariates and two-way interactions from the initial models
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and the reduced model used for final analyses. To correct for multiple comparisons of
levels of perceived provider competence which increase probability of false positive
findings, a false discovery rate (FDR) method was used. The SAS PROC MULTEST
(INPVALUES, FDR) option was used to derive FDR adjusted p-values, and the FDR pvalues <0.05 taken as statistically significant.
Overall model fit for the multiple logistic regression models were assessed using
the Hosmer and Lemeshow goodness of fit test (Hosmer and Lemeshow 2000).
Bivariate probit models developed using STATA were used to test for selection bias
(Pregibon 1980). The link test was used to assess whether the model was properly
specified, using STATA (UCLA: Statistical Consulting Group 2013). Influential subjects
were identified graphically using plots of influence statistics against case number and
predicted probability. Revised analyses of models after removing subjects identified as
having influential covariate patterns were conducted. If significance of model parameter
estimates were not altered in revised analyses then initial models were retained. If
significance of model parameter estimates were altered in revised analyses, then revised
models were used.
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RESULTS

Prevalence of PIM Use
Sample Selection for Prevalence Estimates
A total of 2,705 individuals were identified in the sample for prevalence
estimates, meeting criteria of being age 65 years or older in 2008, enrolled in Medicare
Part D for consecutive months from October 2007 to December 2008, and living in the
community from October 2007 through December 2008 (Figure 1).
Sample Demographic Characteristics
Table 1 presents the distribution of the prevalence sample by demographic
characteristics. The mean age was 76.8 years for PIM users (standard error = 0.24) and
77.6 years for PIM non-users (standard error = 0.17) (p=0.039). More PIM users were
female (67.08%) as compared to PIM non-users (58.44%). There were more Whites in
the PIM non-user group (85.32%) than in the PIM user group (81.30%). A greater
proportion of PIM users (45.91%) than PIM non-users (36.87%) were living in the South
region of the US or Puerto Rico. There were more PIM users at an educational level of
8th grade or lower (20.13%) as compared to PIM non-users (13.78%). More PIM users
(40.31%) than PIM non-users (34.00%) had an annual income of 15,000 dollars or lower.
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Medicare beneficiaries 65 years or
older in 2008
n = 12,017

Beneficiaries enrolled in Part D in
consecutive months from October
2007 to December 2008
n = 4,705

Beneficiaries living in the
community from October 2007 to
December 2008
n = 2705

Figure 1: Sample Selection Flowchart for Prevalence Sample
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Table 1: Demographic Characteristics of PIM Prevalence Sample
________________________________________________________________________

Variable

PIM Users
N = 893

PIM Non-Users
N = 1,812

____________________________________

____________________________________

Number

Number

Percent

Percent

p-valuea

________________________________________________________________________________________________________________________________________________

Age (in years)
65 to 84
85+
Gender
Female
Male
Ethnicity
White
Non-White
Region
South or Puerto Rico
West
Midwest
Northeast
Education
8th Grade or Less
9th to 12th Grade/HS Grad
Post HS excluding College
College Grad/Post Grad
Income
$0 to $15,000
$15,001 to $30,000
$30,001 to $45,000
$45.001+

746
147

83.54
16.46

1,454
358

80.29
19.76

0.039

599
294

67.08
32.92

1,059
753

58.44
41.56

<.001

726
167

81.30
18.70

1,546
266

85.32
14.68

0.007

410
175
180
323

45.91
19.60
20.16
17.83

668
372
449
128

36.87
20.53
24.78
14.33

<.001

179
339
134
177

20.13
44.88
15.07
19.91

249
879
329
350

13.78
48.64
18.21
19.37

0.001

360
295
105
133

40.31
33.03
11.76
14.89

616
613
237
346

34.00
33.83
13.08
19.09

0.004

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Sample Clinical Characteristics
Table 2 presents the distribution of the prevalence sample by clinical
characteristics. The mean number of medications received by PIM users (13.4
medications, standard error = 0.22) was greater than the mean number of medications
received by PIM non-users (7.8 medications, standard error = 0.17) (p=<.001). More
PIM non-users (86.87%) had diagnosis for depression than PIM users (77.08%). A
greater proportion of PIM users (35.95%) than PIM non-users (20.86%) reported their
health status as poor or fair.
One-Year Prevalence of
PIM Use
Inappropriate Drug Choice Category
Table 3 shows the percentages and 95 percent confidence intervals for proportion
of persons receiving PIMs identified in the inappropriate drug choice category at any
time in 2008. Approximately twenty-eight percent (27.6%) of individuals were
prescribed at least one PIM identified in the inappropriate drug choice category in 2008
(95% CI = 25.9 to 29.3). Table 4 presents the prevalence of individual PIMs. The most
three commonly prescribed inappropriate drug choice PIMs were glyburide (4.88%),
promethazine (4.51%) and estrogens (3.95%).
Excess Dose Category
Approximately three percent (3.3%) of individuals in the prevalence sample
received at least one PIM identified in the excess dose category at any time in 2008 (95%
CI = 2.6 to 3.9) as shown in Table 3. The most prevalent excess dose PIMs were Digoxin
at a daily dose greater than 0.125 milligrams (2.29%) and Doxepin at a daily dose of
greater than 6 milligrams (0.81%) as shown in Table 4.
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Table 2: Clinical Characteristics of PIM Prevalence Sample
________________________________________________________________________

Variable

PIM Users
N=893

PIM Non-Users
N=1,812

____________________________________

____________________________________

Number

Number

Percent

Percent

p-valuea

________________________________________________________________________________________________________________________________________________

Number of Medications
0 to 5
6 to 10
11 to 15
16+
Depression Diagnosis
No
Yes
Self-Reported Health Status
Poor
Fair
Good
Very Good/Excellent

78
250
267
298

8.73
28.00
29.90
33.37

671
322
680
139

37.03
17.77
37.53
7.67

<.001

688
205

77.08
22.96

1,574
238

86.87
13.13

<.001

86
235
285
287

9.63
26.32
31.91
32.14

91
287
590
844

5.02
15.84
32.56
46.58

<.001

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 3: Prevalence of Potentially Inappropriate Medications (PIMs)
________________________________________________________________________

PIM Category

Number of
Individuals
Receiving PIM

% Prevalence
N=2,705

95% CI

________________________________________________________________________________________________________________________________________________

At least one PIM
Inappropriate drug choice
Excess dose
Excess duration
Drug-Disease Interaction

893
747
88
94
86

33.01
27.62
3.25
3.48
3.18

31.24 – 34.7
25.93 – 29.30
2.58 – 3.92
2.78 – 4.17
2.52 – 3.84

________________________________________________________________________________________________________________________________________________
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Table 4: Prevalence of Individual Potentially Inappropriate Medications Received by
Community-Dwelling Medicare Part D Beneficiaries
________________________________________________________________________
Total
Individuals by
Therapeutic Class
N= 2,705
_____________________

Therapeutic Class/Medications

n (Percent)

Total
Individuals by
Medication
N= 2,705
___________________

n (Percent)

________________________________________________________________________________________________________________________________________________

Inappropriate drug choice
Alpha agonists, central
Guanabenz
Guanfacine
Methyldopa
Analgesics, narcotic
Meperidine
Pentazocine
Analgesics, non-narcotic
Indomethacin
Ketorolac, includes parenteral
Antiarrhythmic
Disopyramide
Antihistamines, first generation
Brompheniramine
Carbinoxamine
Chlorpheniramine
Clemastine
Cyproheptadine
Dexbrompheniramine
Dexchlorpheniramine
Doxylamine
Hydroxyzine
Promethazine
Triprolidine
Antiemetics
Trimethobenzamide
Metoclopramide (avoid, except
for treatment of gastroparesis)
Antiparkinson agents
Benztropine, oral
Trihexyphenidyl

4

6

88

0
207

67

2

(0.15)
0
3
1

(0.00)
(0.11)
(0.04)

4
2

(0.15)
(0.07)

32
56

(1.18)
(2.07)

0

(0.00)

6
0
16
0
8
0
1
0
68
122
0

(0.22)
(0.00)
(0.59)
(0.00)
(0.30)
(0.00)
(0.04)
(0.00)
(2.51)
(4.51)
(0.00)

0

(0.00)

67

(2.48)

1
1

(0.04)
(0.04)

(0.22)

(3.25)

(0.00)
(7.65)

(2.48)

(0.07)
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Table 4: Continued
________________________________________________________________________
Total
Individuals by
Therapeutic Class
N= 2,705
_____________________

Therapeutic Class/Medications

n (Percent)

Total
Individuals by
Medication
N= 2,705
___________________

n (Percent)

________________________________________________________________________________________________________________________________________________

Antipsychotics
Thioridazine
Mesoridazine
Antithrombotics
Dipyridamole, oral short acting
(does not apply to extended release
combination with aspirin)
Ticlopidine
Barbiturates
Amobarbital
Butabarbital
Butalbital
Mephobarbital
Pentobarbital
Phenobarbital
Secobarbital
Beta-adrenergic agonist
Isoxsuprine
Calcium channel blocker
Nifedipine, immediate release
Hormones
Desiccated thyroid
Estrogens with or without
progestins, oral and patch
Growth hormone (except as hormone
replacement after pituitary gland removal)
Megestrol
Hypnotic/anxiolytic
Chloral hydrate
Meprobamate
Laxative
Mineral oil, oral
Psychotherapeutic agent
Ergot mesylates

2

11

9

0
0
144

2

0
0

(0.07)
2
0

(0.07)
(0.00)

9
2

(0.33)
(0.07)

0
1
0
0
0
8
0

(0.00)
(0.04)
(0.00)
(0.00)
(0.00)
(0.29)
(0.00)

0

(0.00)

0

(0.00)

17

(0.63)

107

(3.95)

0
23

(0.00)
(0.85)

0
2

(0.00)
(0.07)

0

(0.00)

0

(0.00)

(0.40)

(0.33)

(0.00)
(0.00)
(5.32)

(0.07)

(0.00)
(0.00)
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Table 4: Continued
________________________________________________________________________
Total
Individuals by
Therapeutic Class
N= 2,705
_____________________

Therapeutic Class/Medications

n (Percent)

Total
Individuals by
Medication
N= 2,705
___________________

n (Percent)

________________________________________________________________________________________________________________________________________________

Skeletal muscle relaxants
Carisoprodol
Chlorzoxazone
Cyclobenzaprine
Metaxalone
Methocarbamol
Orphenadrine
Sulfonylureas, long duration
Chlorpropamide
Glyburide
Tertiary Tricyclic Antidepressants
Amitriptyline
Clomipramine
Imipramine
Trimipramine

173

132

80

(6.39)
20
3
96
14
30
15

(0.74)
(0.11)
(3.55)
(0.52)
(1.11)
(0.55)

0
13

(0.00)
(4.88)

71
0
9
0

(2.62)
(0.00)
(0.33)
(0.00)

0

(0.00)

62

(2.29)

5

(0.18)

22

(0.81)

10

(0.37)

9
1
76

(0.33)
(0.04)
(2.81)

(4.88)

(2.95)

Excess dose
Alpha agonist, Central
Reserpine (> 0.1 mg/day)
Antiarrhythmic
Digoxin (> 0.125 mg/day)
Diuretic
Spironolactone > 25 mg/d (avoid
in patients with heart failure)
Tertiary Tricyclic antidepressant
Doxepin (> 6mg/day)
Excess duration
Anti-infective
Nitrofurantoin (avoid for
(long-term suppression)
Nonbenzodiazepine hypnotics
Eszopiclone (avoid > 90days)
Zaleplon (avoid > 90days)
Zolpiderm (avoid > 90days)

107

Table 4: Continued
________________________________________________________________________
Total
Individuals
N= 2,705
___________________

Disease/Condition

Medications

n (Percent)

________________________________________________________________________________________________________________________________________________

Drug-disease interaction
Agitation
Chronic kidney
disease, stages IV
and V
Dementia and
cognitive
impairment

Delirium

Epilepsy or
Chronic Seizures

Heart failure

Hypertension

Insomnia

Benzodiazepines

0

(0.00)

NSAIDs; Triamterene

3

(0.11)

13

(0.48)

2

(0.07)

1

(0.04)

31

(1.14)

23

(0.85)

0

(0.00)

Anticholinergics – Benzodiazepines;
H2-receptor antagonists; Zolpiderm;
Antipsychotics
Tricyclic antidepressants ;
Anticholinergics; Benzodiazepines
Chlorpromazine; Corticosteriods
H2-receptor antagonists;
Meperidine; Sedative hypnotics
Thioridazine
Bupropion, Chlorpromazine, Clozapine
Maprotiline, Olanzapine, Thioridazine
Thiothixene, Tramadol
NSAIDs; COX-2 inhibitors;
Calcium channel blockers (avoid for
systolic heart failure) – Diltiazem,
Verapamil; Pioglitazone, Rosiglitazone,
Cilostazol, Dronedarone
Alpha one blockers (avoid use
as antihypertensive) - Doxazosin
Prazosin, Terazosin
Oral decongestants Pseudoephedrine, Phenylephrine
Stimulants – Amphetamine,
Methylphenidate, Pemoline
Theobromines – Theophylline,
Caffeine; Benzodiazepines (avoid
for treatment of insomnia)
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Table 4: Continued
________________________________________________________________________
Total
Individuals
N= 2,705
___________________

Disease/Condition

Medications

n (Percent)

________________________________________________________________________________________________________________________________________________

Lower urinary
tract symptoms,
benign prostatic
hyperplasia

Parkinson’s
Disease

Stress or
mixed urinary
incontinence
Syncope

Urinary
Incontinence

Inhaled anticholinergic agents;
Strongly anticholinergic drugs
(except antimuscarinics for
urinary incontinence) (Avoid in men)
Antipsychotics (except for
Quetiapine and Clozapine);
Antiemetics – Metoclopraminde,
Prochlorperazine, Promethazine

Alpha blockers (avoid in women) Doxazosin, Prazosin, Terazosin
Acetylcholinesterate inhibitors;
Pheripheral alpha blockers Doxazosin, Prazosin, Terazosin;
Tertiary Tricyclic antidepressants;
Chlorpromazine, Thioridazine,
Olanzapine
Estrogens, oral and transdermal
(excludes intravaginal estrogen)
(Avoid in women)

12

(0.44)

1

(0.44)

0

(0.00)

7

(0.26)

2

(0.07)

________________________________________________________________________________________________________________________________________________
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Excess Duration Category
Approximately four percent (3.5%) of individuals in the prevalence sample
received at least one PIM identified in the excess duration category at any time in 2008
(95% CI = 2.8 to 4.2) (Table 3). As shown in Table 4, Zolpiderm, which is potentially
inappropriate beyond duration of use of ninety days (2.81%) and Nitrofurantion,
potentially inappropriate for long-term suppression of infection (0.37%), were the most
prevalent PIMs in the excess duration category.
Drug-Disease Interaction Category
More than three percent (3.2%) of individuals in the prevalence sample received
at least one PIM identified in the drug-disease interaction category at any time in 2008
(95% CI = 2.5 to 3.8) (Table 3). The most prevalent drug-disease interaction PIMs were
non-steroidal anti-inflammatory drugs, cyclooxygenase-2 inhibitors, calcium channel
blockers, pioglitazone, rosiglitazone, cilostazol, or dronedarone in individuals with heart
failure (1.14%); alpha one blockers in individuals with hypertension (0.85%), and
anticholinergics in individuals with dementia/cognitive impairment (0.48%) (Table 4).
Overall PIM Use
Overall, the one-year prevalence of PIM use was 33.0 percent in 2008 (95% CI =
31.2 to 34.8) (Table 3). The three most commonly received PIMs in the prevalence
sample were glyburide (4.88%), promethazine (4.51%) and estrogens (3.95%).
Approximately twenty-four percent (23.96%) of individuals received one PIM only, 6.21
percent received two PIMs only, and 2.84 percent received three or more PIMs
(Appendix Table C1). Approximately twenty-nine percent (28.9%) of individuals
received PIMs identified in one category, and 4.2 percent received PIMs identified in two
or more categories (Appendix Table C2).
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Incidence of Potentially PIM Use
Sample Selection for Incidence Estimates
A total of 2,210 individuals were identified in the sample for incidence estimates,
meeting criteria of being age 65 years or older in 2008, enrolled in Medicare Part D for
consecutive months from October 2007 to December 2008, living in the community from
October 2007 to December 2008, and receiving no PIMs between October 2007 and
December 2007 (Figure 2).
Sample Demographic Characteristics
Table 5 presents the distribution of the incidence sample by demographic
characteristics. The mean age was 77.2 years for PIM users (standard error = 0.32) and
77.7 years for PIM non-users (standard error = 0.17) (p=0.036). More PIM users were
female (62.88%) as compared to PIM non-users (58.28%). There were more Whites in
the PIM non-user group (85.67%) than in the PIM user group (79.91%). A greater
proportion of PIM users (47.38%) than PIM non-users (36.82%) were living in the South
region of the US or Puerto Rico. There were more PIM users at an educational level of
8th grade or lower (20.22%) as compared to PIM non-users (13.84%). More PIM users
(39.74%) than PIM non-users (33.96%) had an annual income of 15,000 dollars or lower.
Sample Clinical Characteristics
Table 6 presents the distribution of the incidence sample by clinical
characteristics. The mean number of medications received by PIM users (13.4
medications, standard error = 0.31) was greater than the mean number of medications

111

Medicare beneficiaries 65 years or
older in 2008
n = 12,017

Beneficiaries enrolled in Part D in
consecutive months from October

2007 to December 2008
n = 4,705

Beneficiaries living in the
community from October 2007 to
December 2008
n = 2,705

Beneficiaries with no receipt of
PIMs between October 2007 and
December 2007
n = 2,210

Figure 2: Sample Selection Flowchart for Incidence Sample
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Table 5: Demographic Characteristics of PIM Incidence Sample
________________________________________________________________________

Variable

PIM Users
N = 458

PIM Non-Users
N = 1,752

____________________________________

____________________________________

Number

Number

Percent

Percent

p-valuea

________________________________________________________________________________________________________________________________________________

Age (in years)
65 to 84
85+
Gender
Female
Male
Ethnicity
White
Non-White
Region
South or Puerto Rico
West
Midwest
Northeast
Education
8th Grade or Less
9th to 12th Grade/HS Grad
Post HS excluding College
College Grad/Post Grad
Income
$0 to $15,000
$15,001 to $30,000
$30,001 to $45,000
$45.001+

387
71

84.50
15.50

1,405
347

80.19
19.81

0.0363

288
170

62.88
37.12

1,021
731

58.28
41.72

0.0741

366
92

79.91
20.09

1,501
251

85.67
14.33

0.0024

217
87
82
72

47.38
19.00
17.90
15.72

645
358
433
316

36.82
20.43
24.71
18.04

0.0003

92
206
91
66

20.22
45.27
20.00
14.51

242
843
342
321

13.84
48.23
19.57
18.36

0.0038

182
151
60
65

39.74
32.97
13.10
14.19

595
593
228
336

33.96
33.85
13.01
19.18

0.0366

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 6: Clinical Characteristics of PIM Incidence Sample
________________________________________________________________________

Variable

PIM Users
N = 458

PIM Non-Users
N = 1,752

____________________________________

____________________________________

Number

Number

Percent

Percent

p-valuea

________________________________________________________________________________________________________________________________________________

Number of Medications
0 to 5
6 to 10
11 to 15
16+
Depression Diagnosis
No
Yes
Self-Reported Health Status
Poor
Fair
Good
Very Good/Excellent

41
140
123
154

8.95
30.57
26.86
33.62

652
663
306
131

37.21
37.84
17.47
7.48

<.0001

366
92

79.91
20.09

1,520
232

86.76
13.24

0.002

37
123
150
148

8.08
26.86
32.75
32.31

87
275
570
820

4.97
15.70
32.53
46.80

<.0001

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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received by PIM non-users (7.8 medications, standard error = 0.12) (p=<.001). A greater
proportion of PIM non-users (86.76%) had diagnosis for depression than PIM users
(79.91%). A greater proportion of PIM users (34.94%) than PIM non-users (20.67%)
reported their health status as poor or fair.
One-Year Incidence of
PIM Use
Inappropriate Drug Choice Category
Table 7 shows the percentages and 95 percent confidence intervals for proportion
of persons with new receipt of PIMs identified in the inappropriate drug choice category
at any time in 2008. More than 17 percent (17.2%) of individuals were prescribed at least
one PIM identified in the inappropriate drug choice category in 2008 (95% CI = 25.9 to
29.3). Table 8 presents the incidence of individual PIMs. The most three commonly
prescribed inappropriate drug choice PIMs were promethazine (3.62%), cyclobenzaprine
(2.68%), and metoclopramide (1.59%).
Excess Dose Category
More than one percent (1.2%) of individuals in the incidence sample received at
least one PIM identified in the excess dose category at any time in 2008 (95% CI = 0.8 to
1.7) as shown in Table 7. The most prevalent excess dose PIMs were Digoxin at a daily
dose greater than 0.125 milligrams (0.81%) and Doxepin at a daily dose of greater than 6
milligrams (0.32%) as shown in Table 8.
Excess Duration Category
Approximately three percent (2.6%) of individuals in the incidence sample
received at least one PIM identified in the excess duration category at any time in 2008
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Table 7: Incidence of Potentially Inappropriate Medications (PIMs)
________________________________________________________________________

PIM Category

Number of
Individuals
Receiving PIM

% Prevalence
N=2,210

95% CI

________________________________________________________________________________________________________________________________________________

At least one PIM
Inappropriate drug choice
Excess dose
Excess duration
Drug-Disease Interaction

458
380
27
58
40

20.72
17.19
1.22
2.62
1.80

19.03 – 22.41
15.62 – 18.77
0.76 – 1.68
1.96 – 3.29
1.25 – 2.37

________________________________________________________________________________________________________________________________________________
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Table 8: Incidence of Individual Potentially Inappropriate Medications Received by
Community-Dwelling Medicare Part D Beneficiaries
________________________________________________________________________
Total
Individuals by
Therapeutic Class
N= 2,210
_____________________

Therapeutic Class/Medications

n (Percent)

Total
Individuals by
Medication
N= 2,210
___________________

n (Percent)

________________________________________________________________________________________________________________________________________________

Inappropriate drug choice
Alpha agonists, central
Guanabenz
Guanfacine
Methyldopa
Analgesics, narcotic
Meperidine
Pentazocine
Analgesics, non-narcotic
Indomethacin
Ketorolac, includes parenteral
Antiarrhythmic
Disopyramide
Antihistamines, first generation
Brompheniramine
Carbinoxamine
Chlorpheniramine
Clemastine
Cyproheptadine
Dexbrompheniramine
Dexchlorpheniramine
Doxylamine
Hydroxyzine
Promethazine
Triprolidine
Antiemetics
Trimethobenzamide
Metoclopramide (avoid, except
for treatment of gastroparesis)
Antiparkinson agents
Benztropine, oral
Trihexyphenidyl
Antipsychotics
Thioridazine
Mesoridazine

2

4

54

0
128

35

0

0

(0.09)
0
2
0

(0.00)
(0.09)
(0.00)

3
1

(0.14)
(0.04)

19
35

(0.86)
(1.58)

0

(0.00)

4
0
10
0
4
0
1
0
33
80
0

(0.18)
(0.00)
(0.45)
(0.00)
(0.18)
(0.00)
(0.04)
(0.00)
(1.49)
(3.62)
(0.00)

0

(0.00)

35

(1.59)

0
0

(0.00)
(0.00)

0
0

(0.00)
(0.00)

(0.18)

(2.44)

(0.00)
(5.79)

(1.59)

(0.00)

(0.00)
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Table 8: Continued
________________________________________________________________________
Total
Individuals by
Therapeutic Class
N= 2,210
_____________________

Therapeutic Class/Medications

n (Percent)

Total
Individuals by
Medication
N= 2,210
___________________

n (Percent)

________________________________________________________________________________________________________________________________________________

Antithrombotics
Dipyridamole, oral short acting
(does not apply to extended release
combination with aspirin)
Ticlopidine

3

Barbiturates
Amobarbital
Butabarbital
Butalbital
Mephobarbital
Pentobarbital
Phenobarbital
Secobarbital
Beta-adrenergic agonist
Isoxsuprine
Calcium channel blocker
Nifedipine, immediate release

3

Hormones
Desiccated thyroid
Estrogens with or without
progestins, oral and patch
Growth hormone (except as hormone
replacement after pituitary gland removal)
Megestrol
Hypnotic/anxiolytic
Chloral hydrate
Meprobamate
Laxative
Mineral oil, oral
Psychotherapeutic agent
Ergot mesylates

0
0
34

0

0
0

(0.14)
3
0

(0.14)
(0.00)

0
1
0
0
0
2
0

(0.00)
(0.04)
(0.00)
(0.00)
(0.00)
(0.09)
(0.00)

0

(0.00)

0

(0.00)

4

(0.18)

22

(0.10)

0
8

(0.00)
(0.36)

0
0

(0.00)
(0.00)

0

(0.00)

0

(0.00)

(0.13)

(0.00)
(0.00)
(1.54)

(0.00)

(0.00)
(0.00)
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Table 8: Continued
________________________________________________________________________
Total
Individuals by
Therapeutic Class
N= 2,210
_____________________

Therapeutic Class/Medications

n (Percent)

Total
Individuals by
Medication
N= 2,210
___________________

n (Percent)

________________________________________________________________________________________________________________________________________________

Skeletal muscle relaxants
Carisoprodol
Chlorzoxazone
Cyclobenzaprine
Metaxalone
Methocarbamol
Orphenadrine
Sulfonylureas, long duration
Chlorpropamide
Glyburide
Tertiary Tricyclic Antidepressants
Amitriptyline
Clomipramine
Imipramine
Trimipramine

110

33

20

(4.98)
11
1
59
11
20
10

(0.50)
(0.04)
(2.68)
(0.50)
(0.91)
(0.45)

0
33

(0.00)
(1.50)

19
0
1
0

(0.86)
(0.00)
(0.04)
(0.00)

0

(0.00)

18

(0.81)

2

(0.09)

7

(0.32)

7

(0.32)

4
1
46

(0.18)
(0.04)
(2.08)

(1.50)

(0.90)

Excess dose
Alpha agonist, Central
Reserpine (> 0.1 mg/day)
Antiarrhythmic
Digoxin (> 0.125 mg/day)
Diuretic
Spironolactone > 25 mg/d (avoid
in patients with heart failure)
Tertiary Tricyclic antidepressant
Doxepin (> 6mg/day)
Excess duration
Anti-infective
Nitrofurantoin (avoid for
(long-term suppression)
Nonbenzodiazepine hypnotics
Eszopiclone (avoid > 90days)
Zaleplon (avoid > 90days)
Zolpiderm (avoid > 90days)
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Table 8: Continued
________________________________________________________________________
Total
Individuals
N= 2,210
___________________

Disease/Condition

Medications

n (Percent)

________________________________________________________________________________________________________________________________________________

Drug-disease interaction
Agitation
Chronic kidney
disease, stages IV
and V
Dementia and
cognitive
impairment

Delirium

Epilepsy or
Chronic Seizures

Heart failure

Hypertension

Insomnia

Benzodiazepines

0

(0.00)

NSAIDs; Triamterene

0

(0.00)

8

(0.36)

0

(0.00)

0

(0.00)

18

(0.81)

7

(0.32)

0

(0.00)

Anticholinergics – Benzodiazepines;
H2-receptor antagonists; Zolpiderm;
Antipsychotics
Tricyclic antidepressants ;
Anticholinergics; Benzodiazepines
Chlorpromazine; Corticosteriods
H2-receptor antagonists;
Meperidine; Sedative hypnotics
Thioridazine
Bupropion, Chlorpromazine, Clozapine
Maprotiline, Olanzapine, Thioridazine
Thiothixene, Tramadol
NSAIDs; COX-2 inhibitors;
Calcium channel blockers (avoid for
systolic heart failure) – Diltiazem,
Verapamil; Pioglitazone, Rosiglitazone,
Cilostazol, Dronedarone
Alpha one blockers (avoid use
as antihypertensive) - Doxazosin
Prazosin, Terazosin
Oral decongestants Pseudoephedrine, Phenylephrine
Stimulants – Amphetamine,
Methylphenidate, Pemoline
Theobromines – Theophylline,
Caffeine; Benzodiazepines (avoid
for treatment of insomnia)
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Table 8: Continued
________________________________________________________________________
Total
Individuals
N= 2,210
___________________

Disease/Condition

Medications

n (Percent)

________________________________________________________________________________________________________________________________________________

Lower urinary
tract symptoms,
benign prostatic
hyperplasia

Parkinson’s
Disease

Stress or
mixed urinary
incontinence
Syncope

Urinary
Incontinence

Inhaled anticholinergic agents;
Strongly anticholinergic drugs
(except antimuscarinics for
urinary incontinence) (Avoid in men)

7

(0.32)

Antipsychotics (except for
Quetiapine and Clozapine);
Antiemetics – Metoclopraminde,
Prochlorperazine, Promethazine

1

(0.04)

0

(0.00)

0

(0.00)

1

(0.04)

Alpha blockers (avoid in women) Doxazosin, Prazosin, Terazosin
Acetylcholinesterate inhibitors;
Pheripheral alpha blockers Doxazosin, Prazosin, Terazosin;
Tertiary Tricyclic antidepressants;
Chlorpromazine, Thioridazine,
Olanzapine
Estrogens, oral and transdermal
(excludes intravaginal estrogen)
(Avoid in women)

________________________________________________________________________________________________________________________________________________
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(95% CI = 2.0 to 3.3) (Table 7). As shown in Table 8, Zolpiderm, which is potentially
inappropriate beyond a duration of use of ninety days (2.08%) and Nitrofurantion,
potentially inappropriate for long-term suppression of infection (0.32%), were the most
commonly received PIMs in the excess duration category.
Drug-Disease Interaction Category
As presented in Table 7, approximately two percent (1.8%) of individuals in the
prevalence sample received at least one PIM identified in the drug-disease interaction
category at any time in 2008 (95% CI = 1.3 to 2.4). The most prevalent drug-disease
interaction PIMs were receipt of non-steroidal anti-inflammatory drugs, cyclooxygenase2 inhibitors, calcium channel blockers, pioglitazone, rosiglitazone, cilostazol, or
dronedarone in individuals with heart failure (0.81%),and anticholinergics in individuals
with dementia or other cognitive impairment (0.36%) (Table 8).
Overall PIM Use
Overall, the one-year incidence of PIM use among community-dwelling Medicare
beneficiaries was 20.7 percent in 2008 (95% CI = 19.0 to 22.4) (Table 7).
The three most commonly received PIMs in the incidence sample were promethazine
(3.62%), cyclobenzaprine (2.68%) and zolpiderm (2.08%). Over seventeen percent
(17.06%) of individuals received one PIM only, 2.71 percent received two PIMs only,
and less than one percent (0.94%) received three or more PIMs (Appendix Table C3).
Approximately nineteen percent (18.7%) of individuals received PIMs identified in one
category, and two percent received PIMs identified in two or more categories (Appendix
Table C4).

122

Associations between Perceived Provider
Communication and PIM Use
Bivariate Associations between Perceived Provider
Communication and PIM Use
Table 9 presents the distribution of perceived provider communication index
scores. To avoid potential problems from small cell counts in logistic regression
analysis, index scores were collapsed into five levels, with each level having not less than
100 observations (Table 10). The five levels of the perceived provider communication
variable were “5 to 14,” “15,” “16,” “17 or 18,” and “19 or 20.” Perceived provider
communication index scores of 5 to 14 was selected as the reference category.
Ten events per degree of freedom are required for reliable parameter estimation in
logistic regression models (Agashivala and Wu 2009; Harrell, Lee et al., 1996; LaValley
2008; Peduzzi, Concato et al., 1996). However, because number of excess dose, excess
duration, or drug-disease interaction PIM users did not satisfy event size requirements for
reliable models, associations between perceived provider communication and excess
dose, excess duration or drug-disease interaction PIM use were not included in analyses.
Bivariate Associations between Perceived Provider
Communication and Inappropriate Drug Choice PIM Use
There was no significant difference in mean perceived provider communication
scores between inappropriate drug choice PIM users (mean score=15.8, Standard
Error=0.12) and non-users (mean score=15.9, SE=0.05). In bivariate analysis of
associations between perceived provider communication and inappropriate drug choice
PIM use, individuals with perceived provider communication index scores of 17 or 18
were less likely to use inappropriate drug choice PIMs than those with index scores
between 5 and 14 (OR=0.49, 95% CI=0.32 to 0.76, p=0.001) (Table 11). There was no
significant difference in risk for inappropriate drug choice PIM use between individuals
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Table 9: Distribution of Perceived Provider Communication Index Scores
________________________________________________________________________
Index Score
Frequency
Percent
_______________________________________________________________________________________________________________________________________________

Five

1

0.05

Six

0

0.00

Seven

5

0.24

Eight

1

0.05

Nine

3

0.15

Ten

13

0.63

Eleven

21

1.02

Twelve

40

1.95

Thirteen

56

2.72

Fourteen

157

7.64

Fifteen

961

46.74

Sixteen

157

7.64

Seventeen

217

10.55

Eighteen

121

5.89

Nineteen

75

3.65

Twenty

228

11.09

________________________________________________________________________________________________________________________________________________
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Table 10: Grouped Distribution of Perceived Provider Communication Index Scores
________________________________________________________________________
Index Score
Frequency
Percent
_______________________________________________________________________________________________________________________________________________

5 to 14

297

14.45

15

961

46.74

16

157

7.64

17 or 18

338

16.44

19 or 20

303

14.45

________________________________________________________________________________________________________________________________________________
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Table 11: Bivariate Associations between Perceived Provider Communication and
Inappropriate Drug Choice PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Perceived Provider
Communication Index
5 to 14
15
16
17 or 18
19 or 20

Reference group
0.767
0.676
0.493

0.556 – 1.058
0.407 – 1.124
0.321 – 0.755

0.106
0.131
0.001

0.881

0.594 – 1.307

0.529

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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with perceived provider communication scores of 15, 16, or 19/20, and individuals with
index scores between 5 and 14.
Bivariate Associations between Perceived Provider
Communication and Overall PIM Use
There was no significant difference in mean perceived provider communication
scores between overall PIM users (mean score=15.7, Standard Error=0.11) and PIM nonusers (mean score=15.9, SE=0.05). Table 12 presents results of bivariate logistic
regression examining associations between perceived provider communication and
overall PIM use. There were no associations found between perceived provider
communication and overall PIM use.
Bivariate Associations between Demographic
Characteristics and PIM Use
Age was grouped into two categories, 65 to 84 years, and 85 years or older, with
the reference category being age 65 to 84 years. The reference category for gender was
female. Ethnicity was categorized as White, or non-White, with White being the
reference category. Education was grouped into four categories including 8th grade or
less, 9th to 12th grade/high school graduate, post high school education excluding college
graduation, or college graduate/post graduate. The reference category for education was
8th grade or less. Income was categorized as zero to 15,000 dollars; 15,001 to 30,000
dollars; 30,001 to 45,000 dollars; or more than 45,000 dollars. The reference category for
income was 15,000 dollars or less. United States census regions were identified in each
of four categories including West, Midwest, Northeast, or South/Puerto Rico. The
reference category for region was South/Puerto Rico.
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Table 12: Bivariate Associations between Perceived Provider Communication and
Overall PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Perceived Provider
Communication Index
5 to 14
15
16
17 or 18
19 or 20

Reference group
0.858
0.755
0.609

0.632 – 1.164
0.470 – 1.212
0.413 – 0.900

0.326
0.246
0.013

0.854

0.585 – 1.249

0.417

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Bivariate Associations between Age and PIM Use
Based on results of bivariate analysis, there were no associations found between
age and inappropriate drug choice PIM use (Table 13). Individuals aged 85 years or
older had decreased likelihood of overall PIM use than those aged 65 to 84 years
(OR=0.74, 95% CI=0.56 to 0.98, p=0.037) (Table 14).
Bivariate Associations between Gender and PIM Use
There were no associations found between gender and inappropriate drug choice
PIM use (Table 15) or associations between gender and overall PIM use in bivariate
analyses (Table 16).
Bivariate Associations between Ethnicity and PIM Use
Non-Whites had higher likelihood of inappropriate drug choice PIM use than
Whites (OR=1.56, 95% CI=1.18 to 2.06, p=0.002) (Table 17). Likewise, non-Whites had
higher likelihood of overall PIM use than Whites in bivariate analysis (OR=1.50, 95%
CI=1.15 to 1.96, p=0.003) (Table 18).
Bivariate Associations between Region and PIM Use
Individuals in the West (OR=0.54, 95% CI=0.39 to 0.74, p=0.023), Midwest
(OR=0.52, 95% CI=0.38 to 0.69, p=<.001), and Northeast regions of the US (OR=0.62,
95% CI=0.45 to 0.85, p=0.003) had lower likelihood of inappropriate drug choice PIM
use than those in the South region or Puerto Rico (Table 19). Individuals in the West
(OR=0.72, 95% CI=0.55 to 0.96, p=0.023), Midwest (OR=0.56, 95% CI=0.46 to 0.75,
p=<.001), and Northeast regions of the US (OR=0.68, 95% CI=0.50 to 0.91, p=0.011)
also had lower likelihood of overall PIM use than those in the South region or Puerto
Rico (Table 20).

129

Table 13: Bivariate Associations between Age and Inappropriate Drug Choice PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Age
65 to 84
85+

Reference group
0.753

0.558 – 1.017

0.065

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 14: Bivariate Associations between Age and Overall PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Age
65 to 84
85+

Reference group
0.743

0.562 – 0.982

0.037

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 15: Bivariate Associations between Gender and Inappropriate Drug Choice PIM
Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Gender
Female
Male

Reference group
0.797

0.634 – 1.002

0.053

________________________________________________________________________________________________________________________________________________

a

Chi-square test

132

Table 16: Bivariate Associations between Gender and Overall PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Gender
Female
Male

Reference group
0.824

0.667 – 1.019

0.074

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 17: Bivariate Associations between Ethnicity and Inappropriate Drug Choice PIM
Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Ethnicity
White
Non-White

Reference group
1.557

1.177 – 2.060

0.002

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 18: Bivariate Associations between Ethnicity and Overall PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Ethnicity
White
Non-White

Reference group
1.504

1.154 – 1.959

0.003

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 19: Bivariate Associations between Region and Inappropriate Drug Choice PIM
Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Region
South or Puerto Rico
West
Midwest
Northeast

Reference group
0.537
0.515
0.617

0.391 – 0.736
0.381 – 0.697
0.448 – 0.850

0.001
<.001
0.003

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 20: Bivariate Associations between Region and Overall PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Region
South or Puerto Rico
West
Midwest
Northeast

Reference group
0.722
0.563
0.677

0.546 – 0.956
0.425 – 0.746
0.502 – 0.913

0.023
<.001
0.011

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Bivariate Associations between Education and PIM Use
The likelihood of inappropriate drug choice PIM use decreased with higher levels
of education. Compared to individuals attaining an educational level of 8th grade or
lower, individuals at an educational level between 9th grade and high school graduation
(OR=0.67, 95% CI=0.48 to 0.91, p=0.001), with post high school education excluding
college graduation (OR=0.62, 95% CI=0.43 to 0.89, p=0.010), or graduating from college
or graduate school (OR=0.52, 95% CI=0.35 to 0.77, p=0.001) were less likely to use
inappropriate drug choice PIMs (Table 21).
Compared to Individuals at an educational level of 8th grade or less, those
between 9th grade and high school graduation (OR=0.64, 95% CI=0.48 to 0.85, p=0.002),
having post high school education excluding college graduation (OR=0.70, 95% CI=0.50
to 0.98, p=0.036), or graduating from college or graduate school (OR=0.63, 95% CI=0.46
to 0.87, p=0.004) had lower likelihood of overall PIM use (Table 22).
Bivariate Associations between Income and PIM Use
Individuals earning more than $45,000 per annum were less likely than those
earning $15,000 or less to receive inappropriate drug choice PIMs (OR=0.56, 95%
CI=0.39 to 0.79, p=0.001). Individuals with yearly incomes between $15,001 and
$30,000 or those with incomes between $30,001 and $45,000 were not significantly
different in likelihood of inappropriate drug choice PIM use from those earning $15,000
or less (Table 23).
Similarly, individuals earning more than $45,000 per annum had lower likelihood
of overall PIM use than those earning $15,000 or less (OR=0.63, 95% CI=0.46 to 0.87,
p=0.004) (Table 24). Individuals with yearly incomes between $15,001 and $30,000 or
those with incomes between $30,001 and $45,000 were not significantly different in
likelihood of overall PIM use from those earning $15,000 or less (Table 24).
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Table 21: Bivariate Associations between Education and Inappropriate Drug Choice PIM
Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Education
8th Grade or Less
Reference group
th
th
9 to 12 Grade/HS Grad
0.671
Post HS excluding College Grad
0.622
College Grad/Post Grad
0.521

0.479 – 0.906
0.434 – 0.893
0.354 – 0.765

0.009
0.010
0.001

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 22: Bivariate Associations between Education and Overall PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Education
8th Grade or Less
Reference group
th
th
9 to 12 Grade/HS Grad
0.643
Post HS excluding College Grad
0.700
College Grad/Post Grad
0.541

0.484 – 0.854
0.501 – 0.976
0.378 – 0.773

0.002
0.036
0.007

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 23: Bivariate Associations between Income and Inappropriate Drug Choice PIM
Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Income
$0 to $15,000
$15,001 to $30,000
$30,001 to $45,000
$45,001+

Reference group
0.834
0.803
0.559

0.643 – 1.081
0.562 – 1.146
0.395 – 0.790

0.169
0.337
0.001

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 24: Bivariate Associations between Income and Overall PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Income
$0 to $15,000
$15,001 to $30,000
$30,001 to $45,000
$45,001+

Reference group
0.832
0.860
0.633

0.652 – 1.062
0.619 – 1.196
0.462 – 0.865

0.141
0.375
0.004

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Bivariate Associations between Clinical
Characteristics and PIM Use
The reference category for depression diagnosis was not having such diagnosis.
Number of unique medications received by each individual was grouped into four
categories including 0 to 5 medications, 6 to 10 medications, 11 to 15 medications, or 16
medications or more. The reference category for number of unique medications was zero
to five. Self-reported health status was categorized as poor, fair, good, or very
good/excellent. The reference category for self-reported health status was poor.
Bivariate Associations between Depression Diagnosis and PIM Use
Having diagnosis for depression diagnosis was associated with higher likelihood
of inappropriate drug choice PIM use (OR=1.49, 95% CI=1.22 to 1.99, p=0.006) (Table
25). Having diagnosis for depression was similarly associated with higher likelihood of
overall PIM use in bivariate analysis (OR=1.65, 95% CI=1.26 to 2.15, p=0.003) (Table
26).
Bivariate Associations between Number of Medications and PIM Use
The likelihood of inappropriate drug choice PIM use and overall PIM use
increased with number of unique medications received by each individual. Individuals
receiving 6 to 10 drugs (OR=3.14, 95% CI=2.12 to 4.66, p=<.001), 11 to 15 drugs
(OR=4.99, 95% CI=3.31 to 7.54, p=<.001), or more than 15 drugs (OR=18.15, 95%
CI=12.03 to 27.39, p=<.001) were more likely to receive inappropriate drug choice PIMs
than those receiving 5 drugs or less (Table 27). Individuals receiving 6 to 10 drugs
(OR=3.36, 95% CI=2.33 to 4.83, p=<.001), 11 to 15 drugs (OR=6.39, 95% CI=4.38 to
9.33, p=<.001), or more than 15 drugs (OR=18.64, 95% CI=12.63 to 27.67, p=<.001)
were at higher likelihood of overall PIM use than those receiving 5 drugs or less (Table
28).
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Table 25: Bivariate Associations between Depression Diagnosis and Inappropriate Drug
Choice PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Depression Diagnosis
No
Yes

Reference group
1.496

1.122 – 1.996

0.006

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 26: Bivariate Associations between Depression Diagnosis and Overall PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Depression Diagnosis
No
Yes

Reference group
1.647

1.261 – 2.151

0.003

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 27: Bivariate Associations between Number of Medications and Inappropriate
Drug Choice PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Number of Medications
0 to 5
6 to 10
11 to 15
16+

Reference group
3.142
4.991
18.152

2.121 – 4.656
3.306 – 7.535
12.025 – 27.399

<.001
<.001
<.001

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 28: Bivariate Associations between Number of Medications and Overall PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Number of Medications
0 to 5
6 to 10
11 to 15
16+

Reference group
3.358
6.392
18.694

2.332 – 4.834
4.377 – 9.334
12.629 – 27.673

<.001
<.001
<.001

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Bivariate Associations between Self-Reported Health Status and PIM Use
Individuals reporting health status as very good/excellent (OR=0.44, 95%
CI=0.28 to 0.68, p=0.003) had lower likelihood of inappropriate drug choice PIM use
than those reporting health status as poor (Table 29). Individuals reporting health status
as good or fair were not significantly different in likelihood of inappropriate drug choice
PIM use from those reporting health status as poor (Table 29).
Better self-reported health status was associated with lower risk for overall PIM
use. Individuals reporting health status as good (OR=0.62, 95% CI=0.41 to 0.95,
p=0.027) or very good/excellent (OR=0.42, 95% CI=0.28 to 0.65, p=<.001) had lower
likelihood of overall PIM use than those reporting health status as poor (Table 30).
Individuals reporting health status as fair were not significantly different in likelihood of
overall PIM use from those reporting health status as poor (Table 30).
Multivariate Associations between Perceived Provider
Communication and PIM Use after Adjusting for Demographic
and Clinical Characteristics
Multivariate Associations between Perceived Provider
Communication and Inappropriate Drug Choice PIM Use
after Adjusting for Demographic and Clinical Characteristics
Multiple logistic regression models were developed to assess associations
between perceived provider communication and use of PIMs identified in the
inappropriate drug choice category, adjusting for demographic and clinical
characteristics. The response variable in the model was inappropriate drug choice PIM
use. The predictor variable in the model was perceived provider communication.
Covariates included in the model were age, gender, ethnicity, region, education, income,
number of medications, depression diagnosis, and self-reported health status. A model
with all two-way interactions and main effects was examined using the FORWARD
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Table 29: Bivariate Associations between Self-Reported Health Status and Inappropriate
Drug Choice PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Self-Reported Health Status
Poor
Fair
Good
Very Good or Excellent

Reference group
1.152
0.658
0.435

0.722 – 1.838
0.418 – 1.036
0.276 – 0.685

0.552
0.071
0.003

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 30: Bivariate Associations between Self-Reported Health Status and Overall PIM
Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Self-Reported Health Status
Poor
Fair
Good
Very Good or Excellent

Reference group
1.052
0.619
0.424

0.678 – 1.632
0.405 – 0.946
0.278 – 0.648

0.882
0.027
<.001

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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SELECTION procedure in SAS PROC LOGISTIC. There were no significant
interactions found, and so the main effects model was retained. A reduced model was
developed that included only significant covariates from the initial model and the reduced
model used for final analyses. Significant covariates in the reduced model were age,
region, and number of medications.
Table 31 presents results of the multiple logistic regression analysis. The model
showed good model fit with a non-significant Homer Lemeshow test (p=0.754). Results
of bivariate probit models developed to account for selection bias indicated no selection
bias (rho p-value =0.297) (Appendix Table D1). Results of link test checking for model
specification error indicated that the model was properly specified and no relevant
variables were left out or irrelevant variables included (hat-square p-value =0.994)
(Appendix Table G1). Graphical plots of influence statistics as shown in Appendix
Figure J1 and Appendix Figure J2 indicated presence of subjects with influential
covariate patterns. However, removing these subjects from analysis did not alter the
significance of model parameter estimates and so the reduced model was retained.
Results from the multiple logistic regression model as shown in Table 31
indicated individuals having more positive perceived provider communication index
scores of 17 or 18 were less likely than those with index scores ranging from 5 to 14 to
use inappropriate drug choice PIMs (OR=0.61, 95% CI=0.38 to 0.96, p=0.034), after
adjusting for age, region, and number of medications. However, after adjusting for
multiple comparisons using a False Discovery Rate correction, no significant associations
were found between perceived provider communication and inappropriate drug choice
PIM use in multivariate analyses (Table 32).
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Table 31: Multivariate Associations between Perceived Provider Communication and
Inappropriate Drug Choice PIM Use, Adjusting for Age, Region, and Number
of Medications
________________________________________________________________________
Variable

Adjusted Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Perceived Provider
Communication Index
5 to 14
15
16
17 or 18
19 or 20
Age
65 to 84
85+
Region
South or Puerto Rico
West
Midwest
Northeast
Number of Medications
0 to 5
6 to 10
11 to 15
16+

Reference group
0.926
0.870
0.608
1.125

0.652 – 1.314
0.503 – 1.503
0.384 – 0.962
0.732 – 1.730

0.666
0.616
0.034
0.591

Reference group
0.708

0.508 – 0.986

0.041

Reference group
0.684
0.571
0.632

0.485 – 0.964
0.409 – 0.797
0.442 – 0.902

0.030
0.001
0.012

Reference group
3.169
5.146
17.203

2.079 – 4.829
3.317 – 7.984
11.070 – 26.733

<.001
<.001
<.001

________________________________________________________________________________________________________________________________________________

a

Chi-square test

Model Statistics:
N=2,056
Likelihood Ratio Test: Chi-square statistic=263.589, DF=11, p=<.001
Hosmer and Lemeshow Goodness of Fit test: Chi-square statistic=5.037, DF=8, p=0.754
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Table 32: Multiplicity Adjusted P-Values for Perceived Provider Communication in
Model Examining Associations between Perceived Provider Communication
and Inappropriate Drug Choice PIM Use, Adjusting for Age, Region, and
Number of Medications
________________________________________________________________________
Variable

Adjusted Odds Ratio

95% CI

FDRa

________________________________________________________________________________________________________________________________________________

Perceived Provider
Communication Index
5 to 14
15
16
17 or 18
19 or 20

Reference group
0.926

0.652 – 1.314

0.666

0.870
0.608
1.125

0.503 – 1.503
0.384 – 0.962
0.732 – 1.730

0.666
0.135
0.666

________________________________________________________________________________________________________________________________________________

a

False Discovery Rate test
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Multivariate Associations between Perceived Provider
Communication and Overall PIM Use after Adjusting for
Demographic and Clinical Characteristics
Multiple logistic regression models were developed to assess associations
between perceived provider communication and overall PIM use, adjusting for
demographic and clinical characteristics. The response variable in the model was overall
PIM use. The predictor variable in the model was perceived provider communication.
Covariates included in the model were age, gender, ethnicity, region, education, income,
number of medical conditions, depression diagnosis, and self-reported health status. A
model with all two-way interactions and main effects was examined using the
FORWARD SELECTION procedure in SAS PROC LOGISTIC. There were no
significant interactions found, and so the main effects model was retained. A reduced
model was developed that included only significant covariates from the initial model and
the reduced model used for final analyses. Significant covariates in the reduced model
were age, region, and number of medications.
Table 33 presents results of the multiple logistic regression analysis. The model
showed good model fit with a non-significant Homer Lemeshow test (p=0.810). Results
of bivariate probit models developed to account for selection bias indicated no selection
bias (rho p-value =0.532) (Appendix Table D2). Results of the link test checking for
model specification error indicated that the model was properly specified and no relevant
variables were left out or irrelevant variables included (hat-square p-value =0.913)
(Appendix Table G2). Graphical plots of influence statistics as shown in Appendix
Figure J3 and Appendix Figure J4 indicated presence of subjects with influential
covariate patterns. However, removing these subjects from analysis did not alter the
significance of model parameter estimates and so the reduced model was retained. As
shown in Table 33, there were no associations found between perceived provider
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Table 33: Multivariate Associations between Perceived Provider Communication and
Overall PIM Use, Adjusting for Age, Region, and Number of Medications
________________________________________________________________________
Variable

Adjusted Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Perceived Provider
Communication Index
5 to 14
15
16
17 or 18
19 or 20
Age
65 to 84
85+
Region
South or Puerto Rico
West
Midwest
Northeast
Number of Medications
0 to 5
6 to 10
11 to 15
16+

Reference group
1.046
0.963
0.756
1.082

0.749 – 1.462
0.577 – 1.608
0.496 – 1.153
0.714 – 1.639

0.790
0.887
0.194
0.712

Reference group
0.688

0.506 – 0.937

0.018

Reference group
0.960
0.645
0.696

0.704 – 1.309
0.473 – 0.880
0.498 – 0.972

0.797
0.006
0.033

Reference group
3.330
6.475
18.032

2.262 – 4.902
4.335 – 9.673
11.894 – 27.338

<.001
<.001
<.001

________________________________________________________________________________________________________________________________________________

a

Chi-square test

Model Statistics:
N=2,056
Likelihood Ratio Test: Chi-square statistic=289.791, DF=11, p=<.001
Hosmer and Lemeshow Goodness of Fit test: Chi-square statistic=4.492, DF=8, p=0.810
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communication and overall PIM use, after adjusting for age, region, and number of
medications.
Associations between Perceived Provider
Knowledge and PIM Use
Bivariate Associations between Perceived Provider
Knowledge and PIM Use
Table 34 presents the distribution of perceived provider knowledge index scores.
To avoid potential problems from small cell counts in logistic regression analysis, index
scores were collapsed into four levels, with each level having not less than 100
observations (Table 35). The four levels of the perceived provider knowledge variable
were “2 to 5,” “6,” “7,” and “8.” Perceived provider knowledge index scores of 2 to 5
was selected as the reference category.
Ten events per degree of freedom are required for reliable parameter estimation in
logistic regression models (Harrell, Lee et al. 1996; LaValley 2008; Peduzzi, Concato et
al. 1996). However, because number of excess dose, excess duration, or drug-disease
interaction PIM users did not satisfy event size requirements for reliable models,
associations between perceived provider knowledge and excess dose, excess duration or
drug-disease interaction PIM use were not included in analyses.
Bivariate Associations between Perceived Provider
Knowledge and Inappropriate Drug Choice PIM Use
There was no significant difference in mean perceived provider knowledge scores
between inappropriate drug choice PIM users (mean score=6.5, SE=0.06) and non-users
(mean score=6.6, SE=0.03). In bivariate logistic regression analysis, individuals with
more positive perceived provider knowledge index scores of 6 (OR=0.62, 95% CI=0.42
to 0.93, p=0.019), 7 (OR=0.47, CI=0.25 to 0.89, p=0.020), or 8 (OR=0.58, CI=0.38 to
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Table 34: Distribution of Perceived Provider Knowledge Index Scores
________________________________________________________________________
Index Score
Frequency
Percent
_______________________________________________________________________________________________________________________________________________

Two

4

0.19

Three

3

0.15

Four

69

3.36

Five

71

3.46

Six

1,123

54.73

Seven

120

5.85

Eight

662

32.26

________________________________________________________________________________________________________________________________________________
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Table 35: Grouped Distribution of Perceived Provider Knowledge Index Scores
________________________________________________________________________
Index Score
Frequency
Percent
_______________________________________________________________________________________________________________________________________________

2 to 5

147

7.16

6

1,123

54.73

7

120

5.85

8

662

32.26

________________________________________________________________________________________________________________________________________________
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0.88, p=0.011) were more likely than those with index scores between 2 and 5 to use
inappropriate drug choice PIMs (Table 36).
Bivariate Associations between Perceived
Provider Knowledge and Overall PIM Use
There was no significant difference in mean perceived provider knowledge scores
between overall PIM users (mean score=6.5, SE=0.05) and PIM non-users (mean
score=6.6, SE=0.03). Table 37 presents results of bivariate logistic regression examining
associations between perceived provider knowledge and overall PIM use. There were no
associations found between perceived provider knowledge and overall PIM use.
Multivariate Associations between Perceived Provider
Knowledge and PIM Use after Adjusting for Demographic
and Clinical Characteristics
Multivariate Associations between Perceived Provider
Knowledge and Inappropriate Drug Choice PIM Use after
Adjusting for Demographic and Clinical Characteristics
Multiple logistic regression models were developed to assess associations
between perceived provider knowledge and inappropriate drug choice PIM use, adjusting
for demographic and clinical characteristics. The response variable in the model was
inappropriate drug choice PIM use. The predictor variable in the model was perceived
provider knowledge. Covariates included in the model were age, gender, ethnicity,
region, education, income, number of medications, depression diagnosis, and selfreported health status. A model with all two-way interactions and main effects was
examined using the FORWARD SELECTION procedure in SAS PROC LOGISTIC.
There were no significant interactions found, and so the main effects model was retained.
A reduced model was developed that included only significant covariates from the initial
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Table 36: Bivariate Associations between Perceived Provider Knowledge and
Inappropriate Drug Choice PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Perceived Provider
Knowledge Index
2 to 5
6
7
8

Reference group
0.622
0.473
0.578

0.417 – 0.927
0.252 – 0.891
0.379 – 0.881

0.019
0.020
0.011

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 37: Bivariate Associations between Perceived Provider Knowledge and
Overall PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Perceived Provider
Knowledge Index
2 to 5
6
7
8

Reference group
0.739
0.634
0.679

0.500 – 1.091
0.354 – 1.135
0.451 – 1.022

0.128
0.125
0.064

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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model and the reduced model used for final analyses. Significant covariates in the
reduced model were age, region, and number of medications.
Table 38 presents results of the multiple logistic regression analysis. The model
showed good model fit with a non-significant Homer Lemeshow test (p=0.845). Results
of bivariate probit models developed to account for selection bias indicated no
selection bias (rho p-value =0.402) (Appendix Table E1). Results of the link test
checking for model specification error indicated that the model was properly specified
and no relevant variables were left out or irrelevant variables included (hat-square pvalue =0.431) (Appendix Table H1). Graphical plots of influence statistics as shown in
Appendix Figure K1 and Appendix Figure K2 indicated presence of subjects with
influential covariate patterns. However, removing these subjects from analysis did not
alter the significance of model parameter estimates and so the reduced model was
retained.
Results from the multiple logistic regression model as shown in Table 38
indicated individuals having more positive perceived provider knowledge index scores of
six (OR=0.62, 95% CI=0.39 to 0.97, p=0.036), seven (OR=0.44, 95% CI=0.22 to 0.87,
p=0.018), or eight (OR=0.55, 95% CI=0.34 to 0.88, p=0.012) were less likely than those
with index scores ranging from two to five to use inappropriate drug choice PIMs, after
adjusting for age, region, and number of medications. Moreover, after adjusting for
multiple comparisons using False Discovery Rate (FDR) correction, individuals having
more positive perceived provider knowledge index scores of six (OR=0.62, 95% CI=0.39
to 0.97, FDR=0.036), seven (OR=0.44, 95% CI=0.22 to 0.87, FDR=0.027), or eight
(OR=0.55, 95% CI=0.34 to 0.88, FDR=0.027) were less likely than those with index
scores ranging from two to five to use inappropriate drug choice PIMs (Table 39).
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Table 38: Multivariate Associations between Perceived Provider Knowledge and
Inappropriate Drug Choice PIM Use, Adjusting for Age, Region, and
Number of Medications
________________________________________________________________________
Variable

Adjusted Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Perceived Provider
Knowledge Index
2 to 5
6
7
8
Age
65 to 84
85+
Region
South or Puerto Rico
West
Midwest
Northeast
Number of Medications
0 to 5
6 to 10
11 to 15
16+

Reference group
0.619
0.437
0.547

0.395 – 0.969
0.219 – 0.869
0.341 – 0.876

0.036
0.018
0.012

Reference group
0.702

0.504 – 0.977

0.036

Reference group
0.673
0.600
0.655

0.477 – 0.948
0.431 – 0.836
0.459 – 0.934

0.024
0.003
0.019

Reference group
3.238
5.180
18.148

2.124 – 4.937
3.338 – 8.040
11.681 – 28.196

<.001
<.001
<.001

________________________________________________________________________________________________________________________________________________

a

Chi-square test

Model Statistics:
N=2,052
Likelihood Ratio Test: Chi-square statistic=269.848, DF=10, p=<.001
Hosmer and Lemeshow Goodness of Fit test: Chi-square statistic=4.135, DF=8, p=0.845
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Table 39: Multiplicity Adjusted P-Values for Perceived Provider Knowledge in Model
Examining Associations between Perceived Provider Knowledge and
Inappropriate Drug Choice PIM Use, Adjusting for Age, Region, and Number
of Medications
________________________________________________________________________
Variable

Adjusted Odds Ratio

95% CI

FDRa

________________________________________________________________________________________________________________________________________________

Perceived Provider
Knowledge Index
2 to 5
6
7
8

Reference group
0.619

0.395 – 0.969

0.036

0.437
0.547

0.219 – 0.869
0.341 – 0.876

0.027
0.027

________________________________________________________________________________________________________________________________________________

a

False Discovery Rate test
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Multivariate Associations between Perceived Provider
Knowledge and Overall PIM Use after Adjusting for
Demographic and Clinical Characteristics
Multiple logistic regression models were developed to assess associations
between perceived provider knowledge and overall PIM use, adjusting for demographic
and clinical characteristics. The response variable in the model was overall PIM use.
The predictor variable in the model was perceived provider knowledge. Covariates
included in the model were age, gender, ethnicity, region, education, income, number of
medical conditions, depression diagnosis, and self-reported health status. A model with
all two-way interactions and main effects was examined using the FORWARD
SELECTION procedure in SAS PROC LOGISTIC. There were no significant
interactions found, and so the main effects model was retained. A reduced model was
developed that included only significant covariates from the initial model and the reduced
model used for final analyses. Significant covariates included in the reduced model were
age, and number of medications.
Table 40 presents results of the multiple logistic regression analysis. The model
showed good model fit with a non-significant Homer Lemeshow test (p=0.844). Results
of bivariate probit models developed to account for selection bias indicated no selection
bias (rho p-value =0.304) (Appendix Table E2). Results of the link test checking for
model specification error indicated that the model was properly specified and no relevant
variables were left out or irrelevant variables included (hat-square p-value =0.878)
(Appendix Table H2). Graphical plots of influence statistics as shown in Appendix
Figure K3 and Appendix Figure K4 indicated presence of subjects with influential
covariate patterns. However, removing these subjects from analysis did not alter the
significance of model parameter estimates and so the reduced model was retained.
As shown in Table 40, there were no associations found between perceived knowledge
and overall PIM use, after adjusting for age, and number of medications.
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Table 40: Multivariate Associations between Perceived Provider Knowledge and
Overall PIM Use, Adjusting for Age and Number of Medications
________________________________________________________________________
Variable

Adjusted Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Perceived Provider
Knowledge Index
2 to 5
6
7
8
Age
65 to 84
85+
Number of Medications
0 to 5
6 to 10
11 to 15
16+

Reference group
0.730
0.591
0.636

0.471 – 1.131
0.313 – 1.115
0.403 – 1.005

0.159
0.104
0.053

Reference group
0.675

0.496 – 0.917

0.012

Reference group
3.368
6.672
19.253

2.288 – 4.960
4.473 – 9.952
12.732 – 29.114

<.001
<.001
<.001

________________________________________________________________________________________________________________________________________________

a

Chi-square test

Model Statistics:
N=2,047
Likelihood Ratio Test: Chi-square statistic=288.568, DF=7, p=<.001
Hosmer and Lemeshow Goodness of Fit test: Chi-square statistic=3.420, DF=7, p=0.844
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Associations between Perceived Provider
Competence and PIM Use
Bivariate Associations between Perceived Provider
Competence and PIM Use
Table 41 presents the distribution of perceived provider competence index scores.
To avoid potential problems from small cell counts in logistic regression analysis, index
scores were collapsed into four levels, with each level having not less than 100
observations (Table 42). The four levels of the perceived provider competence variable
were “2 to 5,” “6,” “7,” and “8.” Perceived provider competence index scores of 2 to 5
was selected as the reference category.
Ten events per degree of freedom are required for reliable parameter estimation in
logistic regression models (Harrell, Lee et al. 1996; LaValley 2008; Peduzzi, Concato et
al. 1996). However, because number of excess dose, excess duration, or drug-disease
interaction PIM users did not satisfy event size requirements for reliable models,
associations between perceived provider competence and excess dose, excess duration or
drug-disease interaction PIM use were not included in analyses.
Bivariate Associations between Perceived Provider
Competence and Inappropriate Drug Choice PIM Use
There was no significant difference in mean perceived provider competence scores
between inappropriate drug choice PIM users (mean score=6.7, SE=0.06) and non-users
(mean score=6.7, SE=0.02). Table 43 presents results of bivariate analysis examining
associations between perceived provider competence and inappropriate drug choice PIM
use. There were no associations found between perceived provider competence and
inappropriate drug choice PIM use.
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Table 41: Distribution of Perceived Provider Competence Index Scores
________________________________________________________________________
Index Score
Frequency
Percent
_______________________________________________________________________________________________________________________________________________

Two

2

0.10

Three

3

0.15

Four

19

0.92

Five

106

5.15

Six

1,059

51.41

Seven

194

9.42

Eight

677

32.86

________________________________________________________________________________________________________________________________________________
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Table 42: Grouped Distribution of Perceived Provider Competence Index Scores
________________________________________________________________________
Index Score
Frequency
Percent
_______________________________________________________________________________________________________________________________________________

2 to 5

130

6.31

6

1,059

51.41

7

194

9.42

8

677

32.86

________________________________________________________________________________________________________________________________________________
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Table 43: Bivariate Associations between Perceived Provider Competence and
Inappropriate Drug Choice PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Perceived Provider
Competence Index
2 to 5
6
7
8

Reference group
0.713
0.637
0.765

0.458 – 1.110
0.361 – 1.123
0.485 – 1.209

0.135
0.119
0.252

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Bivariate Associations between Perceived
Provider Competence and Overall PIM Use
There was no significant difference in mean perceived provider competence
scores between overall PIM users (mean score=6.7, SE=0.05) and PIM non-users (mean
score=6.7, SE=0.03). Table 44 presents results of bivariate logistic regression examining
associations between perceived provider competence and overall PIM use. There were
no associations found between perceived provider competence and overall PIM use.
Multivariate Associations between Perceived Provider
Competence and PIM Use after Adjusting for Demographic
and Clinical Characteristics
Multivariate Associations between Perceived Provider
Competence and Inappropriate Drug Choice PIM Use after
Adjusting for Demographic and Clinical Characteristics
Multiple logistic regression models were developed to assess associations between
perceived provider competence and inappropriate drug choice PIM use, adjusting for
demographic and clinical characteristics. The response variable in the model was
inappropriate drug choice PIM use. The predictor variable in the model was perceived
provider competence. Covariates included in the model were age, gender, ethnicity,
region, education, income, number of medications, depression diagnosis, and selfreported health status. A model with all two-way interactions and main effects was
examined using the FORWARD SELECTION procedure in SAS PROC LOGISTIC.
There were no significant interactions found, and so the main effects model was retained.
A reduced model was developed that included only significant covariates from the initial
model and the reduced model used for final analyses. Significant covariates in the
reduced model were age, region, and number of medications.
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Table 44: Bivariate Associations between Perceived Provider Competence and
Overall PIM Use
________________________________________________________________________
Variable

Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Perceived Provider
Competence Index
2 to 5
6
7
8

Reference group
0.803
0.771
0.827

0.525 – 1.229
0.453 – 1.311
0.533 – 1.284

0.313
0.337
0.398

________________________________________________________________________________________________________________________________________________

a

Chi-square test
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Table 45 presents results of the multiple logistic regression analysis. The model
showed good model fit with a non-significant Homer Lemeshow test (p=0.372). Results
of bivariate probit models developed to account for selection bias indicated no
selection bias (rho p-value =0.129) (Appendix Table F1). Results of the link test
checking for model specification error indicated that the model was properly specified
and no relevant variables were left out or irrelevant variables included (hat-square pvalue =0.544) (Appendix Table I1). Graphical plots of influence statistics as shown in
Appendix Figure L1 and Appendix Figure L2 indicated presence of subjects with
influential covariate patterns. However, removing these subjects from analysis did not
alter the significance of model parameter estimates and so the reduced model was
retained. As shown in Table 45, there were no associations were found between
perceived provider competence and inappropriate drug choice PIM use after adjusting for
age, region, and number of medications.
Multivariate Associations between Perceived Provider
Competence and Overall PIM Use after Adjusting for
Demographic and Clinical Characteristics
Multiple logistic regression models were developed to assess associations
between perceived provider competence and overall PIM use, adjusting for demographic
and clinical characteristics. The response variable in the model was overall PIM use.
The predictor variable in the model was perceived provider competence. Covariates
included in the model were age, gender, ethnicity, region, education, income, number of
medical conditions, depression diagnosis, and self-reported health status. A model with
all two-way interactions and main effects was examined using the FORWARD
SELECTION procedure in SAS PROC LOGISTIC. There were no significant
interactions found, and so the main effects model was retained. A reduced model was
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Table 45: Multivariate Associations between Perceived Provider Competence and
Inappropriate Drug Choice PIM Use, Adjusting for Age, Region, and
Number of Medications
________________________________________________________________________
Variable

Adjusted Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Perceived Provider
Competence Index
2 to 5
6
7
8
Age
65 to 84
85+
Region
South or Puerto Rico
West
Midwest
Northeast
Number of Medications
0 to 5
6 to 10
11 to 15
16+

Reference group
0.923
0.821
0.926

0.567 – 1.504
0.443 – 1.521
0.561 – 1.527

0.749
0.530
0.763

Reference group
0.702

0.504 – 0.978

0.036

Reference group
0.679
0.594
0.635

0.482 – 0.957
0.426 – 0.827
0.444 – 0.908

0.027
0.002
0.013

Reference group
3.118
5.064
17.525

2.047 – 4.748
3.267 – 7.847
11.279 – 27.230

<.001
<.001
<.001

________________________________________________________________________________________________________________________________________________

a

Chi-square test

Model Statistics:
N=2,060
Likelihood Ratio Test: Chi-square statistic=257.819, DF=10, p=<.001
Hosmer and Lemeshow Goodness of Fit test: Chi-square statistic=8.661, DF=8, p=0.372
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developed that included only significant covariates from the initial model and the reduced
model used for final analyses. Significant covariates included in the reduced model were
age, and number of medications.
Table 46 presents results of the multiple logistic regression analysis. The model
showed good model fit with a non-significant Homer Lemeshow test (p=0.926). Results
of bivariate probit models developed to account for selection bias indicated no selection
bias (rho p-value =0.370) (Appendix Table F2). Results of the link test checking for
model specification error indicated that the model was properly specified
and no relevant variables were left out or irrelevant variables included (hat-square pvalue =0.944) (Appendix Table I2). Graphical plots of influence statistics as shown in
Appendix Figure L3 and Appendix Figure L4 indicated presence of subjects with
influential covariate patterns. However, removing these subjects from analysis did not
alter the significance of model parameter estimates and so the reduced model was
retained. As shown in Table 46, there were no associations found between perceived
provider competence and overall PIM use, after adjusting for age, and number of
medications.
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Table 46: Multivariate Associations between Perceived Provider Competence and
Overall PIM Use, Adjusting for Age and Number of Medications
________________________________________________________________________
Variable

Adjusted Odds Ratio

95% CI

p-valuea

________________________________________________________________________________________________________________________________________________

Perceived Provider
Competence Index
2 to 5
6
7
8
Age
65 to 84
85+
Number of Medications
0 to 5
6 to 10
11 to 15
16+

Reference group
1.083
1.026
1.036

0.679 – 1.727
0.576 – 1.828
0.641 – 1.675

0.738
0.932
0.884

Reference group
0.669

0.492 – 0.910

0.010

Reference group
3.319
6.490
18.857

2.256 – 4.883
4.354 – 9.675
12.459 – 28.540

<.001
<.001
<.001

________________________________________________________________________________________________________________________________________________

a

Chi-square test

Model Statistics:
N=2,060
Likelihood Ratio Test: Chi-square statistic=278.645, DF=7, p=<.001
Hosmer and Lemeshow Goodness of Fit test: Chi-square statistic=2.515, DF=7, p=0.926
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SUMMARY AND CONCLUSIONS

Background
Potentially inappropriate medications (PIMs) are defined as medications that
introduce a significant risk of adverse events in older adults or persons aged 65 years or
older where there exists alternative therapy for treating the same condition that are
equally effective and safer (Beers, Ouslander et al., 1991; Stuck, Beers et al., 1994). The
evidence of associations between PIM use and higher risk for morbidity, mortality, and
increased health care expenditures make use of such drugs an important public health
concern (Guaraldo, Cano et al., 2011; Spinewine, Schmader et al., 2007).
The Beers criteria are the most accepted and most commonly used measure of
PIM use in older adults, and were revised in 2012 (American Geriatrics Society 2012
Beers Criteria Update Expert Panel 2012). Prior studies have reported rates of PIM use
based on prior versions of the Beers criteria. No studies were found that reported
estimates of PIM use in older adults based on the 2012 Beers criteria, which is the most
current version of the Beers criteria. This study estimated rates of PIM use among
community-dwelling Medicare Part D beneficiaries based on the 2012 Beers criteria.
Such estimates will provide information on rates of inappropriate drug prescribing in
Medicare beneficiaries based on current clinical evidence.
Providers who are effective communicators, knowledgeable, and competent
should be able to elicit adequate information from patients about their conditions and
medication history, and translate such information into accurate diagnoses and
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appropriate therapy. Because patient perceptions of provider communication, provider
knowledge, and provider competence have been associated with measures of health
quality including satisfaction with care and adherence to therapy in prior studies, it is
expected that patient perceptions of such provider behavior would be associated with
PIM use, another measure of healthcare quality. However, evidence is lacking on
whether patient perceptions of such provider behavior are associated with PIM use. This
study will inform on possible associations between patient perceptions of provider
communication, provider knowledge, and provider competence and PIM use among
community-dwelling Medicare Part D beneficiaries.
Objectives
Study objectives were to:
1. Determine prevalence of PIM use among community-dwelling Medicare Part D
beneficiaries,
2. Determine incidence of PIM use among community-dwelling Medicare Part D
beneficiaries,
3. Examine associations between perceived provider communication and PIM use
among community-dwelling Medicare Part D beneficiaries,
4. Examine associations between perceived provider knowledge and PIM use
among community-dwelling Medicare Part D beneficiaries, and
5. Examine associations between perceived provider competence and PIM use
among community-dwelling Medicare Part D beneficiaries.
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Methods
A retrospective observational analysis was conducted to determine the prevalence
and incidence of PIM use among community-dwelling Medicare beneficiaries, and to
examine associations between patient perceptions of provider communication, provider
knowledge, and provider competence and PIM use among community-dwelling Medicare
beneficiaries. Data for the analyses were obtained from Medicare Current Beneficiary
Survey files maintained by the Office of Strategic Planning of the Centers for Medicare
and Medicaid Services. Claim files from January 2007 through December 2008 were
used.
Individuals were eligible for inclusion in the prevalence sample if they were aged
65 years or older in 2008, continuously enrolled in Medicare Part D from October 2007
through December 2008, and living in the community from October 2007 through
December 2008. There were no exclusion criteria for the prevalence sample. Individuals
were eligible for inclusion in the incidence sample if they were aged 65 years or older in
2008, continuously enrolled in Medicare Part D from October 2007 through December
2008, and living in the community from October 2007 through December 2008.
Individuals were excluded from the incidence sample if they received PIMs at any time
between October 2007 and December 2007.
Potentially inappropriate medications were identified based on the 2012 Beers
criteria (American Geriatrics Society 2012 Beers Criteria Update Expert Panel 2012) in
each of four broad categories including inappropriate drug choice, excess dose, excess
duration, and drug-disease interaction. Inappropriate drug choice PIMs are medications
considered always potentially inappropriate in older adults. Excess dose PIMs are
medications considered potentially inappropriate at daily doses beyond specific limits.
Excess duration PIMs are medications considered potentially inappropriate when used
beyond certain lengths of time. Drug-disease interaction PIMs are medications
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considered potentially inappropriate in older adults having specific concomitant
conditions.
The data elements from Medicare Current Beneficiary Survey prescription claim
files used to identify PIMs were generic name of drug, number of days supplied, drug
quantity, dosage strength, route of administration, and date of service. To identify
whether an individual had diagnosis for a condition listed in the 2012 Beers criteria,
claims records from January 2007 through December 2008 for each individual were
examined for condition-specific ICD-9 CM codes. One source of ICD-9 CM codes was a
systematic search of the Medline database from January 2008 through May 2013, using
‘ICD-9 code’ and name of the condition as keywords to identify published articles
describing use of such codes to identify diagnosis for that condition. Another source was
an online searchable database of ICD-9 CM codes compiled from files available from the
National Center for Health Statistics (National Center for Health Statistics 2009). A third
source was the Clinical Classifications Software for ICD 9-CM maintained by the
Agency for Healthcare Resource and Quality and available online (Agency for
Healthcare Research and Quality 2010). Condition-specific ICD-9 CM codes identified
in at least two of the three sources were used to identify individuals with that condition.
To identify use of inappropriate drug choice PIMs, a separate variable was created
for each inappropriate drug choice PIM and the variable assigned a value of ‘1’ if the
individual received medication associated with the specific variable in 2008. Otherwise a
value of ‘0’ was assigned to the variable. To identify use of excess dose PIMs, a separate
variable was created for each excess dose PIM and assigned a value of ‘1’ if the
individual received medication associated with the specific variable in 2008 and had a
calculated daily dose that exceeded dose limits for that medication. Otherwise a value of
‘0’ was assigned to the variable. To identify use of excess duration PIMs, a separate
variable was created for each excess duration PIM and assigned a value of ‘1’ if the
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individual received medication associated with the specific variable in 2008 and had
duration of use that exceeded duration limits for that medication. Otherwise a value of
‘0’ was assigned to the variable. To identify use of drug-disease interaction PIMs, first
2007 and 2008 claims records for each individual were examined to determine whether
the person had diagnosis for a condition listed in this PIM category. Then a separate
variable was created for each drug-disease interaction PIM and assigned a value of ‘1’ if
the individual received medication considered potentially inappropriate for that specific
condition in 2008 and had diagnosis for the condition prior to receiving the drug.
Otherwise a value of ‘0’ was assigned to the variable.
Patient perceptions of provider communication, provider knowledge and provider
competence were assessed using previously validated indices (Ward and Thomas 2013).
The perceived communication index was created from patient responses to five questions
in the Medicare Current Beneficiary Survey. The perceived knowledge and perceived
competence indices were each created from patient responses to two survey questions.
All questions included in each domain must have been answered for the index to be
created. The response to each question was given a value from one to four. One
indicated a response of strongly disagree, two indicated disagree, three indicated agree,
and four indicated strongly agree. Negatively worded questions were reverse coded and
values within each domain summed to create each index. The communication index had
a theoretical range of 4 to 20. The knowledge index had a range of 2 to 8, and the
competence index had a range of 2 to 8. For all indices, a higher score indicates more
positive patient perception of physicians.
To determine prevalence of PIMs identified in the inappropriate drug choice,
excess dose, excess duration, and drug-disease interaction categories, percentages and 95
percent confidence intervals were calculated for individuals receiving PIMs in each of the
four categories at any time in 2008. To determine prevalence of overall PIM use,
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percentages and 95 percent confidence intervals were calculated for the proportion of
individuals receiving at least one PIM in any of the four PIM categories at any time in
2008. To determine incidence of PIMs identified in the inappropriate drug choice, excess
dose, excess duration, and drug-disease interaction categories, percentages and 95 percent
confidence intervals were calculated for individuals with new receipt of PIMs in each of
the four categories at any time in 2008. To determine incidence of overall PIM use,
percentages and 95 percent confidence intervals were calculated for the proportion of
individuals with new receipt of at least one PIM in any of the four PIM categories at any
time in 2008.
Multiple logistic regression models were developed to examine associations
between perceived provider communication and PIM use, to examine associations
between perceived provider knowledge and PIM use, and to examine associations
between perceived provider competence and PIM use. The incidence of PIM use was
focused on in these models.
Results and Discussion
Prevalence Sample Characteristics
A total of 2,705 individuals were identified in the prevalence sample. The mean
age for PIM users (76.8 years, Standard Error = 0.24) was less than the mean age for PIM
non-users (77.6 years, SE = 0.17). More PIM users were female (67.08%) as compared
to PIM non-users (58.44%). There were more Whites in the PIM non-user group
(85.32%) than in the PIM user group (81.30%). A greater proportion of PIM users
(45.91%) than PIM non-users (36.87%) were living in the South region of the US or
Puerto Rico. There were more PIM users at an educational level of 8th grade or lower
(20.13%) as compared to PIM non-users (13.78%). More PIM users (40.31%) than PIM
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non-users (34.00%) had an annual income of 15,000 dollars or less. The mean number of
medications received by PIM users (13.4 medications, SE = 0.22) was greater than that
received by PIM non-users (7.8 medications, SE = 0.17). More PIM non-users (86.87%)
had diagnosis for depression than PIM users (77.08%). A greater proportion of PIM
users (35.95%) than PIM non-users (20.86%) reported their health status as poor or fair.
Prevalence of PIM Use
Potentially inappropriate medications were identified based on the 2012 Beers
criteria in each of four broad categories including inappropriate drug choice, excess dose,
excess duration, and drug-disease interaction. The one-year prevalence of PIM use
among community-dwelling Medicare Part D beneficiaries was 27.6 percent for
inappropriate drug choice PIMs (95% CI = 25.9 to 29.3), 3.3 percent for excess dose
PIMs (95% CI = 2.6 to 3.9), 3.5 percent for excess duration PIMs (95% CI = 2.8 to 4.2),
and 3.2 percent for drug-disease interaction PIMs (95% CI = 2.5 to 3.8). There were no
studies found that reported PIM prevalence estimates in Medicare beneficiaries based on
the 2012 Beers criteria which is the most current version of the Beers criteria. Prior
studies of PIM use in the Medicare population based on previous versions of the Beers
criteria reported rates ranging from 21.3 percent to 34.4 percent (Cannon, Choi et al.,
2006; Fick, Waller et al., 2001; Skaar and O'Connor 2012; Stuart, Kamal-Bahl et al.,
2003; Woelfel, Patel et al., 2011). Cannon et al., Fick et al., and Stuart et al., identified
PIMs based on a subset of the 1997 Beers criteria consisting solely of inappropriate drug
choice PIMs, whereas, Woelfel et al. and Skarr et al. identified PIMs based on a subset of
the 2002 Beers criteria consisting of inappropriate drug choice, excess dose, and excess
duration PIMs. However, because previous versions of the Beers criteria differ from the
2012 Beers criteria, estimates of PIM prevalence in Medicare beneficiaries from prior
studies may not be directly comparable to estimates from the current study.
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The overall one-year prevalence of PIM use was 33.0 percent (95% CI = 31.2 to
34.8) with the most commonly received PIMs including glyburide (4.88%), promethazine
(4.51%), and estrogens (3.95%). Overall PIM use was defined as receipt of at least one
PIM identified in the inappropriate drug choice, excess dose, excess duration, or drugdisease interaction categories. There were no studies found that reported PIM prevalence
rates in Medicare beneficiaries based on the 2012 Beers criteria. There were also no
studies found that reported PIM prevalence in Medicare beneficiaries based on prior
versions of the Beers criteria using the entire criteria.
Incidence Sample Characteristics
A total of 2,210 individuals were identified in the incidence sample. The mean
age for PIM users (77.2 years, SE = 0.32) was less than the mean age for PIM non-users
(77.7 years, SE = 0.17). More PIM users were female (62.88%) as compared to PIM
non-users (58.28%). There were more Whites in the PIM non-user group (85.67%) than
in the PIM user group (79.91%). A greater proportion of PIM users (47.38%) than PIM
non-users (36.82%) were living in the South region of the US or Puerto Rico. There were
more PIM users at an educational level of 8th grade or lower (20.22%) as compared to
PIM non-users (13.84%). More PIM users (39.74%) than PIM non-users (33.96%) had
an annual income of 15,000 dollars or less. The mean number of medications received
by PIM users (13.4 medications, SE = 0.31) was greater than that received by PIM nonusers (7.8 medications, SE = 0.12). A greater proportion of PIM non-users (86.76%) had
diagnosis for depression than PIM users (79.91%). More PIM users (34.94%) than PIM
non-users (20.67%) reported their health status as poor or fair.
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Incidence of PIM Use
The one-year incidence of PIM use among community-dwelling Medicare Part D
beneficiaries was 17.2 percent for inappropriate drug choice PIMs (95% CI = 15.6 to
18.8), 1.2 percent for excess dose PIMs (95% CI = 0.8 to 1.7), 2.6 percent for excess
duration PIMs (95% CI = 2.0 to 3.3), and 1.8 percent for drug-disease interaction PIMs
(95% CI = 1.3 to 2.4). Sample selection for the incidence sample required exclusion of
individuals receiving PIMs in the three months prior to the study period. The overall
one-year incidence of PIM use was 20.7 percent (95% CI = 19.0 to 22.4), with the most
commonly initiated PIMs including promethazine (3.62%), cyclobenzaprine (2.68%) and
zolpiderm (2.08%).
Associations between Perceived Provider Communication and PIM Use,
Adjusting for Demographic and Clinical Characteristics
Multiple logistic regression models were developed to assess associations
between perceived provider communication and use of PIMs identified in the
inappropriate drug choice category, adjusting for age, gender, ethnicity, region,
education, income, depression diagnosis, number of medications, and self-reported health
status. To avoid potential problems from small cell counts in logistic regression analysis,
perceived provider communication scores were collapsed into five levels of “5 to 14,”
“15,” “16,” “17 or 18,” and “19 or 20,” with each level having not less than 100
observations. A reduced model was developed that included only significant covariates
and two-way interactions from the initial model and the reduced model used for final
analyses. Significant covariates in the reduced model were age, region, and number of
medications. Models were similarly developed for overall PIM use with age, region, and
number of medications included as significant covariates in the reduced model.
Individual models were not developed for excess dose, excess duration, and drug-disease
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interaction PIM use because there were insufficient number of such PIM users to conduct
analyses.
Perceived provider communication was not associated with inappropriate drug
choice PIM use after adjusting for age, region, and number of medications. Perceived
provider communication was also not associated with overall PIM use after adjusting for
age, region, and number of medications. There were no prior studies found that
examined associations between patient perceptions of provider communication and PIM
use. One study was found that examined associations between objective assessments of
provider communication and medication use (Kawasumi, Ernst et al., 2011). The authors
found no associations between provider communication based on test scores from a
physician licensing examination and appropriate prescribing of recommended
corticosteroids in patients with out-of-control asthma, but focused on use of only one
medication class and excluded older adults at higher risk for drug therapy problems.
However, because the objective measure of provider communication used in the study by
Kawasumi et al. may not necessarily assess the same construct as the subjective measure
of provider communication in the current study, comparing findings may be difficult.
Finding no associations between patient perceptions of provider communication
and PIM use were surprising. Although hypothesized relationships between perceived
provider characteristics and PIM use were not based upon the former reflecting actual
provider ability, of the three perceived provider characteristics assessed in this study,
perceived provider communication was thought to be the one most likely to be associated
with PIM use. This is because most patients are better able to directly assess provider
communication than either provider knowledge or provider competence.
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Associations between Perceived Provider Knowledge and PIM Use,
Adjusting for Demographic and Clinical Characteristics
Multiple logistic regression models were developed to assess associations
between perceived provider knowledge and inappropriate drug choice PIM use, adjusting
for age, gender, ethnicity, region, education, income, depression diagnosis, number of
medications, and self-reported health status. Perceived provider knowledge scores were
collapsed into four levels of “2 to 5,” “6,” “7,” and “8,” with each level having not less
than 100 observations. A reduced model was developed that included only significant
covariates and two-way interactions from the initial model and the reduced model used
for final analyses. Significant covariates in the reduced model were age, region, and
number of medications. Models were similarly developed for overall PIM use with age,
and number of medications included as significant covariates in the reduced model.
There were no associations found between perceived provider knowledge and
overall PIM use. However, individuals having more positive perceived provider
knowledge scores were less likely to use inappropriate drug choice PIMs. Prior studies
assessing associations between perceived provider knowledge and PIM use were not
found. One study was found that examined associations between objective assessments
of provider knowledge and non-steroidal anti-inflammatory drug use (Grad, Tamblyn et
al., 1997). Grad et al. found no associations between provider knowledge of appropriate
non-steroidal anti-inflammatory drug prescribing and quality of therapeutic management.
However, they focused on use of only one medication class and analyzed a sample size of
only 37 cases. Nevertheless, because the objective measure of provider knowledge
applied in the study by Grad et al. may not necessarily assess the same construct as the
subjective measure of provider knowledge in the current study, comparing findings may
be difficult.
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Associations between Perceived Provider Competence and PIM Use,
Adjusting for Demographic and Clinical Characteristics
Multiple logistic regression models were developed to assess associations
between perceived provider competence and inappropriate drug choice PIM use,
adjusting for age, gender, ethnicity, region, education, income, depression diagnosis,
number of medications, and self-reported health status. Perceived provider competence
scores were collapsed into four levels of “2 to 5,” “6,” “7,” and “8,” with each level
having not less than 100 observations. A reduced model was developed that included
only significant covariates and two-way interactions from the initial model and the
reduced model used for final analyses. Significant covariates in the reduced model were
age, region, and number of medications. Models were similarly developed for overall
PIM use with age, and number of medications included as significant covariates in the
reduced model.
Perceived provider competence was not associated with inappropriate drug choice
PIM use or overall PIM use. No prior studies were found that examined associations
between patient perceptions of provider competence and PIM use. One study was found
that examined associations between objective assessments of provider competence and
medication use (Kawasumi, Ernst et al. 2011). The authors found no associations
between provider competence based on test scores from a physician licensing
examination and use of recommended steroids in patients with out-of-control asthma, but
focused on use of only one medication class and excluded older adults at higher risk for
drug therapy problems. However, because objective measures of provider competence
used in the study by Kawasumi et al. may not necessarily assess the same construct as the
subjective measure of provider comptence in the current study, findings may not be
comparable.
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Study Limitations
A few limitations should be noted in interpreting study results. The study samples
were limited to community-dwelling Medicare beneficiaries so caution in making
inferences beyond this population is advised. The study uses administrative claims data
from the Medicare Current Beneficiary Survey. Any incomplete, missing, or erroneous
data in claims may affect estimates of medication use. Diagnosis for disease conditions
listed in the 2012 Beers criteria were identified using ICD-9 CM codes in claims data and
use of ICD-9 codes in claims data to identify diagnosis may be imperfect due to coding
variation. However, the ICD-9 CM codes used in the current study have used in prior
studies to identify the specific disease conditions.
A three-month PIM-free interval was used to identify incident PIM users. It is
possible that some individuals included in the incidence sample may have received PIMs
before the three-month PIM-free interval. Thirty-seven percent of PIMs listed in the
2012 Beers criteria could not be identified using information available in claims data and
so estimates of PIM use in the current study may be conservative.
Conclusions
This study determined prevalence and incidence of PIM use among communitydwelling Medicare Part D beneficiaries and assessed associations between patients’
perceptions of provider communication, provider knowledge, and provider competence
with PIM use. The overall one-year prevalence of PIM use was 33 percent. The overall
one-year incidence of PIM use was approximately 21 percent. Because information
required to identify all PIMs listed in the 2012 Beers criteria were not available, the
estimates of PIM use may be conservative.
It was hypothesized that patients’ perceptions of provider communication,
provider knowledge, and provider competence would be associated with PIM use.
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Results from this study indicate that more positive patients’ perceptions of provider
knowledge was associated with lower probability for PIM use. However, there were no
associations found between patients’ perceptions of provider communication or provider
competence and PIM use.
Implications
The considerable use of PIMs among community-dwelling Medicare Part D
beneficiaries is a significant public health concern given prior evidence of associations
between such medication use and higher morbidity, mortality, and healthcare
expenditure. It is possible that patients’ perceptions of provider knowledge accurately
reflect actual provider ability. In which case findings that patients’ perceptions of
provider knowledge was associated with PIM use may provide some direction to efforts
to identify provider-specific risk factors for PIM use. It is also possible that patients’
perceptions of provider knowledge do not accurately reflect actual provider ability. In
that case the findings may suggest that patients’ perceptions of provider knowledge
reflect some aspect of the patient-provider interaction that impacts PIM use and this
needs to be explored further.
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Table A1: List of Medications Considered Potentially Inappropriate for Use in Persons
Aged 65 Years or Older Based on the 2012 Beers Criteria
_______________________________________________________________________
Therapeutic or
Included in
Drug class
Medication
Analysis
______________________________________________________________________________________________________________________________________________

INAPPROPRIATE DRUG CHOICE
Alpha agonists, central
Guanabenz
Guanfacine
Methyldopa





Meperidine
Pentazocine




Indomethacin
Ketorolac, includes parenteral




Disopyramide



Brompheniramine
Carbinoxamine
Chlorpheniramine
Clemastine
Cyproheptadine
Dexbrompheniramine
Dexchlorpheniramine
Doxylamine
Hydroxyzine
Promethazine
Triprolidine













Trimethobenzamide
Metoclopramide (avoid, except
for treatment of gastroparesis)



Analgesics, narcotic

Analgesics, non-narcotic

Antiarrhythmic
Antihistamines, first generation

Antiemetics



Anti-infective
Nitrofurantoin (avoid in persons
with CrCL < 60 ml/min)



Benztropine, oral
Trihexyphenidyl




Thioridazine
Mesoridazine




Antiparkinson agents

Antipsychotics
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Table 1: Continued
_______________________________________________________________________
Therapeutic or
Included in
Drug class
Medication
Analysis
______________________________________________________________________________________________________________________________________________

Antispasmodics (avoid except
in short-term palliative care to
decrease oral secretions)
Belladonna alkaloids
Clidinium-chlordiazepoxide
Dicyclomine
Hyoscyamine
Propantheline
Scopolamine








Dipyridamole, oral short acting
(does not apply to extended release
combination with aspirin)
Ticlopidine



Amobarbital
Butabarbital
Butalbital
Mephobarbital
Pentobarbital
Phenobarbital
Secobarbital









Isoxsuprine



Nifedipine, immediate release



Desiccated thyroid
Estrogens with or without
progestins, oral and patch
Estrogens with or without progestins,
topical (acceptable to use low-dose
vaginal estrogen creams for treatment
of dyspareunia, lower urinary tract
infections, and other vaginal
symptoms)
Growth hormone (except as hormone
replacement after pituitary gland
removal)
Insulin, sliding scale
Megestrol



Antithrombotics

Barbiturates

Beta-adrenergic agonist
Calcium channel blocker
Hormones
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Table 1: Continued
_______________________________________________________________________
Therapeutic or
Included in
Drug class
Medication
Analysis
_____________________________________________________________________________________________________________________________________________

Hormones continued

Methyltestosterone (except used for
for moderate to severe hypogonadism)
Testosterone (except used for
moderate to severe hypogonadism)

Hypnotic/anxiolytic




Chloral hydrate
Meprobamate




Mineral oil, oral



Ergot mesylates



Carisoprodol
Chlorzoxazone
Cyclobenzaprine
Metaxalone
Methocarbamol
Orphenadrine






Chlorpropamide
Glyburide




Amitriptyline
Clomipramine
Imipramine
Trimipramine






Reserpine (> 0.1 mg/d)



Digoxin (> 0.125 mg/d)



Laxative
Psychotherapeutic agent
Skeletal muscle relaxants

Sulfonylureas, long duration

Tertiary Tricyclic Antidepressants

EXCESS DOSE
Alpha agonist, Central
Antiarrhythmic



Diuretic
Spironolactone > 25 mg/d (avoid
in patients with heart failure or with
CrCl < 30 ml/min)
Tertiary Tricyclic antidepressants
Doxepin (> 6mg/d)
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Table 1: Continued
_______________________________________________________________________
Therapeutic or
Included in
Drug class
Medication
Analysis
______________________________________________________________________________________________________________________________________________

EXCESS DURATION
Analgesics, non-narcotic
(avoid chronic use unless other
alternatives not effective and
patient can take gastroprotective agent)
Non-COX selective NSAIDs, oral
Aspirin > 325 mg/d
Diclofenac
Diflunisal
Etodolac
Fenoprofen
Ibuprofen
Ketoprofen
Meclofenamate
Mefenamic acid
Meloxicam
Nabumetone
Naproxen
Oxaprozin
Piroxicam
Sulindac
Tolmetin


















Anti-infective
Nitrofurantoin (avoid for
(long-term suppression)



Eszopiclone (avoid > 90days)
Zolpiderm (avoid > 90days)
Zaleplon (avoid > 90days)





Nonbenzodiazepine hypnotics
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Table 1: Continued
______________________________________________________________________
Included in
Disease/Condition
Medication
Analysis
_____________________________________________________________________________________________________________________________________________

DRUG-DISEASE INTERACTION
Agitation
Benzodiazepines (avoid for treatment
of agitation)
Alprazolam
Estazolam
Lorazepam
Oxazepam
Temazepam
Triazolam
Clorazepate
Chlordiazepoxide
Clonazepam
Diazepam
Flurazepam
Quazepam













Atrial fibrillation
Antiarrhythmic drugs, Class Ia, Ic, III
(avoid as 1st line treatment
for atrial fibrillation)
Amiodarone
Dofetilide
Dronedarone (also avoid in patients
with permanent atrial fibrillation)
Flecainide
Ibutilide
Procainamide
Propafenone
Quinidine
Sotalol











Chronic constipation (avoid
unless no other alternatives)
Oral muscarinics for urinary incontinence
Darifenacin
Fesoterodine
Oxybutynin, oral
Solifenacin
Tolterodine
Trospium
Calcium channel blockers
Diltiazem,
Verapamil
First generation antihistamines
Brompheniramine, Carbinoxamine
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Table 1: Continued
______________________________________________________________________
Included in
Disease/Condition
Medication
Analysis
_____________________________________________________________________________________________________________________________________________

Chronic constipation continued
Chlorpheniramine
Clemastine
Cyproheptadine
Dexbrompheniramine
Dexchlorpheniramine
Diphenhydramine
Doxylamine
Hydroxyzine
Promethazine
Tiprolidine
Anticholinergics and Antispasmodics
Antipsychotics
Belladonna alkaloids
Clidinium-chlordiazepoxide
Dicyclomine
Hyoscyamine
Propantheline
Scopolamine
Tertiary tricyclic antidepressants
Amitriptyline
Clomipramine
Doxepin
Imipramine
Trimipramine












NSAIDs
Triamterene




Anticholinergics
Benzodiazepines
H2-receptor antagonists
Zolpiderm
Antipsychotics







All tricyclic antidepressants
Anticholinergics
Benzodiazepines
Chlorpromazine
Corticosteriods
H2-receptor antagonists
Meperidine, Thioridazine
Sedative hypnotics










Chronic kidney disease,
Stages IV and V

Dementia and
cognitive impairment

Delirium
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Table 1: Continued
______________________________________________________________________
Included in
Disease/Condition
Medication
Analysis
_____________________________________________________________________________________________________________________________________________

Epilepsy or Chronic Seizures
Bupropion
Chlorpromazine
Clozapine
Maprotiline
Olanzapine
Thioridazine
Thiothixene
Tramadol










NSAIDs and COX-2 inhibitors
Calcium channel blockers (avoid
only for systolic heart failure)
Diltiazem,
Verapamil
Pioglitazone
Rosiglitazone
Cilostazol
Dronedarone



Heart failure








History of falls
or fractures (avoid unless
safer alternatives not available)
Anticonvulsants (avoid except for
seizure disorders)
Antipsychotics
Benzodiazepines
Nonbenzodiazepine hypnotics
Eszopiclone
Zaleplon
Zolpiderm
Tricyclic antidepressants
Selective serotonin reuptakeinhibitors










History of gastric or duodenal ulcers
Aspirin (>325mg/d), and NonCox2 NSAIDs (avoid unless other
alternatives not effective and patient
can take gastroprotective agent
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Table 1: Continued
______________________________________________________________________
Included in
Disease/Condition
Medication
Analysis
_____________________________________________________________________________________________________________________________________________

Hypertension
Clonidine (avoid as 1st line
hypertensive)
Alpha one blockers (avoid use
as antihypertensive)
Doxazosin
Prazosin
Terazosin






Insomnia
Oral decongestants
Pseudoephedrine
Phenylephrine
Stimulants
Amphetamine
Methylphenidate
Pemoline
Theobromines
Theophylline
Caffeine
Benzodiazepines (avoid for treatment
of insomnia)










Lower urinary tract symptoms,
benign prostatic hyperplasia
Inhaled anticholinergic agents;
Strongly anticholinergic drugs
(except antimuscarinics for
urinary incontinence) (Avoid in men)



Parkinson’s disease
Antipsychotics (except for
Quetiapine and Clozapine)
Antiemetics
Metoclopraminde
Prochlorperazine
Promethazine






Stress or mixed urinary incontinence
Alpha blockers (avoid in women)
Doxazosin
Prazosin
Terazosin
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Table 1: Continued
______________________________________________________________________
Included in
Disease/Condition
Medication
Analysis
_____________________________________________________________________________________________________________________________________________

Syncope
Acetylcholinesterate inhibitors
Pheripheral alpha blockers
Doxazosin
Prazosin
Terazosin
Tertiary Tricyclic antidepressants
Chlorpromazine, Thioridazine, and
Olanzapine








Urinary incontinence
Estrogen, oral and transdermal
(excludes intravaginal estrogen)
(Avoid in women)

_____________________________________________________________________
 Included in analysis
 Not included in analysis
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Table B1: List and Descriptions of ICD-9 Codes Used to Identify Conditions in the 2012 Beers Criteria
_________________________________________________________________________________________________________
Disease or
ICD-9CM
Condition
Code
Description
__________________________________________________________________________________________________________________________________________________________________________________________________________________

3082 [1, 17, 19]

Predominant psychomotor disturbance

Chronic Kidney
Disease, Stages
IV and V

40301 [1, 19]

5854 [1, 9, 15, 19, 21, 23]
5855 [1, 9, 15, 19, 21, 23]
5856 [1, 9, 15, 19, 21, 23]
586 [9, 19]

Malignant hypertensive chronic kidney disease, with chronic kidney disease stage V
or end stage renal disease
Benign hypertensive chronic kidney disease, with chronic kidney disease stage V
or end stage renal disease
Unspecified hypertensive chronic kidney disease, with chronic kidney disease stage V
or end stage renal disease
Malignant hypertensive heart and chronic kidney disease without heart failure and
with chronic kidney disease stage V or end stage renal disease
Malignant hypertensive heart and chronic kidney disease with heart failure and
with chronic kidney disease stage V or end stage renal disease
Benign hypertensive heart and chronic kidney disease without heart failure and with
chronic kidney disease Stage V or end stage renal disease or end stage renal disease
Benign hypertensive heart and chronic kidney disease with heart failure and
chronic kidney disease Stage V or end stage renal disease or end stage renal disease
Unspecified hypertensive heart and chronic kidney disease without heart failure and
with chronic kidney disease Stage V or end stage renal disease
Unspecified hypertensive heart and chronic kidney disease with heart failure and
chronic kidney disease Stage V or end stage renal disease
Chronic kidney disease, stage IV
Chronic kidney disease, stage V
Chronic kidney disease, stage IV requiring chronic dialysis
Renal failure unspecified

29011 [1, 7, 18, 19]
2903 [1, 7, 18, 19]
29041 [1, 7, 18, 19]
29281 [1, 18, 19]
2930 [1, 7, 18, 19]

Presenile dementia with delirium
Senile dementia with delirium
Vascular dementia with delirium
Drug-induced delirium
Delirium due to conditions classified elsewhere

40311 [1, 19]
40391 [1, 19]
40402 [1, 19]
40403 [1, 19]
40412 [1, 19]
40413 [1, 19]
40492 [1, 19]
40493 [1, 19]

Delirium
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Agitation
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Table 1: Continued
_________________________________________________________________________________________________________
Disease or
ICD-9CM
Condition
Code
Description
__________________________________________________________________________________________________________________________________________________________________________________________________________________

Dementia and
Cognitive
Impairment

Subacute delirium
Alteration of consciousness, other

04611 [1, 10, 19]
04619 [1, 10, 19]
0463 [1, 10, 19]
0941 [1, 10, 19]
2900 [1, 10, 12, 19]
29010 [1, 10, 12, 19]
29011 [1, 10, 12, 19]
29012 [1, 10, 12, 19]
29013 [1, 10, 12, 19]
2902 [19]
29020 [1, 10, 12, 19]
29021 [1, 10, 12, 19]
2903 [1, 10, 12, 19]
2904 [1, 10, 12, 19]
29040 [1, 10, 12, 19]
29041 [1, 10, 12, 19]
29042 [1, 10, 12, 19]
29043 [1, 10, 12, 19]
2909 [1, 19]
2912 [1, 10, 19]
29282 [1, 10, 19]
29283 [1, 10, 19]
2940 [1, 10, 19]
2941 [1, 10, 12, 19]
29410 [1, 10, 12, 19]
29411 [1, 10, 12, 19]
29420 [1, 10, 12]

Variant Creutzfeldt-Jakob disease
Other and unspecified Creutzfeldt-Jakob disease
Progressive multifocal leukoencephalopathy
General paresis
Senile dementia, uncomplicated
Presenile dementia, uncomplicated
Presenile dementia, with delirium
Presenile dementia, with delusional features
Presenile dementia, with depressive features
Senile dementia with delusional or depressive features
Senile dementia with delusional features
Senile dementia with depressive features
Senile dementia with delirium
Vascular dementia
Vascular dementia, uncomplicated
Vascular dementia with delirium
Vascular dementia with delusions
Vascular dementia with depressed mood
Unspecified senile psychotic condition
Alcohol-induced persisting dementia
Drug-induced persisting dementia
Drug-induced persisting amnestic dementia
Amnestic syndrome (Korsakoff’s psychosis or syndrome, nonalcoholic)
Dementia in other diseases
Dementia in conditions classified elsewhere without behavioral disturbance
Dementia in conditions classified elsewhere with behavioral disturbance
Dementia, unspecified without behavioral disturbance
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2931 [1, 7, 18, 19]
78009 [1, 7, 19]
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Table 1: Continued
_________________________________________________________________________________________________________
Disease or
ICD-9CM
Condition
Code
Description
__________________________________________________________________________________________________________________________________________________________________________________________________________________

Epilepsy or
Chronic seizures

29421 [1, 10, 12]
2948 [1, 10, 19]
2949 [10, 19]
3310 [1, 10, 12, 19]
3311 [1, 10, 12, 19]
33111 [1, 12, 19]
33119 [1, 12, 19]
3312 [1, 10, 12, 19]
3317 [1, 10, 19]
33182 [1, 10, 12, 19]
33183 [1, 10, 12, 19]
33189 [1, 10, 19]
3319 [1, 10, 19]
3330 [1, 10, 19]
4830 [1, 10, 19]
797 [1, 10, 12, 19]
78093 [1, 10, 19]

Dementia, unspecified with behavioral disturbance
Other specific organ brain syndrome (chronic)
Unspecified persistent mental disorders due to conditions classified elsewhere
Alzheimer’s disease
Frontotemporal dementia
Pick disease
Other frontotemporal dementia
Senile degeneration of brain
Cerebral degeneration in diseases classified elsewhere
Dementia with Lewy bodies
Mild cognitive impairment, so stated
Other cerebral degeneration
Cerebral degeneration, unspecified
Other degenerative disorders of the basal ganglia
Cognitive deficits
Senility without mention of psychosis
Memory loss

3332 [1, 16, 19]
34500 [1, 11, 14, 16, 19]
34501 [1, 11, 14, 16, 19]
34510 [1, 11, 14, 16, 19]
34511 [1, 11, 14, 16, 19]
3452 [1, 11, 14, 16, 19]
3453 [1, 11, 14, 16, 19]
34540 [1, 11, 14, 16, 19]

Progressive myoclonic epilepsy
Generalized nonconvulsive epilepsy without mention of intractable epilepsy
Generalized nonconvulsive epilepsy with intractable epilepsy
Generalized convulsive epilepsy without mention of intractable epilepsy
Generalized convulsive epilepsy with intractable epilepsy
Petit mal status
Grand mal status
Localization-related (focal) (partial) epilepsy and epileptic syndromes with
complex partial seizures without mention of intractable epilepsy
Localization-related (focal) (partial) epilepsy and epileptic syndromes with
complex partial seizures and intractable epilepsy

34541 [1, 11, 14, 16, 19]
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Table 1: Continued
_________________________________________________________________________________________________________
Disease or
ICD-9CM
Condition
Code
Description
__________________________________________________________________________________________________________________________________________________________________________________________________________________

34550 [1, 11, 14, 16, 19] Localization-related (focal) (partial) epilepsy and epileptic syndromes with simple
partial seizures without mention of intractable epilepsy
34551 [1, 11, 14, 16, 19] Localization-related (focal) (partial) epilepsy and epileptic syndromes with simple
partial seizures and intractable epilepsy
34570 [1, 11, 14, 16, 19] Epilepsia partialis continua without mention of intractable epilepsy
34571 [1, 11, 14, 16, 19] Epilepsia partialis continua with intractable epilepsy
34580 [1, 11, 14, 16, 19] Other forms of epilepsy and recurrent seizures without mention of intractable epilepsy
34581 [1, 11, 14, 16, 19] Other forms of epilepsy and recurrent seizures with intractable epilepsy
34590 [1, 11, 14, 16, 19] Epilepsy, unspecified without mention of intractable epilepsy
34591 [1, 11, 14, 16, 19] Epilepsy, unspecified with intractable epilepsy
78031 [1, 11, 14, 16, 19] Febrile convulsions (simple), unspecified
78032 [1, 11, 14, 16, 19] Complex febrile convulsions
78033 [1, 11, 14, 16]
Post traumatic convulsions
78039 [1, 11, 14, 16, 19] Other convulsions
Heart Failure

39891 [1, 6, 19, 22]
40201 [1, 6, 8, 19, 22]
40211 [1, 6, 8, 19, 22]
40291 [1, 6, 8, 19, 22]
40401 [1, 6, 8, 19, 22]
40403 [1, 6, 8, 19, 22]
40411 [1, 8, 19, 22]
40413 [1, 6, 8, 19, 22]
40491 [1, 6, 8, 19, 22]

Rheumatic heart failure (congestive)
Malignant hypertensive heart disease with heart failure
Benign hypertensive heart disease with heart failure
Unspecified hypertensive heart disease with heart failure
Malignant hypertensive heart and chronic kidney disease with heart failure and chronic
kidney disease stage I through stage IV, or unspecified
Malignant hypertensive heart and chronic kidney disease with heart failure and chronic
kidney disease stage V or end stage renal disease
Benign hypertensive heart and chronic kidney disease with heart failure and chronic
kidney disease stage I through stage IV, or unspecified
Benign hypertensive heart and chronic kidney disease with heart failure and chronic
kidney disease stage V or end stage renal disease
Unspecified hypertensive heart and chronic kidney disease with heart failure and
chronic kidney disease stage I through stage IV, or unspecified
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Table 1: Continued
_________________________________________________________________________________________________________
Disease or
ICD-9CM
Condition
Code
Description
__________________________________________________________________________________________________________________________________________________________________________________________________________________

40493 [1, 6, 8, 19, 22]
4280 [1, 6, 8, 19, 22]
4281 [1, 6, 8, 19, 22]
42820 [1, 8, 19, 22]
42821 [1, 8, 19, 22]
42822 [1, 8, 19, 22]
42823 [1, 8, 19, 22]
42830 [1, 8, 19, 22]
42831 [1, 8, 19, 22]
42832 [1, 8, 19, 22]
42833 [1, 8, 19, 22]
42840 [1, 8, 19, 22]
42841 [1, 8, 19, 22]
42842 [1, 8, 19, 22]
42843 [1, 8, 19, 22]
4289 [1, 6, 8, 19, 22]
Hypertension

4010 [1, 4, 5, 19]
4011 [1, 4, 5, 19]
4019 [1, 4, 5, 19]
40200 [1, 4, 5, 19]
40201 [1, 4, 5, 19]
40210 [1, 4, 5, 19]
40211 [1, 4, 5, 19]
40290 [1, 4, 5, 19]
40291 [1, 4, 5, 19]
40300 [1, 4, 5, 19]

Unspecified hypertensive heart and chronic kidney disease with heart failure and
chronic kidney disease stage V or end stage renal disease
Congestive heart failure, unspecified
Left heart failure
Systolic heart failure, unspecified
Systolic heart failure, acute
Systolic heart failure, chronic
Systolic heart failure, acute on chronic
Diastolic heart failure, unspecified
Diastolic heart failure, acute
Diastolic heart failure, chronic
Diastolic heart failure, acute on chronic
Combined systolic and diastolic heart failure, unspecified
Combined systolic and diastolic heart failure, acute
Combined systolic and diastolic heart failure, chronic
Combined systolic and diastolic heart failure, acute on chronic
Heart failure, unspecified
Malignant essential hypertension
Benign essential hypertension
Unspecified essential hypertension
Malignant hypertensive heart disease, without heart failure
Malignant hypertensive heart disease, with heart failure
Benign hypertensive heart disease, without heart failure
Benign hypertensive heart disease, with heart failure
Unspecified hypertensive heart disease without heart failure
Unspecified hypertensive heart disease with heart failure
Malignant hypertensive chronic kidney disease with chronic kidney disease
stage I to stage IV, or unspecified
224

225

Table 1: Continued
_________________________________________________________________________________________________________
Disease or
ICD-9CM
Condition
Code
Description
__________________________________________________________________________________________________________________________________________________________________________________________________________________

40301 [1, 4, 5, 19]
40310 [1, 4, 5, 19]
40311 [1, 4, 5, 19]
40390 [1, 4, 5, 19]
40391 [1, 4, 5, 19]
40400 [1, 4, 5, 19]
40401 [1, 4, 5, 19]
40402 [1, 4, 5, 19]
40403 [1, 4, 5, 19]
40410 [1, 4, 5, 19]
40411 [1, 4, 5, 19]
40412 [1, 4, 5, 19]
40413 [1, 4, 5, 19]
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Malignant hypertensive chronic kidney disease with chronic kidney disease
stage V or end stage renal disease
Benign hypertensive chronic kidney disease with chronic kidney disease
stage I to stage IV, or unspecified
Benign hypertensive chronic kidney disease with chronic kidney disease
stage V or end stage renal disease
Unspecified hypertensive chronic kidney disease with chronic kidney disease
stage I to stage IV, or unspecified
Unspecified hypertensive chronic kidney disease with chronic kidney disease
stage V or end stage renal disease
Malignant hypertensive heart and chronic kidney disease with chronic kidney disease
without heart failure and with chronic kidney disease stage I to stage IV, unspecified
Malignant hypertensive heart and chronic kidney disease with chronic kidney disease
with heart failure and with chronic kidney disease stage I to stage IV, unspecified
Malignant hypertensive heart and chronic kidney disease with chronic kidney disease
without heart failure and with chronic kidney disease stage V or end stage renal
disease
Malignant hypertensive heart and chronic kidney disease with chronic kidney disease
with heart failure and with chronic kidney disease stage V or end stage renal
disease
Benign hypertensive heart and chronic kidney disease with chronic kidney disease
without heart failure and with chronic kidney disease stage I to stage IV, unspecified
Benign hypertensive heart and chronic kidney disease with chronic kidney disease
with heart failure and with chronic kidney disease stage I to stage IV, unspecified
Benign hypertensive heart and chronic kidney disease with chronic kidney disease
without heart failure and with chronic kidney disease stage V or end stage renal
disease
Benign hypertensive heart and chronic kidney disease with chronic kidney disease
with heart failure and with chronic kidney disease stage V or end stage renal
disease
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Table 1: Continued
_________________________________________________________________________________________________________
Disease or
ICD-9CM
Condition
Code
Description
__________________________________________________________________________________________________________________________________________________________________________________________________________________

40490 [1, 4, 5, 19]
40491 [1, 4, 5, 19]
40492 [1, 4, 5, 19]
40493 [1, 4, 5, 19]
40501 [1, 4, 5, 19]
40509 [1, 4, 5, 19]
40511 [1, 4, 5, 19]
40519 [1, 4, 5, 19]
40591 [1, 4, 5, 19]
40599 [1, 4, 5, 19]
4160 [1, 19]
4168 [1, 19]
4372 [1, 5, 19]
4591 [1, 19]
45930 [1, 19]
45931 [1, 19]
45932 [1, 19]
45933 [1, 19]
45939 [1, 19]
5723 [1, 19]
99791 [1, 19]

Unspecified hypertensive heart and chronic kidney disease with chronic kidney
disease without heart failure and with chronic kidney disease stage I to stage IV,
unspecified
Unspecified hypertensive heart and chronic kidney disease with chronic kidney
disease with heart failure and with chronic kidney disease stage I to stage IV,
unspecified
Unspecified hypertensive heart and chronic kidney disease with chronic kidney
disease without heart failure and with chronic kidney disease stage V or end stage
renal disease
Unspecified hypertensive heart and chronic kidney disease with chronic kidney
disease with heart failure and with chronic kidney disease stage V or end stage
renal disease
Malignant secondary hypertension, renovascular
Malignant secondary hypertension, other
Benign secondary hypertension, renovascular
Benign secondary hypertension, other
Unspecified secondary hypertension, renovascular
Unspecified secondary hypertension, other
Primary pulmonary hypertension
Secondary pulmonary hypertension
Hypertensive encephalopathy
Chronic venous hypertension due to deep vein thrombosis
Chronic venous hypertension without complications
Chronic venous hypertension with ulcer
Chronic venous hypertension with inflammation
Chronic venous hypertension with ulcer and inflammation
Chronic venous hypertension with other complications
Portal hypertension
Hypertension
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Table 1: Continued
_________________________________________________________________________________________________________
Disease or
ICD-9CM
Condition
Code
Description
__________________________________________________________________________________________________________________________________________________________________________________________________________________

Insomnia

04672 [1, 19]
30740 [1, 13, 19]
30741 [1, 3, 13, 19]
30742 [1, 3, 13, 19]
30749 [1, 3, 19]
32700 [1, 19]
32701 [1, 19]
32702 [1, 19]
32709 [1, 19]
78050 [1, 3, 13, 19]
78051 [1, 19]
78052 [1, 3, 13, 19]
78055 [1, 3]
78056 [1, 3]
78059 [1, 3, 19]

Fatal familial insomnia
Nonorganic sleep disorder, unspecified
Transient disorder of initiating or maintaining sleep
Persistent disorder of initiating or maintaining sleep
Specific disorders of sleep of nonorganic origin, other
Organic insomnia, unspecified
Insomnia due to medical condition classified elsewhere
Insomnia due to mental disorder
Other organic insomnia
Sleep disorders, unspecified
Insomnia with sleep apnea, unspecified
Insomnia, unspecified
Irregular sleep-wake rhythm, unspecified
Sleep stage dysfunctions
Sleep disturbances, other

Lower Urinary Tract
Symptoms or Benign
Benign Prostatic
Hyperplasia

60000 [1, 19]

Benign hypertrophy of prostrate without urinary obstruction and lower urinary
tract symptoms
Benign hypertrophy of prostrate without urinary obstruction and lower urinary
tract symptoms
Nodular prostrate without urinary obstruction
Nodular prostrate with urinary obstruction
Benign localized hyperplasia of prostrate without urinary obstruction and lower
urinary tract symptoms
Benign localized hyperplasia of prostrate with urinary obstruction and lower
urinary tract symptoms
Cyst of prostrate
Hyperplasia of prostrate, unspecified, without urinary obstruction and other
lower urinary tract symptoms

60001 [1, 19]
60010 [1, 19]
60011 [1, 19]
60020 [1, 19]
60021 [1, 19]
6003 [1, 19]
60090 [1, 19]
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Table 1: Continued
_________________________________________________________________________________________________________
Disease or
ICD-9CM
Condition
Code
Description
__________________________________________________________________________________________________________________________________________________________________________________________________________________

60091 [1, 19]

Hyperplasia of prostrate, unspecified, with urinary obstruction and other
lower urinary tract symptoms

Parkinson’s Disease

09482 [1, 19]
33182 [1, 19]
3320 [1, 19, 20, 24]
3321 [1, 19, 20, 24]
3330 [1, 19, 20, 24]
3331 [1, 19, 20]
7810 [1, 19, 24]

Syphilitic Parkinsonism
Dementia with Parkinson’s
Paralysis agitans
Secondary Parkinsonism
Other degenerative diseases of the basal ganglia
Essential and other specified forms of tremor
Abnormal involuntary movements

Stress or Mixed
Urinary Incontinence

6256 [1, 2, 19, 25]
78832 [1, 19]
78833 [1, 19, 25]

Stress incontinence, female
Stress incontinence, male
Mixed incontinence, (female) (male)

Syncope

33701 [1, 19]
7802 [1, 8, 14, 19]
9921 [1, 19]

Carotid sinus syncope
Syncope and collapse
Heat syncope

Systolic Heart Failure 42820 [1, 8, 19, 22]
42821 [1, 8, 19, 22]
42822 [1, 8, 19, 22]
42823 [1, 8, 19, 22]
42840 [1, 8, 19, 22]
42841 [1, 8, 19, 22]
42842 [1, 8, 19, 22]
42843 [1, 8, 19, 22]

Systolic heart failure, unspecified
Systolic heart failure, acute
Systolic heart failure, chronic
Systolic heart failure, acute on chronic
Combined systolic and diastolic heart failure, unspecified
Combined systolic and diastolic heart failure, acute
Combined systolic and diastolic heart failure, chronic
Combined systolic and diastolic heart failure, acute on chronic
228
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Table 1: Continued
_________________________________________________________________________________________________________
Disease or
ICD-9CM
Condition
Code
Description
__________________________________________________________________________________________________________________________________________________________________________________________________________________

Urinary Incontinence

3076 [1, 19]
59651 [1, 2, 19]
59652 [1, 2, 19]
59659 [1, 2, 19]
59981 [1, 2, 19]
59982 [1, 2, 19, 25]
59983 [1, 2, 19]
6256 [1, 2, 19]
78830 [1, 2, 19, 25]
78831 [1, 2, 19]
78832 [1, 19]
78833 [1, 2, 19, 25]
78834 [1, 2, 19, 25]
78835 [1, 19]
78836 [1, 19]
78837 [1, 2, 19, 25]
78838 [1, 19]
78839 [1, 19, 25]
78891 [1, 19]

Urinary incontinence of nonorganic origin
Hypertonicity of bladder
Low bladder compliance
Other functional disorder of bladder
Urethral hypermobility
Intrinsic (urethral) sphincter deficiency
Urethral instability
Stress incontinence, female
Urinary incontinence, unspecified
Urge incontinence
Stress incontinence, male
Mixed incontinence, (female) (male)
Incontinence without sensory awareness
Post-void dribbling
Nocturnal enuresis
Continuous leakage
Overflow incontinence
Other urinary incontinence
Urinary incontinence due to cognitive impairment or severe physical disability
or immobility
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Table C1: Total Count of PIMs Received in Each Category by Individuals in
Prevalence Sample
________________________________________________________________________

Number of PIMs in Category

Number of
Individuals
by Category
N= 2,705

Number of
Individuals
by PIM Use
N= 2,705

_____________________

_____________________

n

n

(Percent)

(Percent)

________________________________________________________________________________________________________________________________________________

At least one PIM
One
Two
Three
Four
Five
Six
Inappropriate drug choice
One
Two
Three
Four
Five
Excess dose
One
Two
Excess duration
One
Two
Drug-disease interaction
One
Two
Three
Four
Five
Six

893

747

88

94

86

(33.01)
648
168
53
15
5
4

(23.96)
(6.21)
(1.96)
(0.55)
(0.18)
(0.15)

586
128
27
4
2

(21.67)
(4.73)
(1.00)
(0.15)
(0.07)

87
1

(3.22)
(0.04)

92
2

(3.40)
(0.07)

67
12
3
3
0
3

(2.48)
(0.44)
(0.11)
(0.11)
(0.00)
(0.11)

(27.62)

(3.25)

(3.48)

(3.18)

________________________________________________________________________________________________________________________________________________

234
Table C2: Distribution of Individuals in Prevalence Sample by Number of PIM
Categories Received
________________________________________________________________________
Number of
PIM Categories

Number of Individuals
by PIM Use in Category

Percent
N = 2,705

_______________________________________________________________________________________________________________________________________________

Zero

1,812

66.9

One

781

28.9

Two

102

3.8

Three

10

0.4

________________________________________________________________________________________________________________________________________________
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Table C3: Total Count of PIMs Received in Each Category by Individuals in
Incidence Sample
________________________________________________________________________

Number of PIMs in Category

Number of
Individuals
by Category
N= 2,210

Number of
Individuals
by PIM Use
N= 2,210

_____________________

_____________________

n

n

(Percent)

(Percent)

________________________________________________________________________________________________________________________________________________

At least one PIM
One
Two
Three
Four
Five
Six
Inappropriate drug choice
One
Two
Three
Four
Excess dose
One
Excess duration
One
Drug-disease interaction
One
Two
Three
Four

458

380

27
58
40

(20.72)
377
60
15
4
0
2

(17.06)
(2.71)
(0.67)
(0.18)
(0.00)
(0.09)

335
39
5
1

(15.16)
(1.76)
(0.23)
(0.05)

27

(1.22)

58

(2.62)

32
5
1
2

(1.45)
(0.23)
(0.05)
(0.09)

(17.19)

(1.22)
(2.62)
(1.80)

________________________________________________________________________________________________________________________________________________
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Table C4: Distribution of Individuals in Incidence Sample by Number of PIM Categories
Received
________________________________________________________________________
Number of
PIM Categories

Number of Individuals
by PIM Use in Category

Percent
N = 2210

_______________________________________________________________________________________________________________________________________________

Zero

1,752

79.8

One

414

18.7

Two

41

1.9

Three

3

0.1

________________________________________________________________________________________________________________________________________________
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Table D1: Associations between Perceived Provider Communication and Inappropriate
Drug Choice PIM Use after Adjusting for Demographic and Clinical
Characteristics using Bivariate Probit Models
Seemingly unrelated bivariate probit
Log likelihood = -2154.2042

Number of obs
Wald chi2(27)
Prob > chi2

=
=
=

2051
346.83
0.0000

---------------------------------------------------------------------------------------------------------|
Coef.
Std. Err.
z
P>|z|
[95% Conf. Interval]
--------------------+-----------------------------------------------------------------------------------Idc|
_Icommindx3_2 | .5062558
.40038
1.26
0.206
-.2784746 1.290986
_Iagegroup_2 | -.2078162
.0916011 -2.27
0.023
-.3873511 -.0282813
_Imed_count_2 | .7967579
.1233712
6.46
0.000
.5549548 1.038561
_Imed_count_3 | .5541809
.1069133
5.18
0.000
.3446347 .7637272
_Imed_count_4 | 1.514999
.153835
9.85
0.000
1.213488
1.81651
_Iregion_2 | .0069781
.1260474
0.06
0.956
-.2400702 .2540264
_Iregion_3 | .2797041
.0998346
2.80
0.005
.0840319 .4753764
_Iregion_4 | .0953641
.1117949
0.85
0.394
-.1237499 .3144782
_cons | -2.00183
.1754024 -11.41
0.000
-2.345612 -1.658048
--------------------+------------------------------------------------------------------------------------_Icommindx3_2 |
_Iagegroup_2 | .0600585
.0738462
0.81
0.416
-.0846774 .2047943
_Igender_2 | .132023
.0627505
2.10
0.035
.0090342 .2550117
_Iethnicity_2 | -.1214484
.0871801 -1.39
0.164
-.2923182 .0494215
_Ipay_2 | -.0127646
.0749439 -0.17
0.865
-.1596519 .1341227
_Ipay_3 | -.0119781
.1011484 -0.12
0.906
-.2102252 .1862691
_Ipay_4 | -.2434472
.0959027 -2.54
0.011
-.4314131 -.0554813
_Imed_count_2 | -.0105917
.087424 -0.12
0.904
-.1819396 .1607562
_Imed_count_3 | -.019629
.0712981 -0.28
0.783
-.1593708 .1201127
_Imed_count_4 | .0451804
.1044842
0.43
0.665
-.1596049 .2499657
_Iregion_2 | .2526829
.0918288
2.75
0.006
.0727017 .4326641
_Iregion_3 | .1027587
.0752479
1.37
0.172
-.0447244 .2502418
_Iregion_4 | .0604281
.0868763
0.70
0.487
-.1098463 .2307026
_Ieducation_2 | -.0536702
.0905525 -0.59
0.553
-.2311499 .1238094
_Ieducation_3 | -.3031493
.1107774 -2.74
0.006
-.5202689 -.0860296
_Ieducation_4 | -.1372714
.1074467 -1.28
0.201
-.347863 .0733203
_Idepress_d_2 | .0903394
.08704
1.04
0.299
-.0802558 .2609345
_Igenhelth2_2 |
.18493
.069074
2.68
0.007
.0495475 .3203126
_Igenhelth2_3 | .2497615
.0884607
2.82
0.005
.0763817 .4231414
_Igenhelth2_4 | .0755502
.130898
0.58
0.564
-.1810052 .3321056
_cons | .2733175
.1317817
2.07
0.038
.0150302 .5316049
---------------------+-----------------------------------------------------------------------------------/athrho | -.2910475
.2771954 -1.05
0.294
-.8343406 .2522455
---------------------+-----------------------------------------------------------------------------------rho | -.2830987
.2549796
-.6827998 .2470283
----------------------------------------------------------------------------------------------------------Likelihood-ratio test of rho=0:
chi2(1) = 1.08345
Prob > chi2 = 0.2979
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Table D2: Associations between Perceived Provider Communication and Overall PIM
Use after Adjusting for Demographic and Clinical Characteristics using
Bivariate Probit Models
Seemingly unrelated bivariate probit
Log likelihood = -2245.3755

Number of obs
Wald chi2(27)
Prob > chi2

=
=
=

2051
351.68
0.0000

----------------------------------------------------------------------------------------------------------|
Coef.
Std. Err.
z
P>|z|
[95% Conf. Interval]
---------------------+-----------------------------------------------------------------------------------Pim
|
_Icommindx3_2 | 3422409
4259827
0.80
0.422
-.4926698 1.177152
Iagegroup_2 | .2104524
.0878372 -2.40
0.017
-.3826102 -.0382947
_Imed_count_2 | .9755782
.1144262
8.53
0.000
.7513069
1.19985
_Imed_count_3 | .605426
.100242
6.04
0.000
.4089553 .8018967
_Imed_count_4 | 1.602259
.136659 11.72
0.000
1.334412 1.870106
_Iregion_2 | .0323901
.12181
0.27
0.790
-.206353 .2711332
_Iregion_3 | .2367586
.0947546
2.50
0.012
.0510431 .4224742
_Iregion_4 | .2147245
.1060303
2.03
0.043
.0069088 .4225401
_cons | -1.854069
.2099093 -8.83
0.000
-2.265483 -1.442654
---------------------+------------------------------------------------------------------------------------_Icommindx3_2 |
_Iagegroup_2 | .0612903
.0738489
0.83
0.407
-.0834509 .2060315
_Igender_2 | .1389918
.0624783
2.22
0.026
.0165365 .2614471
_Iethnicity_2 | -.1153682
.0886043 -1.30
0.193
-.2890294
.058293
_Ipay_2 | -.0186492
.0751982 -0.25
0.804
-.166035 .1287366
_Ipay_3 | -.0149661
.1029711 -0.15
0.884
-.2167857 .1868535
_Ipay_4 | -.2424427
.0966211 -2.51
0.012
-.4318167 -.0530687
_Imed_count_2 | -.0127245
.0873237 -0.15
0.884
-.1838759 .1584269
_Imed_count_3 | -.0203094
.0713021 -0.28
0.776
-.1600589 .1194402
_Imed_count_4 | .0432067
.1045837
0.41
0.680
-.1617737 .2481871
_Iregion_2 | .2541524
.0918407
2.77
0.006
.074148 .4341568
_Iregion_3 | .1021415
.0752758
1.36
0.175
-.0453964 .2496794
_Iregion_4 | .0593768
.086977
0.68
0.495
-.1110951 .2298487
_Ieducation_2 | -.0543133
.0925748 -0.59
0.557
-.2357565
.12713
_Ieducation_3 | -.3052152
.1121884 -2.72
0.007
-.5251003 -.0853301
_Ieducation_4 | -.1310915
.1080553 -1.21
0.225
-.3428761
.080693
_Idepress_d_2 | .1008831
.0864256
1.17
0.243
-.068508 .2702743
_Igenhelth2_2 | .1866289
.0697543
2.68
0.007
.049913 .3233449
_Igenhelth2_3 | .2493972
.0891962
2.80
0.005
.0745759 .4242186
_Igenhelth2_4 | .0817562
.1321498
0.62
0.536
-.1772526
.340765
_cons | .2653313
.1344871
1.97
0.049
.0017414 .5289212
--------------------+------------------------------------------------------------------------------------/athrho | -.1738983
.2775919 -0.63
0.531
-.7179685 .3701718
--------------------+------------------------------------------------------------------------------------rho | -.1721663
.2693637
-.6156493
.354142
----------------------------------------------------------------------------------------------------------Likelihood-ratio test of rho=0:
chi2(1) = .390341
Prob > chi2 = 0.5321
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Table E1: Associations between Perceived Provider Knowledge and Inappropriate Drug
Choice PIM Use after Adjusting for Demographic and Clinical Characteristics
using Bivariate Probit Models
Seemingly unrelated bivariate probit
Log likelihood = -2244.1918

Number of obs
Wald chi2(27)
Prob > chi2

=
=
=

2047
355.06
0.0000

---------------------------------------------------------------------------------------------------------|
Coef.
Std. Err.
z
P>|z|
[95% Conf. Interval]
---------------------+-----------------------------------------------------------------------------------Idc
|
_ Iknowindx3_2 | -.4989673
.4291858 -1.16
0.245
-1.340156 .3422214
_Iagegroup_2 | -.2256142
.0926558 -2.43
0.015
-.4072162 -.0440123
_ Imed_count_2 | .8199352
.1158974
7.07
0.000
.5927805
1.04709
_ Imed_count_3 | .576448
.10443
5.52
0.000
.3717689 .7811271
_ Imed_count_4 | 1.598469
.1268645 12.60
0.000
1.349819 1.847119
_Iregion_2 | .0176394
.1271057
0.14
0.890
-.2314832 .2667621
_Iregion_3 | .2680323
.1006097
2.66
0.008
.0708408 .4652238
_Iregion_4 | .0773035
.1117905
0.69
0.489
-.1418017 .2964088
_cons | -1.515713
.2789818 -5.43
0.000
-2.062507 -.9689187
---------------------+-----------------------------------------------------------------------------------_ Iknowindx3_2 |
_Iagegroup_2 | -.1092435
.0744504 -1.47
0.142
-.2551635 .0366766
_Igender_2 | -.1110661
.0626558 -1.77
0.076
-.2338692 .0117371
_ Iethnicity_2 | .114341
.0871137
1.31
0.189
-.0563987 .2850806
_Ipay_2 | .0121317
.0749354
0.16
0.871
-.134739 .1590023
_Ipay_3 | .0133216
.1015813
0.13
0.896
-.185774 .2124173
_Ipay_4 | .1640031
.0965678
1.70
0.089
-.0252662 .3532725
_ Imed_count_2 | .1281933
.087807
1.46
0.144
-.0439054 .3002919
_Imed_count_3 | .0893872
.0720439
1.24
0.215
-.0518161 .2305906
_ Imed_count_4 | .2568974
.1041376
2.47
0.014
.0527914 .4610033
_Iregion_2 | -.2460176
.0921855 -2.67
0.008
-.4266979 -.0653373
_Iregion_3 | -.1189223
.0755962 -1.57
0.116
-.267088 .0292434
_Iregion_4 | -.0640113
.0871444 -0.73
0.463
-.2348111 .1067885
_ Ieducation_2 | .003087
.0909406
0.03
0.973
-.1751533 .1813273
_ Ieducation_3 | .3185727
.1104477
2.88
0.004
.1020991 .5350462
_ Ieducation_4 | .0867452
.107895
0.80
0.421
-.1247251 .2982156
_ Idepress_d_2 | -.0644477
.0864153 -0.75
0.456
-.2338186 .1049232
_Igenhelth2_2 | -.1392557
.0688543 -2.02
0.043
-.2742077 -.0043037
_ Igenhelth2_3 | -.312822
.0895336 -3.49
0.000
-.4883047 -.1373394
_ Igenhelth2_4 | -.1693519
.1344086 -1.26
0.208
-.432788 .0940842
_cons | -.3224825
.132848 -2.43
0.015
-.5828598 -.0621052
---------------------+-----------------------------------------------------------------------------------/athrho | .2467007
.2920354
0.84
0.398
-.3256782 .8190796
---------------------+-----------------------------------------------------------------------------------rho | .2418148
.2749588
-.3146321 .6745686
----------------------------------------------------------------------------------------------------------Likelihood-ratio test of rho=0:
chi2(1) = .702372
Prob > chi2 = 0.4020
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Table E2: Associations between Perceived Provider Knowledge and Overall PIM Use
after Adjusting for Demographic and Clinical Characteristics using Bivariate
Probit Models
Seemingly unrelated bivariate probit
Log likelihood = -2244.1918

Number of obs
Wald chi2(27)
Prob > chi2

=
=
=

2047
355.06
0.0000

---------------------------------------------------------------------------------------------------------|
Coef.
Std. Err.
z
P>|z|
[95% Conf. Interval]
--------------------+-----------------------------------------------------------------------------------pim
|
_ Iknowindx3_2 | -.5489017
.3981071 -1.38
0.168
-1.329177 .2313739
_Iagegroup_2 | -.2405217
.087314 -2.75
0.006
-.4116539 -.0693894
_ Imed_count_2 | .9852611
.1129046
8.73
0.000
.7639722
1.20655
_ Imed_count_3 | .6089598
.0985486
6.18
0.000
.4158081 .8021115
_ Imed_count_4 | 1.649516
.1284045 12.85
0.000
1.397848 1.901184
_cons | -1.275228
.2329358 -5.47
0.000
-1.731774 -.8186824
---------------------+-----------------------------------------------------------------------------------_ Iknowindx3_2 |
_Iagegroup_2 | -.1092694
.0743746 -1.47
0.142
-.2550409 .0365021
_Igender_2 | -.1108913
.0619911 -1.79
0.074
-.2323917
.010609
_ Iethnicity_2 | .1179734
.0867095
1.36
0.174
-.0519741 .2879209
_Ipay_2 | .0116595
.0743197
0.16
0.875
-.1340044 .1573234
_Ipay_3 | .0068793
.1016583
0.07
0.946
-.1923672 .2061259
_Ipay_4 | .1617336
.0962103
1.68
0.093
-.0268352 .3503024
_ Imed_count_2 | .1298819
.0875685
1.48
0.138
-.0417492
.301513
_ Imed_count_3 | .0905978
.0719937
1.26
0.208
-.0505073 .2317028
_ Imed_count_4 | .2585306
.1040002
2.49
0.013
.0546939 .4623673
_Iregion_2 | -.2470651
.0912798 -2.71
0.007
-.4259701 -.0681601
_Iregion_3 | -.1446654
.0772202 -1.87
0.061
-.2960142 .0066834
_Iregion_4 | -.0855806
.0878254 -0.97
0.330
-.2577153 .0865541
_ Ieducation_2 | .0156857
.0925846
0.17
0.865
-.1657768 .1971482
_ Ieducation_3 | .3259347
.1102334
2.96
0.003
.1098811 .5419882
_ Ieducation_4 | .0888782
.1074443
0.83
0.408
-.1217088 .2994651
_ Idepress_d_2 | -.0700456
.0846811 -0.83
0.408
-.2360175 .0959263
_ Igenhelth2_2 | -.1367353
.0688295 -1.99
0.047
-.2716387 -.0018319
_ Igenhelth2_3 | -.3080866
.0897946 -3.43
0.001
-.4840809 -.1320923
_ Igenhelth2_4 | -.1712973
.133739 -1.28
0.200
-.4334209 .0908263
_cons | -.3191247
.130808 -2.44
0.015
-.5755037 -.0627458
---------------------+------------------------------------------------------------------------------------/athrho | .2901004
.2793267
1.04
0.299
-.2573698 .8375706
---------------------+------------------------------------------------------------------------------------rho | .2822272
.2570777
-.2518338 .6845201
-----------------------------------------------------------------------------------------------------------Likelihood-ratio test of rho=0:
chi2(1) = 1.05393
Prob > chi2 = 0.3046
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Table F1: Associations between Perceived Provider Competence and Inappropriate Drug
Choice PIM Use after Adjusting for Demographic and Clinical Characteristics
using Bivariate Probit Models
Seemingly unrelated bivariate probit
Log likelihood = -2193.4568

Number of obs
Wald chi2(26)
Prob > chi2

=
=
=

2055
354.30
0.0000

---------------------------------------------------------------------------------------------------------|
Coef.
Std. Err.
z
P>|z|
[95% Conf. Interval]
---------------------+-----------------------------------------------------------------------------------Idc
|
_ Icmpindx3_2 | -.7091829
.3773197 -1.88
0.060
-1.448716 .0303501
_Iagegroup_2 | -.2310595
.0896202 -2.58
0.010
-.4067119 -.055407
_ Imed_count_2 | .7768859
.1252515
6.20
0.000
.5313974 1.022374
_ Imed_count_3 | .5492973
.1053881
5.21
0.000
.3427405 .7558541
_ Imed_count_4 | 1.518502
.153705
9.88
0.000
1.217245 1.819758
_Iregion_2 | -.034141
.1237087 -0.28
0.783
-.2766057 .2083237
_Iregion_3 | .2379918
.1009708
2.36
0.018
.0400927
.435891
_Iregion_4 | .0789298
.1084252
0.73
0.467
-.1335797 .2914393
_cons | -1.316405
.3220982 -4.09
0.000
-1.947706 -.6851041
---------------------+-----------------------------------------------------------------------------------_ Icmpindx3_2 |
_Iagegroup_2 | -.1194297
.0729747 -1.64
0.102
-.2624575 .0235982
_ Iethnicity_2 | -.0257932
.0847452 -0.30
0.761
-.1918907 .1403042
_Ipay_2 | -.0698384
.0710055 -0.98
0.325
-.2090067 .0693299
_Ipay_3 | -.0638936
.097002 -0.66
0.510
-.254014 .1262269
_Ipay_4 | .0852041
.0912987
0.93
0.351
-.0937381 .2641464
_ Imed_count_2 | .0592401
.0865755
0.68
0.494
-.1104446 .2289249
_ Imed_count_3 | .0779837
.0707379
1.10
0.270
-.06066 .2166273
_ Imed_count_4 | .1744868
.1028578
1.70
0.090
-.0271107 .3760843
_Iregion_2 | -.2728877
.0907508 -3.01
0.003
-.450756 -.0950194
_Iregion_3 | -.1444222
.0743548 -1.94
0.052
-.290155 .0013105
_Iregion_4 | -.0683931
.0864378 -0.79
0.429
-.2378081 .1010218
_ Ieducation_2 | .0978144
.0865948
1.13
0.259
-.0719083 .2675371
_ Ieducation_3 | .3599551
.1079578
3.33
0.001
.1483617 .5715486
_ Ieducation_4 | .1657627
.1037874
1.60
0.110
-.0376569 .3691824
_ Idepress_d_2 | .0782289
.0816266
0.96
0.338
-.0817562
.238214
_ Igenhelth2_2 | -.1721875
.0676807 -2.54
0.011
-.3048392 -.0395358
_Igenhelth2_3 | -.2702774
.0870802 -3.10
0.002
-.4409515 -.0996034
_ Igenhelth2_4 | -.1209927
.1275527 -0.95
0.343
-.3709914
.129006
_cons | -.1284341
.1273528 -1.01
0.313
-.378041 .1211728
---------------------+-----------------------------------------------------------------------------------/athrho | .4718199
.2980834
1.58
0.113
-.1124127 1.056053
---------------------+-----------------------------------------------------------------------------------rho | .4396686
.2404613
-.1119416 .7841484
----------------------------------------------------------------------------------------------------------Likelihood-ratio test of rho=0:
chi2(1) = 2.29403
Prob > chi2 = 0.1299
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Table F2: Associations between Perceived Provider Competence and Overall PIM Use
after Adjusting for Demographic and Clinical Characteristics using Bivariate
Probit Models
Seemingly unrelated bivariate probit
Log likelihood = -2286.3292

Number of obs
Wald chi2(24)
Prob > chi2

=
=
=

2055
336.19
0.0000

---------------------------------------------------------------------------------------------------------|
Coef.
Std. Err.
z
P>|z|
[95% Conf. Interval]
---------------------+-----------------------------------------------------------------------------------pim
|
_ Icmpindx3_2 | -.4400994
.4278292 -1.03
0.304
-1.278629 .3984305
_Iagegroup_2 | -.2397496
.0880708 -2.72
0.006
-.4123652 -.0671341
_ Imed_count_2 | .9749466
.1151439
8.47
0.000
.7492687 1.200624
_ Imed_count_3 | .6077318
.0982472
6.19
0.000
.4151709 .8002927
_Imed_count_4 | 1.63522
.1292781 12.65
0.000
1.38184 1.888601
_cons | -1.302598
.2632806 -4.95
0.000
-1.818619 -.7865778
---------------------+-----------------------------------------------------------------------------------_ Icmpindx3_2 |
_Iagegroup_2 | -.1336924
.073249 -1.83
0.068
-.2772578
.009873
_Igender_2 | -.1119321
.0615512 -1.82
0.069
-.2325703 .0087061
_ Iethnicity_2 | -.0375685
.0864454 -0.43
0.664
-.2069983 .1318614
_Ipay_2 | -.0503682
.0729806 -0.69
0.490
-.1934074 .0926711
_Ipay_3 | -.0361766
.1012371 -0.36
0.721
-.2345977 .1622446
_Ipay_4 | .1152524
.0953795
1.21
0.227
-.0716881 .3021928
_Imed_count_2 | .062052
.0865434
0.72
0.473
-.1075699 .2316739
_Imed_count_3 | .076361
.0708107
1.08
0.281
-.0624254 .2151475
_ Imed_count_4 | .1755447
.1027903
1.71
0.088
-.0259206
.37701
_Iregion_2 | -.2768844
.0902787 -3.07
0.002
-.4538274 -.0999413
_Iregion_3 | -.1655117
.0760963 -2.18
0.030
-.3146578 -.0163656
_Iregion_4 | -.0916177
.0873887 -1.05
0.294
-.2628963 .0796609
_ Ieducation_2 | .0867248
.0911586
0.95
0.341
-.0919428 .2653923
_ Ieducation_3 | .3677971
.1103822
3.33
0.001
.151452 .5841423
_ Ieducation_4 | .1458636
.1065873
1.37
0.171
-.0630437
.354771
_ Idepress_d_2 | .057528
.0829317
0.69
0.488
-.1050151 .2200712
_ Igenhelth2_2 | -.1700465
.0687804 -2.47
0.013
-.3048536 -.0352393
_ Igenhelth2_3 | -.271415
.0881145 -3.08
0.002
-.4441163 -.0987137
_ Igenhelth2_4 | -.1259037
.1307503 -0.96
0.336
-.3821696 .1303622
_cons | -.0620662
.1308727 -0.47
0.635
-.3185719 .1944396
---------------------+-----------------------------------------------------------------------------------/athrho | .2704912
.2937355
0.92
0.357
-.3052197 .8462022
---------------------+-----------------------------------------------------------------------------------rho | .2640819
.2732506
-.2960821 .6890802
----------------------------------------------------------------------------------------------------------Likelihood-ratio test of rho=0:
chi2(1) = .800883
Prob > chi2 = 0.3708
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Appendix G:
Results of Link Test Checking for Model Specification Error in Model Assessing
Associations between Perceived Provider Communication and PIM Use
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Table G1: Results of Link Test Checking for Model Specification Error in Model
Assessing Associations between Perceived Provider Communication and
Inappropriate Drug Choice PIM Use
Logistic regression
Log likelihood = -823.48519

Number of obs
LR chi2(2)
Prob > chi2
Pseudo R2

=
=
=
=

2056
263.59
0.0000
0.1380

---------------------------------------------------------------------------------------------------------idc |
Coef.
Std. Err.
z
P>|z|
[95% Conf. Interval]
-------------------- +-----------------------------------------------------------------------------------_hat | 1.001152
.1675696
5.97
0.000
.6727216 1.329582
_hatsq | .0004439
.0591827
0.01
0.994
-.1155521 .1164399
_cons | .0003605
.1178246
0.00
0.998
-.2305715 .2312925
-----------------------------------------------------------------------------------------------------------
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Table G2: Results of Link Test Checking for Model Specification Error in Model
Assessing Associations between Perceived Provider Communication and
Overall PIM Use
Logistic regression
Log likelihood = -917.38495

Number of obs
LR chi2(2)
Prob > chi2
Pseudo R2

=
=
=
=

2056
289.80
0.0000
0.1364

---------------------------------------------------------------------------------------------------------pim |
Coef.
Std. Err.
z
P>|z|
[95% Conf. Interval]
-------------------- +-----------------------------------------------------------------------------------_hat | 1.014559
.1485744
6.83
0.000
.7233587
1.30576
_hatsq | .0062903
.0577114
0.11
0.913
-.106822 .1194027
_cons | .0032864
.096992
0.03
0.973
-.1868144 .1933871
-----------------------------------------------------------------------------------------------------------
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Appendix H:
Results of Link Test Checking for Model Specification Error in Model Assessing
Associations between Perceived Provider Knowledge and PIM Use
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Table H1: Results of Link Test Checking for Model Specification Error in Model
Assessing Associations between Perceived Provider Knowledge and
Inappropriate Drug Choice PIM Use
Logistic regression
Log likelihood = -826.94653

Number of obs
LR chi2(2)
Prob > chi2
Pseudo R2

=
=
=
=

2052
270.48
0.0000
0.1406

---------------------------------------------------------------------------------------------------------idc |
Coef.
Std. Err.
z
P>|z|
[95% Conf. Interval]
-------------------- +-----------------------------------------------------------------------------------_hat | .8857866
.1582626
5.60
0.000
.5755976 1.195976
_hatsq | -.0460731
.0584731 -0.79
0.431
-.1606783 .0685322
_cons | -.0304874
.1124204 -0.27
0.786
-.2508273 .1898526
-----------------------------------------------------------------------------------------------------------
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Table H2: Results of Link Test Checking for Model Specification Error in Model
Assessing Associations between Perceived Provider Knowledge and Overall
PIM Use
Logistic regression
Log likelihood = -922.25327

Number of obs
LR chi2(2)
Prob > chi2
Pseudo R2

=
=
=
=

2052
288.59
0.0000
0.1353

---------------------------------------------------------------------------------------------------------pim |
Coef.
Std. Err.
z
P>|z|
[95% Conf. Interval]
-------------------- +-----------------------------------------------------------------------------------_hat | .9796952
.1466363
6.68
0.000
.6922934 1.267097
_hatsq | -.0090337
.0586339 -0.15
0.878
-.123954 .1058867
_cons | -.0040964
.0953158 -0.04
0.966
-.190912 .1827192
-----------------------------------------------------------------------------------------------------------
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Appendix I:
Results of Link Test Checking for Model Specification Error in Model Assessing
Associations between Perceived Provider Competence and PIM Use
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Table I1: Results of Link Test Checking for Model Specification Error in Model
Assessing Associations between Perceived Provider Competence and
Inappropriate Drug Choice PIM Use
Logistic regression
Log likelihood = -826.95584

Number of obs
LR chi2(2)
Prob > chi2
Pseudo R2

=
=
=
=

2060
258.19
0.0000
0.1350

---------------------------------------------------------------------------------------------------------idc |
Coef.
Std. Err.
z
P>|z|
[95% Conf. Interval]
-------------------- +-----------------------------------------------------------------------------------_hat | .9043291
.1707122
5.30
0.000
.5697393 1.238919
_hatsq | -.0375075
.061843 -0.61
0.544
-.1587176 .0837026
_cons | -.0290817
.1183212 -0.25
0.806
-.260987 .2028237
-----------------------------------------------------------------------------------------------------------
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Table I2: Results of Link Test Checking for Model Specification Error in Model
Assessing Associations between Perceived Provider Competence and Overall
PIM Use
Logistic regression
Log likelihood = -922.59694

Number of obs
LR chi2(2)
Prob > chi2
Pseudo R2

=
=
=
=

2060
278.65
0.0000
0.1312

---------------------------------------------------------------------------------------------------------pim |
Coef.
Std. Err.
z
P>|z|
[95% Conf. Interval]
-------------------- +-----------------------------------------------------------------------------------_hat | 1.009905
.1544907
6.54
0.000
.7071085 1.312701
_hatsq | .0042961
.0606534
0.07
0.944
-.1145825 .1231747
_cons | .0023032
.0989175
0.02
0.981
-.1915715 .1961779
-----------------------------------------------------------------------------------------------------------
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Appendix J:
Diagnostic Plots of Influence Statistics for Model Assessing Associations between
Perceived Provider Communication and PIM Use
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Figure J1: Plots of Pearson Residual, Deviance Residual, Leverage, and CI
Displacements C against Case Number for Model Assessing Associations
between Perceived Provider Communication and Inappropriate Drug Choice
PIM Use
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Figure J2: Plots of Pearson Chi-Square Difference and Deviance Difference against
Predicted Probability for Model Assessing Associations between Perceived
Provider Communication and Inappropriate Drug Choice PIM Use
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Figure J3: Plots of Pearson Residual, Deviance Residual, Leverage, and CI
Displacements C against Case Number for Model Assessing Associations
between Perceived Provider Communication and Overall PIM Use
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Figure J4: Plots of Pearson Chi-Square Difference and Deviance Difference against
Predicted Probability for Model Assessing Associations between Perceived
Provider Communication and Overall PIM Use
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Appendix K:
Diagnostic Plots of Influence Statistics for Model Assessing Associations between
Perceived Provider Knowledge and PIM Use
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Figure K1: Plots of Pearson Residual, Deviance Residual, Leverage, and CI
Displacements C against Case Number for Model Assessing Associations
between Perceived Provider Knowledge and Inappropriate Drug Choice
PIM Use
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Figure K2: Plots of Pearson Chi-Square Difference and Deviance Difference against
Predicted Probability for Model Assessing Associations between Perceived
Provider Knowledge and Inappropriate Drug Choice PIM Use
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Figure K3: Plots of Pearson Residual, Deviance Residual, Leverage, and CI
Displacements C against Case Number for Model Assessing Associations
between Perceived Provider Knowledge and Overall PIM Use
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Figure K4: Plots of Pearson Chi-Square Difference and Deviance Difference against
Predicted Probability for Model Assessing Associations between Perceived
Provider Knowledge and Overall PIM Use
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Appendix L:
Diagnostic Plots of Influence Statistics for Model Assessing Associations between
Perceived Provider Competence and PIM Use
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Figure L1: Plots of Pearson Residual, Deviance Residual, Leverage, and CI
Displacements C against Case Number for Model Assessing Associations
between Perceived Provider Competence and Inappropriate Drug Choice
PIM Use
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Figure L2: Plots of Pearson Chi-Square Difference and Deviance Difference against
Predicted Probability for Model Assessing Associations between Perceived
Provider Competence and Inappropriate Drug Choice PIM Use
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Figure L3: Plots of Pearson Residual, Deviance Residual, Leverage, and CI
Displacements C against Case Number for Model Assessing Associations
between Perceived Provider Competence and Overall PIM Use
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Figure L4: Plots of Pearson Chi-Square Difference and Deviance Difference against
Predicted Probability for Model Assessing Associations between Perceived
Provider Competence and Overall PIM Use
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